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Abstract 
Coxiella burnetii is the causative agent of the zoonotic disease, Q fever.  The disease Q 
fever is diagnosed globally, however Australia, and in particular Queensland, has the 
highest rates of notifications in the world.   
This study is the first comprehensive investigation of Q fever in Queensland, with a special 
focus on paediatric infections. At the time of commencement, very limited data were 
available on the incidence of Q fever in Queensland, the risk factors associated with 
infection, and the presentation of the disease in children.  
Analysis of 6,797 notified Queensland Q fever cases, confirmed the disease to be mainly 
confined to rural populations, yet there were a noteworthy number of cases reported from 
urban and non-rural communities.  Alarmingly there were 235 notifications from children in 
Queensland.  Globally, Q fever is considered to be under-reported and therefore a 
seroprevalence study was performed to truly assess the rate of exposure in the 
Queensland population. 
This seroprevalence study highlighted a wider exposure to the organism, with a substantial 
number of people being exposed from non-rural communities, along with an increased 
prevalence in children. Further investigations were performed to identify the sources of 
exposure, especially in “low risk” populations using PCR. This study identified a number of 
potential sources of infection to humans including domestic pets, flying foxes and dust.  
Q fever is an infectious disease presenting with a wide variety of symptoms which may 
obscure the clinician’s diagnostic approach and treatment.  This thesis investigated 
specific cases of Q fever in both children and adults where there were unusual 
presentations, including whole families infected, and a serve case in which the patient had 
complete organ failure.  These cases showed the need for greater understanding and 
awareness of the disease and also demonstrated that indirect transmission of infection 
from a family member working in a high risk occupation, to other family members may 
occur. 
Prevention of Q fever in the population through vaccination is highly desirable. To ensure 
adequate vaccine coverage, genotypic characterisation of the Coxiella strains circulating in 
the population is necessary. This study determined the range of different genotypes 
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detected, and found new, novel genotypes circulating in Queensland, as well as genotypes 
that were unique to Australia. 
Q fever is a vaccine preventable disease in Australia and has had Federal Government 
funding to protect workers in high risk occupations. Yet the data generated in this thesis 
highlighted the need for the vaccine strategy to be revised so that children and family, 
members of at risk workers are included. The current vaccine has many limitations, 
including that it requires extensive pre-screening procedures to prevent previously 
exposed subjects from having an adverse reaction upon vaccination. The vaccine can 
induce a hyper-sensitised reaction in some subjects, eliciting symptoms of Q fever.  
As part of this thesis a cell mediated immunity assay was developed to enable vaccine 
candidates to be screened for previous exposure without having to be re-exposed to the 
bacteria in the widely applied skin test. This pre-screening tool will allow children to be 
screened without the potential for an adverse hypersensitive reaction to occur, and should 
facilitate the wider administration of the vaccine to this younger age group. 
In summary, the results presented in this Thesis, address the knowledge gap regarding 
the epidemiology and clinical impact of Q fever in the Queensland population. It presents 
evidence of other populations at risk, which may help to formulate an improved 
vaccination strategy for Queenslanders, and help shape the Public Health approach to the 
management of this serious disease. 
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1.1. Introduction 
Q fever is a zoonosis caused by the intracellular, gram negative bacterium Coxiella 
burnetii, and has a worldwide distribution with the exception of New Zealand and 
Antarctica 1–3 (Figure  1.1).  Human infection with C. burnetii results in the disease known 
as Q fever. The disease was first described in Brisbane, Australia in abattoir workers and 
has been a notifiable disease in Australia since 19524.  The disease in humans is thought 
to be contracted by direct contact with large ruminants: cattle, sheep or goats and is hence 
a disease largely associated with animal handlers.  The organism C.burnetii can survive 
for long periods of time in the soil and dust as a result of the dissemination from infected 
animals.  Natural forces such as wind and dust movement, along with animal 
transportation have long been considered to be secondary sources through which humans 
can be exposed to C. burnetii  and go on to acquire Q fever 5,6. 
  
Figure 1.1: Map showing the global distribution of Q fever as at 20147 
1.2. History of Q Fever  
“Query” fever or Q fever was first identified by an Australian scientist Dr Edward H Derrick 
in 1936. Dr Derrick was the pathologist in charge at the Royal Women’s and Brisbane 
Hospital. He was investigating a disease outbreak associated with a severe febrile illness 
in nine abattoir workers residing and working in Brisbane.  However, at the time this new  
disease “Query fever” was identified, the organism responsible was unable to be 
identified8.  Dr Derrick sent emulsions of infected guinea pig livers to Frank MacFarlane 
Burnet in Victoria, who was able to infect healthy guinea pigs, monkeys and mice in his 
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laboratory, and by employing new staining techniques, was able to identify large numbers 
of rickettsial-like organisms9. 
Subsequently, Cox et al. identified cells containing a rickettsia-like organism from guinea 
pigs in Montana, USA, which had contracted a febrile illness after being fed on by ticks. 
This agent was named “Nine Mile”, and caused a febrile illness in guinea pigs that were 
inoculated with blood from the diseased animals10.  The organism was able to be cultured 
in chicken embryonated eggs11.  It was through a series of immunological studies and the 
accidental infection of a visiting scientist that the Q fever agent and the organism isolated 
from Montana ticks were recognized as being the same organism12. 
 In further collaborative studies on Q fever and the rickettsia-like organism isolated in 
Montana, it was confirmed that five of the guinea pigs which had recovered from Q fever 
were subsequently immune to the newly identified organism isolated from ticks.  
Furthermore, serum taken from a patient infected from Montana ticks was able to 
neutralise the infectivity of the Q fever agent12.  The organism identified was named 
Rickettsia diaporica in the U.S and Rickettsia burnetii in Australia, but after further 
characterization studies it was renamed Coxiella burnetii in 1948 to honor the two scientist 
Cox and Burnet for their dedication 11–14.   
1.3. Bacteriology of Coxiella burnetii 
1.3.1. Classification 
C. burnetii was initially classified in the class of α-proteobacteria due to the similarities it 
shared with the family Rickettsiaceae.  The bacterium is small in size, 0.3µm x 1 µm, is 
pleomorphic and has a poor staining affinity with commonly used microbiological stains9,11.  
However, there were other characteristics that set it apart from the rickettsiae. Coxiella 
resides within phagolysosomes and is able to withstand greater exposure to physical and 
chemical agents than is observed for the ricketsia15,16.   
With the development of molecular techniques, and in particular with genome sequencing, 
it was revealed that Coxiella has a much closer genetic relationship to Legionella 
pneumophila than the rickettsia.  This led to Coxiella being assigned to the γ-subdivision of 
proteobacteria17.  C.  burnetii is the only species belonging to the genus Coxiella based on 
the sequencing of the 16s rRNA gene in which all strains examined showed >99% 
homology18. 
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1.3.2. The Infectious Agent 
C. burnetii is an obligate, intracellular, gram negative coccobacillus responsible for Q fever 
disease. On infection, this organism resides within host macrophages and replicates in the 
placenta and reproductive tissues of infected animals.  Coxiella has the unique 
characteristic of being able to genetically change via a chromosomal deletion, resulting in 
a change of the O-antigen polysaccharide (LPS) in the cell wall membrane which in turn 
alters its antigenic phase19.    
1.3.3. Phase Variation 
Phase variation occurs among many species of pathogenic bacteria, and allows the 
organism to evade the host cells immune system. 
A virulent phase I lipopolysaccharide (LPS) structure of the bacterium (wild-type), is 
responsible for natural infection.  The phase I stage of the organism slowly changes after 
several reproductive passages to produce phase II, containing a chromosomal alteration 
which has genetic deletions in the gene responsible for LPS biosynthesis. Phase II is 
avirulent and has an altered lipopolysaccharide antigenic structure which  prevents the 
organism from reverting back to phase I and allows the organism to be phagocytosed 
more readily by host cells than phase I20,21.  Typical phase variation is observed in both 
animal and human infections.  It is the irreversible avirulent phase II form that causes 
acute disease in man22. 
1.3.4. Intracellular Interaction of Coxiella and Phagocytes 
Cellular uptake of the Coxiella bacterium varies based on the phase variants. The phase II 
form of the bacteria is more readily phagocytosed than phase I 22.  The internalization of 
the bacteria is linked to integrin CR3 which is expressed on the surface of the monocytes 
and macrophages. Phase II organisms engage another integrin, αvβ3, which in turn 
triggers activation of CR3 via a protein IAP23.  Adherence of the phase I bacteria causes a 
rearrangement of the actin cytoskeleton changing the physical shape of the membrane of 
the host cell24.  These protrusions contain αvβ3 but not the CR3 and so the interaction 
between integrins does not occur (Figure 1.2)23. 
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Figure 1.2: Diagram showing phagosome uptake and internalisation of Coxiella 
highlighting the different pathways initiated by the two phase variations of Coxiella26. 
 
Other non-phagocytic cells involved in the uptake of the bacteria also show variation in the 
rates of internalization.  The mechanism though to be responsible is the LPS structure 
which is different for each phase. The phase I LPS was shown to impair the uptake of this 
phase of the Coxiella compared to the uptake of phase II organism without the LPS27. 
Once inside the phagocyte Coxiella are contained within a phagosome, a membrane 
bound vacuole. In the normal cellular destruction of foreign agents the phagosome 
matures, becoming acidic and fuse with secondary lysosomes to form phagolysosomes. 
This is the host cell’s natural defense mechanism by which most foreign agents are 
destroyed28.  However, this is not the case with Coxiella.  The Coxiella bacterium causes 
the phagosome to form a large compartment known as a parasitophorous vacuole which 
acts as the perfect acidic environment in which Coxiella can replicate29.  This acidic, 
bacteria filled, vacuole remains non-toxic to the host cell (Figure 1.3)30. 
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Figure 1.3:  Electron micrograph of a Coxiella-infected cell and the lumen of the 
parasitophorous vacuole revealing the organisms inside31 (Image reproduced with permission 
by Elizabeth Fischer of the Rocky Mountain Laboratories Microscopy Unit). 
1.4. Coxiella burnetii and Human Infection 
C.burnetii is an extremely infectious pathogen.  The disease Q fever can be induced 
through the inhalation or invasion of a single bacterium32.  The extremely high infectivity, 
the ability to withstand harsh environmental conditions, and the potential to cause severe 
disease in man, has deemed this organism to be considered as a biological terrorist agent.  
It has been listed as a Category B biological warfare agent by the Centre’s of Disease 
Control and Prevention33.  C.burnetii fulfils all of the requirements for a biological weapon: 
it consistently causes disease; it can be produced on a mass scale; it remains stable under 
production, storage, transportation and delivery conditions; it can readily be disseminated 
into the environment; and it can remain viable in the environment for years.  Its 
classification as a category B biological agent rather than Class A is due to its inability to 
cause  large-scale fatalities as is the case with category A agents such as smallpox, 
anthrax, botulism and the viral hemorrhagic fevers33. 
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1.4.1. Routes of Transmission  
Q fever in humans is contracted by the inhalation of contaminated dust particles or 
bacterium-containing aerosols shed  from infected animals and their products34.  This 
makes Q fever infection to be primarily an occupational disease associated with animal 
handlers and workers, including veterinarians, abattoir workers, meat handlers, shearers, 
tanners, and farmers. There have been other routes of transmission reported, including 
human to human cases, but these are rare. Also, cases have been reported as a result of 
sexual transmission, and cases in mortuary assistants attending an autopsy in which the 
patient died as a result of Q fever. There was also  a case of an obstetrician contracting 
the disease after delivering an aborted foetus from an infected pregnant women35–37.  
Although inhalation of the organism is the most common route for Coxiella transmission 
there are other routes by which the organism can gain entry into the human body, such as 
vertical transmission from an infected mother to her unborn child38,39.  The ingestion of 
contaminated dairy products from infected animals is also a known source of transmission 
to humans34,40, and ticks have also been identified as transmission vectors as 
demonstrated by the original isolation of C.burnetii from a tick41,42. 
1.4.2. Groups at Risk of Q fever Infection 
The transmission routes for infection with Q fever largely originate in animal sources. This 
has made Q fever disease an occupational hazard for persons working with large 
ruminants, in particular, cattle, sheep and goats26.  There are reports of people from 
communities who have been infected with Q fever as the result of direct or indirect 
transmission from parturient animals, via wind, exposure to animal transporters, and stock 
sale yard sand from living close to these environmental exposures 5,43–48.    There are 
people at risk of Q fever who do not work regularly with animals yet may come in contact 
with areas where animals and or their products have previously been. These also include 
people working as contractors or maintenance workers, and visitors to farms or animal 
fairs/shows, in fact anywhere where animals or their products are  present49.  
Infections are not only restricted to those working with cattle, sheep and goats. There have 
been many outbreaks in which other host animals have been identified as the source of 
infection. Parturient cats and their kittens have been implicated in many outbreaks of Q 
fever in Canada and Nova Scotia50–54.  
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1.4.3. Pathogenesis 
Although discovered over 60 years ago, and despite control measures being implemented, 
Q fever still remains a serious public health issue and a significant burden on health care 
resources55,56.  Q fever disease may present as either acute or chronic infection, based on 
the clinical manifestation, with the prognosis of chronic infection ranging from highly 
favorable to potentially fatal.  The spectrum of clinical syndromes range from an 
asymptomatic, acute “flulike” illness, acute hepatitis or acute pneumonia, to chronic 
endocarditis and or chronic hepatitis.  Host factors, such as age, gender and certain 
medical conditions, may influence the disease presentations57.  Age has been identified as 
a risk factor for Q fever, with a higher risk associated with increasing age.  This was 
demonstrated in a Q fever outbreak in Switzerland in 1983, showing that subjects older 
than 15 years had a five times greater risk of contracting the disease58.   Similarly, a  study 
in Greece showed an increase of confirmed clinical cases with an increase in age59.   
Although Q fever has rarely been reported in children younger than 15 years, it is likely 
that globally, the disease is under reported in this population60.  This is largely due to the 
non-specific and varied clinical presentations that occur in children infected with Coxiella. 
However, when symptoms do present in children they are similar to those observed in 
adults 61–66.  Q fever disease largely affects males at a ratio of up to 5.3:1 compared to 
females67.  Predisposing conditions for the development of chronic Q fever disease include 
pregnancy, immunosuppression and preexisting heart valve lesions 49.  
1.4.4. Clinical Disease States of Q fever 
The large majority of all C. burnetii infections are asymptomatic or self-limiting, and resolve 
with very little impact to the patients, and often requiring no formal medical treatment.  It is 
only when extensive laboratory investigations into Q fever are performed, often 
retrospectively, that it becomes evident exposure has occurred in these patients. Of those 
patients that acquire acute Q fever, 10-30% go on to develop chronic Q fever, in which 2% 
are diagnosed with endocarditis. The diverse range of clinical manifestations of the 
disease, gives rise to an increase in misdiagnosed cases which in turn increases the 
mortality and morbidity associated with the disease.   
 
1.4.4.1. Acute Q fever 
Acute Q fever infections are often asymptomatic, subclinical or cause an extremely mild 
disease. It usually manifests after a 1-3 week incubation period depending on the 
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infectious dose received.  It has been reported that up to 60% of patients diagnosed with 
acute Q fever are asymptomatic32,34,62,66.  The other 40% are symptomatic patients 
showing a number of varied clinical manifestations ranging from fevers, sweats and 
headaches to hepatitis and pneumonia, and of these 2% are hospitalised68 .  The classical 
presentation of Q fever is a “flu-like” illness with a rapid and severe fever lasting longer 
than seven days.  However, this mimics symptoms by many other infections. This may be 
accompanied with severe headaches, myalgia, rigors, arthralgia, and general fatigue, 
reflecting the cytokine cascade of the acute phase response and the developing cellular 
immune response69.  Infection may also present as pneumonia or acute hepatitis. The 
illness generally subsides within two to six weeks with some patients reporting bouts of 
extended fatigue69. 
In 1973 Derrick et al. noted that in 173 patients diagnosed with Q fever the length of the 
fever varied with age, showing that fever duration increased with increasing age of the 
patient70. Approximately 5% of acute Q fever patients require hospitalisation68. 
1.4.4.2. Chronic Q fever 
Approximately 5 % of acute Q fever cases go on to develop chronic Q fever72. People may 
become chronically infected without having being previously diagnosed with acute 
disease, and chronic Q fever may manifest months or years after an acute infection72.  In 
these chronic infections, C. burnetii multiply in host macrophages, producing a permanent 
rickettsaemia, characterised by high levels of persistent antibodies.  The heart is the most 
commonly affected organ followed by the liver.  Clinically, chronic Q fever presents as 
endocarditis in 60-70% of cases, but  the arteries, bones and liver may also be affected68.   
Endocarditis usually occurs in patients with underlying heart valve damage or 
immunocompromised patients and it generally results in cardiac failure, mitral valve and or 
aortic valve dysfunction73.  Chronic Q fever may also present with low grade fevers which 
are remittent, malaise, weakness, fatigue, night sweats, chills and weight loss.  
Hepatomegaly, renal insufficiency and splenomegaly are often seen in patients suffering 
from chronic Q fever over a long period of time74.   
 
Other less frequently observed complications associated with chronic Q fever are vascular 
infections,  chronic hepatitis and chronic pulmonary infections68,75,76. In addition, 
osteoarticular infections may occur, and can be of three types, osteomyelitis, osteoarthritis 
and aortic graft infection with adjacent spinal osteomyelitis68,77,78. 
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1.4.4.3. Post Q fever Fatigue Syndrome (QFS) and Chronic Fatigue 
Chronic fatigue syndrome (CFS) following Q fever was first described in Australian abattoir 
workers79.  These patients presented with prolonged fatigue well after the acute phase of 
the illness70,79,80.  Whilst controversial, chronic fatigue has now been accepted by the 
courts in Australia as a sequelae of Q fever infection, and it is estimated that post-QFS 
occurs in approximately 20% of acute cases80.    
Patients that suffer from QFS continue to experience chronic fatigue-like symptoms for 
over 12 months post-acute illness, and some for much longer, with up to ten years post 
infection79.  Symptoms vary with acute and chronic disease presentation, with the most 
common being debilitating fatigue, nausea, headaches, blurred vision, night sweats and 
joint pain79,81.   
Retrospective diagnosis of QFS has been reported following Q fever outbreaks in the UK, 
Canada and now The Netherlands82–84.  These studies have validated the initial reports of 
CFS as a recognized consequence of Q fever disease.  
1.4.4.4. Q fever and Pregnancy  
Despite numerous associations between Q fever infections and adverse outcomes of 
pregnancies in animals, relatively little has been documented about outcomes of 
pregnancy and Q fever infections in humans76.  This may be due to a lack of awareness of 
Q fever as a serious human pathogen by obstetricians, resulting in an underestimate of the 
incidence of the disease 85.  
 
In 2007 a review of Q fever in pregnancy involving 38 human cases, demonstrated that Q 
fever in pregnancy was associated with a high morbidity and mortality86.  The study 
showed that spontaneous abortion occurred in 26% of Q fever related pregnancies, with 
5.3% of pregnancies resulted in intrauterine death, 45% resulted in premature birth and 
5.1% reported intrauterine growth retardation86.  In another study, of 53 pregnant women 
with Q fever, it was identified that more than 50% of these mothers developed a Q fever 
serological profile consistent with chronic Q fever, compared to a 5% conversion rate in 
the general population86.  This study also highlighted the link between placentitis and 
obstetric complications.  Contracting Q fever during pregnancy, results in long term risk of 
developing chronic Q fever disease, along with adverse outcomes for the unborn child. 
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1.5. Diagnosis of Q fever 
1.5.1. Serological Methods 
The diagnosis of Q fever is based on the detection of specific antibodies produced against 
the organism C.burnetii following exposure.  Until relatively recently, the complement 
fixation test (CFT) and the micro agglutination assay were  the methods employed in the 
detection of antibodies against C.burnetii87. However, the indirect immunofluorescence 
assay (IFA) is now considered the reference method or “Gold standard” for the diagnosis 
of Q fever by serology88,89.  This has proven to be the most sensitive and specific for the 
detection of Coxiella antibodies (Table1.1)89.  
The IFA method can differentiate between the different classes of antibodies produced by 
a host in response to Q fever infection. Testing of serum for the presence of acute Q fever 
antibody testing is generally performed on paired sera.  These samples are ideally taken 
14-21 days apart and the change in antibody levels can be directly compared.  An 
alternate method is the detection of the acute antibody marker immunoglobulin M (IgM), 
also by IFA, which is indicative of a current infection90.  This IFA method is subjective and 
there have been studies performed to measure inter-laboratory variation, with one showing 
only a 35% agreement rate between laboratories91. 
There are other systems designed to measure antibody levels which also have high 
sensitivity and specificity such as the enzyme linked immunosorbant assay (ELISA). This 
assay can be automated and reduce turnaround times, and  produces a measurable end 
point which allows for standardization of the assay results across laboratories92. 
Only phase I organisms are virulent towards humans, however, serologically the anti-
phase II antibodies are the first to be detected in an acute infection using the previously 
described methods. High levels of specific anti-phase I antibodies are normally associated 
with a chronic Q fever profile, whereas specific anti-phase II antibodies dominate during 
acute Q fever infections. This is largely due to the phase II antigens being more 
immunogenic than the phase I surface components93–95.  Phase I antibody may be 
detected following initial infection in conjunction with a phase II antibody titre. However, the 
phase I titre seldom exceeds the phase II titre.  
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As seen with many other infectious diseases, IgM antibodies are the first to appear and 
generally the first to be detected.  These acute markers are usually detectable within one 
week after the onset of symptoms and may be detectable for up to 17 weeks96.  
Immunoglobulin G (IgG) may be detectable at the same time as IgM.  However, it has 
been shown that the titres of IgG are lower in the first week post infection than IgM titres. 
The IgG levels peak, and on average can persist for years, even life long, as opposed to 
the short, higher titred production of IgM95,97.  The presence of immunoglobulin A (IgA) to 
phase I antigen strongly correlates with endocarditis and is indicative of a chronic 
infection74,97.   However, some experts dismiss the value of phase I IgA detection as a 
definitive marker for chronic Q fever and state that only IgG and IgM titres should be 
assessed when considering acute and chronic Q fever98.   The detection of phase II IgA 
has been noted in many studies at low titres, but  questions regarding its role as a 
diagnostic marker continue89,95,99–102. 
Table 1.1: Sensitivity and specificity of the various serological methods used to diagnose 
acute Q fever. 
Test Sensitivity Specificity Reference 
Micro-agglutination 82% 97% Nguyen 1996103 
Complement Fixation 78% 99% Peter 1985104 
Immunofluorescence 98% 100% Slaba 200598 
ELISA 84% 99% Waag 199596 
 
1.5.2. Molecular Methods 
Molecular techniques have been employed in the detection of many bacterial and viral 
pathogens and have become the gold standard of testing for many infectious agents105. 
Serological tests have proven to be inadequate for detecting Q fever infections in the very 
early phase of the disease, when antibody levels are low or developing106.  The 
development of molecular methods such as the polymerase chain reaction (PCR) and the 
continuing advances made by molecular diagnostics such as sequencing whole genomes, 
have vastly improved the early and accurate diagnosis of acute Q fever, along with the 
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ability to confirm chronic cases of Q fever.  Rapid and accurate diagnostic methods such 
as nucleic acid detection, of which PCR is the most widespread are imperative in 
identifying the biology and pathogenesis of this organism in order to reduce the morbidity 
and mortality associated with Q fever disease. 
There have been many PCR assays designed for the detection of Coxiella DNA, and these 
have targeted different areas of the organism’s genome107–111. The target most often 
chosen to detect Coxiella DNA is the repetitive insertion element sequence IS1111, which 
has multiple copies throughout the Coxiella genome112. The com1 gene is the other 
commonly selected gene target which encodes for a 27-kDa outer membrane protein113. 
PCR has also allowed the detection of Q fever disease from a variety of different sample 
types including serum. Acute Q fever is often diagnosed by PCR in the very early stages of 
disease using sera that has tested negative to Coxiella antibodies107. PCR has also been 
used widely for the detection of Coxiella DNA in chronic Q fever patient samples.  These 
generally are tissue samples taken directly from infected organs which highly loaded with 
bacteria; for example: heart valves in the cases of endocarditis69. PCR has already 
improved the turnaround times for diagnosis and treatment of many Q fever sufferers.  
1.5.3. Isolation of Coxiella by Culture 
Culturing of Coxiella is no longer employed as a diagnostic tool for Q fever disease in 
many laboratories due the difficulties and dangers working with the organism. Coxiella can 
be isolated from clinical samples using a shell vial centrifugation and inoculation onto 
Human Embryonic Lung cell layers114.   Isolation can also be achieved by inoculating 
patient samples into embryonated chicken eggs and animal models, including guinea pigs 
and mice. 
1.5.4. Microarray Technology 
C. burnetii infects the macrophages and induces an immune response.  Different 
pathogens trigger specific pattern-recognition receptors that are expressed on the surface 
of leukocytes115–117.  Microarray technology can be used to analyse different gene 
expression patterns in the leucocytes from patients who have been exposed to specific 
pathogens such as C. burnetii.  This type of technology has already brought a new 
perspective to the diagnosis and prognosis in cancer. The gene expression patterns 
produced from the leukocytes have led to a better understanding of the mechanisms 
behind the cancer118, and have been used to identify genes regulated by the immune 
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response117,119.  These specific patterns are “signatures” of the leukocytes and are 
indicative of disease. 
1.6. Treatment and Prevention  
1.6.1. Treatment of Q fever Infections  
Treatment of Q fever remains difficult due to its varied clinical presentation and 
misdiagnosis of infection.  Most acute infections are subclinical and recover spontaneously 
without medical intervention. However, when a positive diagnosis of acute Q fever is made 
treatment should commence immediately and continue for  2-3 weeks69.  Doxycycline is 
the antibiotic of choice because of its ability to readily permeate cell membranes and 
destroy the intracellular organism within a few weeks120.  
 
Chronic Q fever patients have a much poorer prognosis73.  This disease persists for longer 
periods of time and has a mortality rate of up to 60%121.  Endocarditis is the main clinical 
manifestation of chronic Q fever and is much more difficult to treat effectively, requiring a 
combination of antibiotics, usually:  
a) Doxycycline in combination with quinolones for at least 4 years; or  
b) Doxycycline in combination with hydrochloroquine for 1.5 to 3 years.   
These treatment regimens are some of the lengthiest reported for bacterial infections121, 
and relapse of the disease may occur after the termination of treatment. Therefore clinical 
and biological evaluation should be performed at least annually for the rest of the patient’s 
life68.  Often surgery is the only treatment in the case of endocarditis requiring the removal 
and replacement of damaged heart valves in conjunction with antibiotic treatment.  
1.6.2. Vaccine 
Derrick’s early work on Q fever and the discovery of C. burnetii as the aetiological agent, 
led to the development of a crude vaccine122,123.  This vaccine was imperative to reduce 
the high number of infections among abattoir workers and laboratory personal.   
 
 During initial vaccine development, the antigenic structure and nature of C. burnetii was 
unknown, and  it was later proven that the potency and the efficacy of the vaccine were 
dependent upon the antigenic phase of the organism124.  Vaccines developed with phase I 
organisms have a potency of 100-300 times that of cellular vaccines produced using the 
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phase II organism124.  In Australia, a whole cell vaccine against Q fever “Q Vax®” was 
manufactured by the Commonwealth Serum Laboratory (CSL), Australia, and was 
licensed for use in 1989.  This vaccine was implemented for wide-spread use into a 
government funded vaccination program with the aim to substantially reduce the number 
of Q fever infections associated with occupational outbreaks.  This nationally available 
vaccination program was called the National Q Fever Management Program (NQFMP).  
The vaccine is recommended for use in at risk candidates aged 15 years or older, and is 
not administered to children younger than 15 years. However, there is a compelling case 
to include children in a wider vaccination program, but the efficacy and safety for this lower 
age group is not known125. Australia is the only country in the world that has a licensed 
vaccine for the prevention of Q fever in humans. 
1.6.2.1. Adverse Reactions Associated with Vaccination 
The vaccine was trialed as a preventative measure in personnel employed in four South 
Australian abattoirs during 1981-8.  During this time over 4000 vaccines were administered 
to workers and it was shown to have an efficacy of 100% with protection lasting at least 5 
years123.  However, there were many adverse reactions associated with the administration 
of the vaccine.  Vaccinees very commonly showed local tenderness (48%) and erythema 
(33%) at the site of injection.  General symptoms occurred commonly in 10% of vaccinees 
and may include transient headaches, flu-like symptoms, fevers, chills and sweats125.  
There was also evidence of more significant adverse reactions which were documented for 
an estimated 130, 000 individuals vaccinated from 1989-2004126.  These reactions 
included intensified local reactions at the site of injection, which may occur in individuals 
previously immunologically sensitized from either a subclinical infection or from repeated 
vaccination.  Other reactions  observed were painless hardened lumps which took months 
to heal, sterile abscesses requiring excision and drainage before resolving, and systemic 
symptoms mimicking post QFS125,127.  It was recognized that these adverse reaction could 
be avoided by testing for preexisting immunity123,127–129.  While antibodies are required to 
clear extracellular organisms, sensitization of lymphocytes to the Q fever antigens, and 
their subsequent secretion of lymphokines, is the mechanism that clears the intracellular 
infection and provides immunogenic memory. 
1.6.2.2. Pre-vaccination Sero-profiling 
 In 1983, an initial investigation of pre-vaccination profiling by skin test was initiated using 
the Q-fever phase I antigen on  74 subjects128. The results revealed that 38 (51.3%) 
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developed erythema less than 8 mm, and 36 (48.6%) had erythema greater than or equal 
to 10 mm’s.  Of these, only 14 subjects had positive serology or evidence of past 
exposure.  All skin test-positive individuals and one skin test-negative individual developed 
mild local reactions.  
A trial was initiated in volunteer abattoir workers in South Australia to assess the safety of 
the vaccine130, and to survey any adverse effects after vaccination.  Adverse reactions 
were limited by pre-assessing the vaccination candidate’s serological results and cell-
mediated immunity via skin tests.  Q fever antibodies were measured using complement 
fixation and immunofluorescence assays.  Seronegative subjects were skin tested by 
intradermal inoculation of Q fever vaccine containing 0.02µg of purified organism.  The 
sites of injection were examined 5-7 days after inoculation, and an indurated area of 7mm 
or more was regarded as a positive reaction131.  The results of these studies by Marmion 
et al. and Ascher et al., prompted the introduction of routine Q fever skin tests to aid in the 
sero-profiling of pre vaccination candidates by directly measuring the candidate’s cell 
mediated immune response128,130. 
 
1.6.2.3. Limitations of Sero-profiling   
In Australia, pre-vaccination sero-profiling is mandatory when vaccination against Q fever 
is considered using the current vaccine 125. However, there are potential difficulties that 
may be encountered when testing for prior immunity.  Using antibody titres as an indicator 
of immunity and hence prior infection, may not eliminate the risk of adverse reactions as 
specific antibody levels start to diminish after an acute infection or previous exposure.  
Therefore antibody absence may not always reflect the immune status of the vaccine 
candidate132,133.  Skin tests however, are able to provide an accurate indication of cell 
mediated immunity, and provide an insight into the likelihood of adverse reactions 
following vaccination.   These tests however, carry have a degree of uncertainty and 
subjectivity as the interpretation of results is  based on individual judgment125. This 
requires that skin tests must be performed correctly and only by experienced, trained 
personnel. With this in consideration, skin testing is very time consuming as there is a 7-10 
day window before the results can be read and interpreted.  This in turn results in the skin 
test being costly and having the potential to be misinterpreted, especially if performed 
incorrectly49,128. 
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It would be advantageous and cost effective to develop a vaccine that is less of a risk to 
candidates that have been previously exposed to C.burnetii and thereby reduce the risk 
and time associated with a Q fever vaccination.   Recent Q fever vaccines that are 
currently being trialed include the chloroform methanol residual (CMR) extracted phase I 
whole cell vaccine, which unfortunately has not correlated well serologically with immune 
status 132,134,135.  However, it is proposed that this newly developed vaccine carries the 
appropriate antigens needed to prime a host response and this is enhanced by the use of 
a booster vaccine which stimulates the immune system to produce detectable IgG 
antibody levels, which were previously not detectable after initial vaccination.  There have 
been other vaccines developed that have been unsuccessful in providing protective 
immunity. These included a fusion protein vaccine comprised of a C.burnetii outer 
membrane protein I and heat shock protein B, but this vaccine provided only minimal 
protection136.  The protective mechanisms of the immune response to Coxiella exposure 
are still not fully understood and this has hampered the development of a safer, protective 
vaccine. 
1.7. Epidemiology 
The disease Q fever, is a zoonosis reported worldwide excluding New Zealand and 
Antarctica2,136,137.  The causative agent, C. burnetii, has a wide range of animal reservoirs, 
and has been detected in all the animal kingdoms, with domestic ruminants the most 
frequent source of human infections138.  Generally, C.burnetii infections in animals are 
asymptomatic, however, in mammals the infections can lead to abortion and stillbirths139, 
in which case the organism is found in large numbers in products of conception and 
birthing by-products139.   Animals may also shed the organism in milk, faeces, and urine, 
and it may be present in large numbers in wool, due to infestations with ticks and their 
faeces140.  For humans, exposure to these animal products is considered to be the major 
source of infection. Transmission of Coxiella and Q fever infection in humans is through 
inhalation of particulate matter generated from infected animals during parturition or 
through the inhalation of air borne contaminated dust 5,31,141,142.  Due to the highly resistant 
nature of this organism it may persist in the environment for weeks or months, with a 
common source of dissemination by the wind5,42,45,143. The latter would account for Q fever 
infections in humans without direct animal contact.  There are also a small number of 
infections that occur as a direct result of ingestion of contaminated milk144, and even fewer 
cases of Q fever result from tick bites66. Although very rare, human to human spread has 
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been documented, with early cases contracted during an autopsy, one documented case 
of sexual transmission and transmission from bone marrow transplants and blood 
transfusions33,34,145.   
 
Although at greatest risk of Q fever infection are those in direct contact with farm animals, 
there is also a significant risk associated with laboratory personnel working with infected 
specimens and laboratory animals146.  For those workers at risk of Q fever infection, 
access to an appropriate and comprehensive vaccine strategy is of the utmost importance 
and should be part of their Occupational Health and Safety consideration.   
 
  1.7.1. Q Fever Notifications 
The true prevalence of Q fever is difficult to assess as many countries are not vigilant with 
disease recognition or reporting cases. In some countries Q fever is a notifiable condition, 
including Australia, USA, Germany, France, United Kingdom and Netherlands. The cases 
of Q fever that have been reported for these countries over the past 60 years have been 
compared in Figure 1.4.  Australia has constantly reported on average more notifications 
than any other country in the world, with the exception of The Netherlands during a Q fever 
outbreak in 2007 which saw over 4, 000 cases reported147.  There have been over 370 
outbreaks of Q fever worldwide since 1954, with over 28,508 cases reported7. Table 1.2 
highlights some of the countries that have encountered Q fever outbreaks7.   
 
  
   
1
9
 
 
Figure 1.4:  Q fever Notifications from Australia, USA, Germany, France, The Netherland and the United Kingdom for the years 
1954 to 20137. 
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Table 1.2: Summary of the number of Q Fever outbreaks reported around the world from 
1940-2014. 
 
 
 
  
Countries Outbreaks 
Worldwide Outbreaks 6 
 Australia 7 
 Bosnia and Herzegovina 3 
 Bulgaria 2 
 Canada 6 
 Croatia 4 
 Cyprus 1 
 Czech Republic 2 
 France 1 
 Germany 9 
 Israel 1 
 Italy 2 
 Madagascar 1 
 Netherlands 1 
 Poland 1 
 Romania 1 
 Russian Federation 1 
 Serbia and Montenegro 1 
 Spain 1 
 Taiwan 1 
 United Kingdom 5 
 United States 3 
Grand Total 60 
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1.7.1.1. Australian Outbreaks 
There have been 11 significant outbreaks of Q fever reported in Australia between 1959 
and 2013 (Table 1.3). Details of each of the outbreaks, the state of Australia in which it 
occurred along with the numbers of confirmed cases that occurred in each outbreak.  
Table 1.3: Summary of Australian Q fever Outbreaks from 1954 to 2013 
Year Outbreak Details 
1959 
An outbreak of Q-fever in Queensland was associated with sheep contact 
148 
1962 An outbreak was reported in a meat-works in South Australia 149 
1969 An outbreak in a Brisbane "meat works" affected 7.9% of workers150 
1979 An outbreak (110 cases) was reported at an abattoir in Victoria151,152 
1998 
An outbreak (29 confirmed and 8 suspect cases) was reported at an 
abattoir in New South Wales. 153,154 
2004 
An outbreak (9 confirmed and 6 suspect cases) was reported among 
farmers in South Australia. 44 
2005 
An outbreak (5 cases) was reported among persons involved in calving 
activities, in New South Wales. 155 
2006 
An outbreak (4 cases) was reported among workers at a cosmetics 
factory 156 
2006 An outbreak (27 cases) was reported in rural South Australia107 
2007 
An outbreak (5 cases confirmed, 1 possible fatal case) was associated 
with an abattoir in South Australia157 
2013 
Two separate outbreaks were reported in two separate veterinary 
hospitals (2cases and 3 case)158,159  
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In 2012, Australia reported 358 confirmed case of Q fever disease, or 1.6 cases per 100 
000 population, and the majority of these cases were reported from Queensland and New 
South Wales. 
As previously noted, Australia has one of the highest reported incidence rates of Q fever in 
the world, with rates 2, 3 and 6 times higher than in France, the European Union and the 
United Kingdom (UK) respectively56. Based on very little data available, Queensland and 
Northern New South Wales have the highest notification rates in Australia (Figure 1.5). In 
Australia, Q fever became a notifiable disease in 1977, and since then, Q fever infections 
are extensively monitored as shown by notification numbers67,127. 
 
Figure 1.5: Australian Q fever notification rates (per 100,000) by ABS Statistical 
Subdivision (2006) (Australian Bureau of Statistics)56. 
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1.7.2. Seroprevalence 
1.7.2.1. Worldwide Prevalence 
Q fever cases and epidemics have been reported in many countries around the world; 
however,despite the global prevalence of C. burnetii, there have been few large 
population-based studies examining the epidemiology of this infection.  Much of the 
literature states that there is a lack of prevalence studies and that the prevalence within 
populations are still very much undetermined. Also, there is little information regarding the 
distribution of Q fever infection of humans25,65,67,145,158,159 .   
As far back as 1955 it was documented that Q fever was known to exist in 51 countries159.  
In 2007, both Britain and the USA, reported that annually there are approximately 100 
human cases of Q fever identified in those countries, but diagnosis remains problematic160.  
Published seroprevalence studies are limited and generally performed in an “at risk 
population” or performed on small patient populations. With this in mind, those studies that 
have been conducted give prevalence rates ranging from 18% to 37% from blood donors 
in  Morocco, Tunisia, Zimbabwe, Nigeria and North Africa1.  In  2007, a study in Albacete, 
Spain, reported prevalence rates of phase II antibodies to be 23.1%, with 0.3% of 
participants (blood donors) having positive IgM titers161. Turkey has recently (2008) 
reported a seroprevalence of anti-phase II IgG of 32.3%, with 2.8% being IgM positive162. 
In both these studies it was shown that men were more frequently seropositive than 
women and this difference was not related to occupational exposure to animals.  In Tianjin, 
People's Republic of China, seroprevalence rates of 6.4% for C. burnetii were reported in 
farm workers in 2008163.  
 
Despite this high seroprevalence for C. burnetii, there have been few large population-
based studies performed examining the epidemiology of this infection.  Northern Ireland in 
2008 performed an extensive population based study in order to gain a more accurate 
insight into the seroprevalence of Q fever. C. burnetii phase II specific IgG antibodies were 
measured by enzyme-linked immunosorbent assay in stored serum from 2,394 randomly 
selected subjects, aged 12-64, collected in 1986 - 1987. The overall prevalence of C. 
burnetii antibody was 12.8%. The prevalence was slightly higher in males than in females 
(14.3% versus 11.2%).  Sero-positivity was low in children (<10%), increasing to 19.5% 
and 16.4% respectively, in males and females in the 25-34 age group. This prevalence 
remained fairly consistent with increasing age. Sero-positivity among farmers, was 48.8%, 
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which was significantly higher than the general population. More sero-positive than sero-
negative women had a history of a miscarriage or still-birth (19.5% versus 9.8%).  The 
authors estimated that 20% of Q fever infections in Northern Ireland occurred in 
farmers164. 
 
Recently, The Netherlands experienced large population outbreaks of Q fever, in particular 
in Noord Brabant.  This area has a large goat farming industry, and recorded large 
numbers of herd abortions on some farms, which were blamed for the outbreaks.  The 
notification rates of Q fever in The Netherlands up until the recent outbreaks in 2006 were 
on average 17 cases annually.  The recent outbreaks saw notification rates rise almost 
ten-fold in 2007 to 168 confirmed case and then to a staggering 1000 registered cases 
reported in 2008165.  This outbreak raised an awareness for clinicians worldwide,  to 
consider Q fever as a possible cause, when assessing patients with “flu-like” illnesses, and 
or those in contact with ruminant and or parturient animals. 
1.7.2.2. Seroprevalence in the Australian Population 
The seroprevalence of C.burnetii in Australia is largely unknown and there are no recent 
published data on the seroprevalence of Q fever in either the rural or urban populations at 
either a national or state level.  The studies that have been documented generally target 
the groups with high occupational hazards such as veterinarians, farmers and abattoir 
workers166. 
 
Studies performed in North-Western Australia have not reported any confirmed cases of Q 
fever for 15 years up to and including 2002.  Yet, during a Q fever vaccination study 
targeting this area, 39 of 59 (66%) subjects showed serological evidence of previous 
exposure. It was suggested that there was a low incidence of adult infections due to the 
high level of exposure to Coxiella during childhood, resulting in asymptomatic infections169. 
The seroprevalence surveys that have been performed were often difficult to compare 
since researchers use different populations, different diagnostic tests and cut-off criteria for 
these assays168. No recent seroprevalence studies have been published for the 
Queensland population. 
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1.8. Q fever in Children 
Although Q fever has historically been regarded as an occupational hazard among adults 
in high risk occupations,  an increasing number of reports of children being infected with 
Coxiella and contracting Q fever have emerged. These infections often present as an 
atypical pneumonia, which has a high rate of morbidity, and therefore an accurate 
diagnosis is important to institute rapid and appropriate treatment106.  There is the 
continual, underlying consensus that Q fever in children has been rarely reported and most 
probably remains under diagnosed6,59,61,63–65,68,169,170.  Most of the literature on Q fever in 
children centers on specific case reports 63,170,171. Even with the limited data published on 
seroprevalence, seems to indicates a high level of exposure in children60.  A study form 
Africa reported that the seroprevalence rate was higher in children <5 years of age 
(16.9%) than that of adults (8.9% )61. 
1.8.1. Disease States  
Historically this disease has been mainly regarded as an occupational illness of adults. 
With this in mind, Q fever is often not considered for children presenting with “flu-like 
illnesses”, fever, headache, pneumonia, fatigue or hepatitis. Q fever infections in children 
occur through the same routes as that described earlier for adults 
1.8.1.1. Acute Q fever 
Q fever can result in a multi-system disease68.  The clinical presentation of the acute 
disease, in children is predominantly a self-limiting, febrile illness as described for adults60.  
Other syndromes that have been noted in children with acute Q fever are myocarditis, 
central nervous system infections including atypical pneumonia, encephalitis, meningitis 
and pericarditis, hepatitis, haemophagocytosis and rhabdomyolysis.  In Switzerland a 
study was done during an outbreak of Q fever, and it showed that only 12% (10 out of 80) 
paediatric cases confirmed with Q fever, were symptomatic compared to 64% of adults 
with the disease172.  It was noted that the older children (11-14 year olds) tended to be 
more symptomatic than the younger children60.  This correlates with adult infections as 
there is an increase in noted symptoms with an increase in age.  There is greater disease 
severity also associated with an increase in age164,173.  The literature shows that infections 
occur equally between boys and girls; this however,is not mimicked in the adult population 
where studies report that men are more often diagnosed with Q fever than women60,63,66. 
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Q fever has been identified as one of the major infectious agents responsible for atypical 
pneumonias in children.  Other organisms responsible for atypical pneumonia include 
Mycoplasma pneumonia, Legionella and Chlamydia pneumoniae which, together with 
Coxiella, may be responsible for over 40% of these infections174.   
1.8.1.2. Chronic Q fever 
There are very few reported cases of chronic Q fever in children in the literature.   There 
have only been two recorded clinical manifestations of chronic Q fever that occur in 
children, Q fever endocarditis and osteomyelitis.  It is thought that children who suffer from 
chronic Q fever are likely to have a specific immunological defect, resulting in a delayed 
clearance of the organism170.   
A clinical review of Q fever in children reported that endocarditis in 4 out of 5 reported 
cases was coupled with an underlying congenital heart condition60.  All the cases 
presented revealed vegetations on examination of echocardiograms and were identified 
serologically as having chronic Q fever.  All the children in the recognised case reports had 
prolonged symptoms for several months before a diagnosis was made.  There are six 
documented cases of osteomyelitis in children due to chronic Q fever to date61,170.  The 
majority of children had bone lesions for up to 5 years before the diagnosis of Q fever was 
established and appropriate treatment could commence. 
1.8.2. Treatment of Q fever in Children 
As is the treatment for adults, children require prolonged courses of tetraxycycline, 
rifampicin, ciprofloxacin and hydroxychloroquine to combat the disease.  Treatment may 
be recommended for up to 3 years for chronic Q fever endocarditis and even longer for 
children with chronic osteomyelitis121.  There is prolonged follow-up in Q fever patients to 
avoid and or identify possible later relapses of the disease73. 
1.8.3. Vaccination of Children 
In Australia a whole cell vaccine against Q fever, Q Vax® was trialed and released for use 
by CSL in 1989 for those aged 16 years and over125.  The vaccine was designed to protect 
the “at risk population”, that is, those that had a high occupational risk of contracting Q 
fever. The majority of these vaccine candidates were 16 years or over and hence children 
were not included in vaccine trials.   The lower age limit for the Q Vax® is not known, as 
there is limited safety and efficacy data with regard to children under 16 years of age63,125.  
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With increasing numbers of notifications in children, especially in South East Queensland, 
it seems likely that the vaccine should be made more widely available to include this age 
group.  Although the current literature reports far more cases of Q fever in adults than 
children, studies of seroprevalence in children are limited. However, those that do contain 
data on children, indicate that they are frequently exposed to C.burnetii, and published 
data suggests that there is an increase in symptomatic infections of Q fever with 
age60,66,166.  The lack of information regarding Q fever infection in children may be 
attributed to the a number of factors, a) symptomatic Q fever infection increases with age, 
and therefore is more rare in children than adults b) the exposure to C.burnetii in children 
is different from adults or c) Q fever is often not considered and diagnosed as a childhood 
infection60. 
1.9. Thesis Summary 
At the commencement of this study, there was considerable lack of information regarding 
the epidemiology of Coxiella burnetii in Queensland, and to some extent Australia. A 
national vaccine strategy was in place, but this strategy was based on only fragmentary 
historical data gathered more than 20 years ago, and focused on adult males working in 
high risk occupations. Also, children were not considered for Q fever vaccination, and 
there had been no information about the risk or incidence of Q fever in children.  Clearly, 
such data are vital if Australia is to develop a comprehensive vaccine strategy that 
includes all community groups at risk, including children. 
To address this knowledge gap, the sections described in the following research Chapters 
of this study sought to address these specific aims: 
Chapter 2:  General Materials and Methods 
In this section of the study, a comprehensive range of laboratory tools was developed to 
detect Coxiella and to determine the presence of Coxiella specific antibodies in clinical 
specimens. 
Chapter 3: Analysis of Q fever Notification Data in Queensland 
There were no previous studies that had analysed Q fever notification data for the 
Queensland population. The broad assumption was that Q fever was predominantly a 
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disease associated with rural communities. However, this assumption appeared to be 
based on anecdotal evidence rather than published scientific analysis. 
The study in this Chapter did examine the comprehensive Queensland notification data 
available between the years 1984 to 2014, aiming to determine which communities and 
population groups report the greater incidence of disease. A particular emphasis was be to 
examine the rate of disease in children. 
Chapter 4: Seroprevalence of Coxiella burnetii in Humans and Animals in 
Queensland 
Although the analysis of notification data is important to identify the incidence of disease, 
such data do not give an indication of the rate of exposure to Coxiella in the general 
population. Also, there were no data to indicate if domestic and native animals are 
exposed to the bacterium. 
The study in this Chapter sought to determine the level of exposure to Coxiella in both 
humans and animals by determining seroprevalence in these groups of subjects. Such 
data was be compared to the notification data from Chapter 3, to determine if the risk of Q 
fever disease is confined to specific population groups, or if the risk of exposure is wider 
than assumed. 
Chapter 5: Potential Environmental Sources of Q fever Infection for Humans 
Residing in Queensland.  
The acquisition of Q fever disease in Queensland is considered to be higher than most 
other populations, yet there is little published data to identify the potential sources of 
infection to the Queensland population. 
The study described in this Chapter did examine a range of animal, dust and soil samples 
to determine the presence of Coxiella, and identify those that may pose a risk for infection 
to the human population. 
Chapter 6: Factors Contributing to the Potential Under-Diagnosis of Q fever in 
Queensland 
The incidence of Q fever as gathered by health statistics relies on accurate diagnosis of 
the disease in the laboratory. However, many different diagnostic algorithms are used with 
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different performance characteristics in terms of sensitivity and specificity. In addition, Q 
fever may present with a wide range of symptoms, and therefore is often not considered in 
the wider clinical context. 
This study did examine the diagnostic algorithm used by most laboratories in Queensland 
and determine the rate of successful diagnosis associated with these. In addition, it 
investigated samples submitted for the laboratory diagnosis of infections which present 
with symptoms that may be due to a Coxiella infection, yet have not been tested for this 
disease. This data provided an estimate of the level of under-reporting of Q fever, which 
has a direct impact on the accurate estimation of disease incidence in Queensland. 
Chapter 7: Clinical Case Studies of Q fever from Queensland 
The clinical diagnosis of Q fever infection is often difficult, particularly when the patient 
presents outside the clinical context normally associated with the disease. To highlight the 
diverse range of factors that lead to infection, many not normally associated with traditional 
Coxiella acquisition, a number of case studies was examined, with a particular emphasis 
on the manifestation of Q fever infections in children. 
Chapter 8: Molecular Typing of Coxiella burnetii in Queensland Samples 
At the time of commencement of this study, there were no data regarding the molecular 
epidemiology of Coxiella burnetii in Queensland, and only very limited data regarding 
Australia. Identifying genotypes is important for studies in bacterial evolution and 
pathogenesis, and have an important impact on the design and development of vaccines, 
particularly in the local context. 
The study in this Chapter applied genotypic analysis to identify Coxiella strains circulating 
in Queensland, and examine their relationship to other Australian genotypes, and to those 
that have been reported globally. 
Chapter 9: Development of a Cell Mediated Immunity Assay to Determine Previous 
Exposure to Coxiella burnetii 
One of the serious limitations of vaccination for Q fever in humans has been the range of 
adverse reactions that are associated with pre-vaccination screening using the skin test. 
This is particularly the case for children. Secondly, the skin test, and the determination of 
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Coxiella antibody status are notoriously problematical, and do often not provide an 
accurate assessment of previous exposure to the bacterium. 
This study established and validated a method to measure the cell mediated immunity in 
vaccine candidates, pre-vaccination, by measuring IFN- Ɣ in a cytokine release assay. 
This method has many advantages over existing pre-screening methods, and is highly 
applicable for measuring pre-existing exposure in children. The use of this method may 
allow the wider introduction of the vaccine to population groups that are now excluded 
because of inadequate pre-screening protocols. 
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Research Policy (2011) including codes of conduct, authorship, student integrity and 
misconduct.   
Ethics was requested and granted for the following projects: 
2.1.1. Determining the Seroprevalence of Any Infectious and/or Potentially 
Infectious Agent Including Viruses and Bacteria in the Population. 
Reference HREC 2008/087 
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2.1.2. Review of Q Fever Notifications and Vaccine Coverage in Queensland 
Reference HREC/08/QRCH/66 and Queensland Health RD001050 
2.1.3. Comparison of Laboratory Diagnostic Methods for the Identification of Q 
Fever 
Reference HREC/08/QRCH/88  
2.1.4. Comparison of the Cellular Immune Response and the Humoral Immune 
Response in People Naturally Infected or Vaccinated Against Q fever.  
Reference HREC/10/QRCH/17 and UQ 2010000431 
2.1.5. Prevalence of Q fever in the Environment in Queensland  
Reference HREC/11/QRCH/21. 
2.1.6. A Review of Q fever Cases from Queensland Health. 
Reference Permission granted letter dated: 8th January, 2014 by Professor John Pearn 
(Chair) Children’s Health Services Queensland Human 
2.2. General Methods Applied Throughout the Thesis: 
2.2.1. DNA Extraction for Coxiella burnetii PCR:  
Nucleic acids were extracted from a wide variety of samples for the screening of Coxiella 
burnetii using PCR.  The samples were extracted using commercially available kits from 
Qiagen (Brisbane, Australia). Before DNA sample extraction commenced, a known volume 
of equine herpes virus (EHV) standard, equivalent to 1x104 copies of EHV DNA, was 
added to each of the different sample types.  This step is performed to examine the 
efficiency and reproducibility of the various extraction processes by comparing and 
monitoring Crossing Threshold (CT) values for the EHV standard PCR 1,2. Nucleic acids 
were then extracted using the methods below for each of the various sample types; using 
either the Mini stool kit (Qiagen, Brisbane, Australia), the QIAampDNA Mini kit (Qiagen, 
Brisbane, Australia) or the DNeasy Blood and Tissue kits (Qiagen, Brisbane, Australia)3.  
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2.2.1.1. Extraction of Blood, Milk and Urine 
Both human and animal blood, milk and urine samples were extracted using the DNeasy 
Blood and Tissue kits (Qiagen, Brisbane, Australia) as per the manufacturer’s instructions.  
Briefly, 200µL of each sample was spiked with 5µL of EHV standard and was processed 
using the QIAampDNA Mini kit (Qiagen, Brisbane, Australia), a spin column DNA 
extraction method with DNA being eluted in a final volume of 100uL.   
2.2.1.2. Extraction of Serum Samples 
Serum samples from humans were processed in batches of 95 samples and one water 
sample as a negative control. Samples were extracted using the QIAxtractor semi-
automated system (Qiagen, Brisbane, Australia) according to the manufacturer’s 
instructions. The QIAxtractor DNA procedure involves the specific binding of nucleic acids 
to silica membranes using simple bind, wash, and elution steps.  
During the process, 200µL of serum is loaded to a lysis plate and cell lysis is performed 
using lysis and binding buffers.  The DNA released adheres to the silica filter matrix which 
is then washed using alcohol wash buffers to remove contaminants (PCR inhibitors) This 
is followed by the addition of elution buffer to alter the charge in solution which releases 
the bound DNA from the matrix into a capture plate in a 100µL final volume. These were 
stored in 96 well racks (Matrix, Thermo Scientific, Australia) and stored at minus 80oC.  
2.2.1.3. Extraction of Animal Stool Samples 
Animal stool samples were extracted using the QIAamp DNA Stool Mini kit (Qiagen, 
Brisbane, Australia) following the manufacturer’s recommendations. Briefly, one pellet of 
sample (approximately 1.5-2.0 g) was added to kit ASL buffer for cell lysis and heated to 
95°C for 15 minutes. Inhibitors were removed by absorption using the InhibitEX tablets 
(Qiagen, Brisbane, Australia) followed by centrifugation. DNA in the supernatant was then 
extracted using the QIAamp spin columns as described in the kit insert and DNA was 
eluted in a final volume of 100µL. 
2.2.1.4. Extraction of Whole Tick Samples  
Tick samples were extracted whole using the DNeasy Blood and Tissue kits (Qiagen, 
Brisbane, Australia).  Briefly, ticks were placed on glass slides and the blood and tissue 
was released by teasing out the tick with a scalpel blade.  All parts of the tick were added 
to 200µL of tissue lysis buffer containing 20µL of proteinase K and incubated overnight at 
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56°C on a mechanical rocker at low speed for cell lysis.  The samples were then treated as 
per manufacturer’s instruction.  Briefly, 200µL of lysed tick sample spiked with 5µL of 
standard EHV and was processed using an ethanol buffer and a spin column DNA 
extraction method with the DNA being eluted in a final volume of 100µL.   
2.2.1.5. Extraction of Environmental Soil Samples   
Nucleic acids in soil samples were extracted as by a previously published protocol by 
Fitzpatrick et al. and Kersh et al., using commercially available extraction kits 4,5.  Soil 
samples were pre-treated prior to DNA extraction. Briefly, 5g of soil was mixed with 
phosphate buffer saline (PBS) and put on a mechanical rocker at room temperature for 
one hour.  Samples were then centrifuged for 5 minutes at 123g/800 rpm to remove large 
particles and the supernatant was retained for further centrifugation at 20,000g to pellet 
bacteria.  The pellet was resuspended in 1ml of PBS and used in the DNA extraction 
protocol previously described for the QIAamp DNA Stool kit (Qiagen, Brisbane, Australia), 
where the cellular material was lysed and then inhibitors were removed before continuing 
with the column extraction method and eluting the DNA in a final elution volume of 100µL.  
2.2.1.6. Extraction of Environmental Dust Samples  
Atmospheric dust samples are collected on Whatman glass fibre filter paper with a nominal 
pore size of 1.6µm from a high-volume air sampler (HVS), and were placed in sterile tubes 
containing 5 ml of sterile water. These were incubated at room temperature on a 
mechanical rocker overnight to release bacterial particles, followed by DNA extraction. 
Briefly, 200µL from the 5ml dust suspension was processed using the DNeasy Blood and 
Tissue kits (Qiagen, Brisbane, Australia) following the manufacturer’s method for blood 
extraction using the spin column method.  The DNA was eluted in a final volume of 100µL 
of water for PCR. 
Dust swabs were processed as previously described by Kersh et el 5. Briefly, swabs were 
placed in 1ml of sterile PBS and vortexed for 1 minute to release dust and bacteria trapped 
in the swab.  A volume of 200µL was then processed using the QIAamp DNA Stool kit 
(Qiagen, Brisbane, Australia) as per the previously published protocol by Kersh et al in 
which the PBS containing dust and bacteria are lysed, treated for inhibitors, followed by a 
silica spin column extraction method. Extracted DNA was eluted in 100µL of water for 
PCR. 
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2.2.2. Real-time (RT) PCR Methods 
2.2.2.1. Coxiella burnetii PCR 
Real-time PCR for the detection of C. burnetii was performed using two individual PCR 
assays with specific primers and probes targeting two different gene targets in order to 
increase specificity of the result.  The first gene was that of the repetitive transposon-like 
element IS1111 of the transposase gene, which can be repeated up to 20 times 
throughout the Coxiella genome.  The second gene target was the Coxiella Outer 
membrane (com1) gene, coding for the 27kD protein. Both these assays were previously 
described by Klee et al. (2006a) and Lockhart et al. (2011)(see Table 2.1) 6,7.  
Briefly, each reaction mix consisted of 12.5 µL of Quantitect Probe PCR Mix (Qiagen, 
Brisbane, Australia), 10 pmol of each com1 primers or IS1111 primers, 5 pmol of com1 
probe or IS1111 probe and 5 µL of template DNA in a final reaction volume of 25 µL. 
Amplification was performed in a ABI7500 (Applied Biosystems, Australia) or a Rotor-
Gene Q or a Rotor-Gene 6000 (Qiagen, Brisbane, Australia) using the following cycling 
conditions: 15 minutes incubation at 95°C, followed by 50 cycles of 95°C for 15 seconds 
and 60°C for 1 minute. Previous validation had shown that these instruments gave 
identical results. 
All primers and probes were synthesised by GeneWorks (Hindmarsh ,Australia).  
Lyophilised primers and probes were reconstituted to a standard 200µM stock 
concentration with sterile, distilled water and were stored in a dedicated PCR set up 
laboratory in a -20°C freezer.  Working stocks of primers and probes were made fresh as 
and when required for PCR testing.  The following PCR procedures were followed for all Q 
fever and EHV reactions (Table 2.2 and 2.3).  
2.2.2.2. EHV Real-Time PCR 
EHV real-time PCR was performed on all extracted samples. Briefly, EHV PCR mix 
consisted of 10 pmol each primer; EQHSV-F and EQHSV-R, and 4 pmol of probe EQHSV 
(Table 2.1), and 12.5 ml of Quantitect Probe master mix (Qiagen, Brisbane, Australia). 
This assay was performed in a ABI 7500 (Applied Biosystems) or a Rotor-Gene Q or a 
Rotor-Gene 6000 (Qiagen, Brisbane, Australia) using the following cycling conditions: 15-
min incubation at 95°C, followed by 50 cycles of 95°C for 15 s and 60°C for 1 min. 
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C.burnetii was considered to be present in a sample if a positive result was obtained for 
either gene target. 
Table 2.1: List of C.burnetii primers and probe sequences used for PCR assays 
throughout this thesis including the extraction control primers EQHSV 
Target Gene Name Oligonucleotide Sequence Reference 
IS1111 
Transposase 
Gene 
 
Cox-F  GTC TTA AGG TGG GCT GCG TG 
Klee (2006)6 Cox-R CCC CGA ATC TCA TTG ATC AGC 
Cox-Probe 
FAM-AGC GAA CCA TTG GTA TCGGAC GTT 
TAT GG-BHQ 
com1  
Outer 
Membrane 
Gene 
Com1-F AAA ACC TCC GCG TTG TCT TCA 
Lockhart 
(2007)7 
Com1-R GCT AAT GAT ACT TTG GCA GCG TAT TG 
Com1-Probe  
FAM AGA ACT GCC CAT TTT TGG CGG 
CCA -BHQ1 
Equine Herpes 
Virus  
EQHSV-F GAT GAC ACT AGC GAC TTC GA  
Rockett 
(2011)1  
Schuller 
(2010)8 
EQHSV-R AGG GCA GAA ACC ATA GAC A 
EQHSV-Probe FAM-TTT CGC GTG CCT CCT CCA G-BHQ-1 
 
Table 2.2: Preparations of working stock primers (1:20 of 200M stock) and probes (1:10 of 
200M stock) 
Reagents 
Stock  
Concentration
  
x1 
Final 
Concentration 
H2O  450 µL  
Specific Forward Primer [200µM] 25 µL [10µM] 
Specific Reverse Primer [200µM] 25 µL [10µM] 
Total Volume   500 µL  
Reagents 
Stock  
Concentration 
x1 
Final 
Concentration 
 H2O  90 µL  
Specific Probe  [100µM] 10 µL [10µM] 
Total Volume   100 µL  
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Table 2.3:  Composition of general PCR reaction mix used for PCR reactions in all the 
studies described throughout this thesis 
 
Reagents 
Working 
Concentration 
x1(µL) 
Final 
Concentration 
H2O  6.25  
Quantitect Probe PCR Mix 
(Qiagen) 
 12.50  
Specific Probe [20µM] 0.25 [0.2µM] 
Specific Primers [10µM] 1.0 [0.4µM] 
DNA  5.0  
Total  25.0  
 
2.2.3. Immunofluorescence Assay for Q fever (IFA) 
2.2.3.1. The General Principle of IFA:  
The IFA method used throughout this thesis was an adaptation of the IMVS IFA 
methodology employed by Marmion et al. (personal communication).  
Dilutions of the test serum were placed onto microscope slides previously coated with 
phase I and phase II organisms of C.burnetii. If the serum contained specific antibody, the 
antibodies adhered to the Coxiella antigens during the initial incubation step. After washing 
to remove non-specific antibodies, fluorescein-labelled anti-human class specific 
immunoglobulin conjugate was added. During the second incubation step, the conjugate 
adhered to the patient antibodies bound to the bacterial antigens in the initial incubation 
step. Further washing to remove excess unbound conjugate was performed.  The slides 
were dried and mounting fluid added before examining the slides on a fluorescent 
microscope. If the serum tested contained Q fever antibodies, the organisms with the 
antibodies bound showed apple- green fluorescence as illustrated in Figure 2.1. 
2.2.3.2. Specimen of Choice for IFA  
The sample of choice for the IFA assay is serum stored at 2-8°C for 5-7 days or stored at -
20°C. 
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2.2.3.3. Reagents and Materials used in IFA 
1. Teflon coated microscope slides with 24 wells from Menzel-Gläser (Thermo Fisher 
Scientific Inc , Australia, Cat #  MIC040).  
2. Virion /Serion (Wurzburg, Germany) C. burnetii phase I (Cat # 1227) and phase II (Cat 
# 1123) organisms lyophilised. Stored at 2-8 ⁰C. 
3. PBS -phosphate buffered saline pH7.2  
4. 3% Chicken yolk sac (CYS) in PBS (IMVS - Adelaide, South Australia) - 
i. Stock solution stored at –20 ⁰C.   
ii. Working solution (0.5% suspension): Used for serum dilution and antigen 
preparation.   
5. Controls - Positive and negative control sera, pooled from previously characterised 
specimens. 
6. Anti-human IgG (Sigma - Cat # 982041020 GDF) and anti-human IgM (Sigma -Cat # 
983031020 MAF), both FITC conjugated. Stored at 2-8 ⁰C. Fresh dilutions were made 
for each test batch. 
7.  Evans Blue dye – for counterstaining cells; 1 drop of dye (10% solution) to 5 ml of 
PBS, stored at 2-8 ⁰C; also used in conjugate dilutions. 
8.  Buffered glycerol mounting medium pH 8.0 – 8.4. 
2.2.3.4. Equipment and Apparatus: 
1. 37°C incubator 
2. Microscope: Nikon Eclipse E600; Excitation peak wavelength = 490 nm, Emission 
peak wavelength = 520 nm 
3. Wash station with magnetic stirrer 
4. Microtitre  plates with 96 U bottom wells for serum dilutions 
2.2.3.5. Slide Preparation: 
1. Clean microscope slides with methanol and rub with tissue to remove any residue if 
required, label slides. 
2. Reconstitute the vial of phase I and phase II CF antigens with 1 ml of distilled H2O as 
per manufacturer’s instructions. Mix well. 
3. Dilute the rehydrated commercial antigens 20 times with 0.5% CYS. 
4. Require 3ml of working antigen suspension to make 25 (24 well) slides. 
 60 
 
 
For example:  150μL reconstituted antigen 
500 μL 3% egg yolk sac 
2350 μL distilled water 
5. Add 4μL of the suspensions to each well and allow to air dry. 
6. When fully dry, immerse the slides in methanol for 5 minutes, to fix the organisms. 
7. Remove slides from the methanol and allow to dry for 10 minutes. 
8. Place the slides into labelled boxes for storage at - 20°C 
2.2.3.6. Screening Assay Method 
1. Remove the required number of slides from the storage box in the freezer and place in 
a humid chamber whilst preparing serum dilutions. Ensure the slides are well dried by 
placing in the drying chamber for a few minutes before adding specimen dilutions. 
2. Use a microtitre plate to prepare specimen and control dilutions. 
3. For IgG testing - for patient and control sera, prepare 1:10 dilutions by pipetting 10μL 
serum to 90μL of 3% CYS in dedicated microtitre plate. 
4. For IgM testing - for patient and control sera, add 10μL of serum to 70μL of RF 
Absorbent plus 20μL of 3% CYS in dedicated microtitre plate. 
5. Label the slides with control and specimen dilution numbers, phase type and specific 
immunoglobulin.  Load 10μL of each dilution (controls and sample) to the appropriate 
slides. 
6. Incubate for 30 minutes at 37°C in a moist chamber. 
7. Wash all slides in fresh PBS buffer, employing a brief rinse followed by two 5-minute 
washes in wash station with stirrer, and finally a brief rinse into distilled water. 
8. Gently blot all slides before air-drying. 
9. Calculate the amount of each conjugate needed, allowing for 10 μL / well. Conjugate 
dilutions are on each reagent bottle; dilute in PBS with Evans blue 1/100 
counterstaining of the FITC IgG  (previously determined for specific lot number) 
10. Add 5-10 μL of specific conjugate to the appropriate wells; incubate for 30 minutes at 
37 °C. 
11. Repeat the washing and drying steps. 
Apply mounting fluid and coverslip for each slide and examine the slides using a 
fluorescent microscope at a magnification of x100 for apple green fluorescence (Figure2.1)  
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Figure 2.1: Image: Fluorescence observed of Coxiella phase II bacteria following staining 
with positive human IgG antibodies (100x magnification). 
2.2.4. Commercial CFT Antigen: Coxiella burnetii whole cell bacteria 
Whole cell bacteria suspensions (C.burnetii - Nine Mile Strain) were used in the 
preparation of both IFA slides, and as a positive control for all PCR assays.  The bacteria 
were obtained commercially from Virion /Serion (Wursburg,Germany – Table 2.3) in the 
form of whole cell bacteria, formalin inactivated phase I and II from the Nine Mile strain.   
This source of whole cell bacteria was used as a control to validate PCR assays, and 
strain typing methods. 
Table 2.4: Coxiella burnetii antigen used in IFA; catalogue numbers - Source: Virion 
/Serion (Wursburg,Germany). 
Antigen                       Catalogue  Number 
Coxiella burnetii (phase I) 1227 
Coxiella burnetii (phase II) 1123 
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2.2.5. Commercial ELISA Kit Method for Q fever Antibody Screening 
The Panbio (Brisbane, Australia) Coxiella burnetii (Q fever) ELISA kits were used for the 
qualitative detection of IgG and IgM antibodies to C.burnetii in serum.  This is a commonly 
used tool in the clinical diagnosis of Q fever as well as a tool for assessing immune status 
in potential Q fever vaccination candidates.  The presence of Q Fever IgM antibodies is 
highly suggestive of recent or active Q fever infection.  Presence of Q fever IgG antibodies 
indicates previous or resolving infection.  
2.2.5.1. Principle of the Q fever ELISA 
Diluted patient serum containing IgM or IgG class antibodies bind with C. burnetii antigen 
(Henzerling strain), which has been fixed to the polystyrene surface of a micro-well in a 
microtitre plate.  After washing, to remove all unbound antibodies and excess serum, 
peroxidase conjugated, anti-human IgG or IgM class-specific antibody, is added to the 
wells which in turn bind to the immobilised patient’s C.burnetii antibodies.  After a second 
washing to remove unbound conjugate, a colourless chromogenic substrate, 
tetramethylbenzidine (TMB) is added. On incubation this produces a blue colour reaction, 
which is stopped using acid producing a yellow end colour. The optical density of the final 
colour can be read with an ELISA plate reader. 
In the IgM assay, patient’s samples are initially treated with absorbent solution designed to 
reduce non-specific reactions by removing competing IgG antibody that may cause false 
negatives and rheumatoid factor that may cause false positive reactions. 
2.2.5.2. Specimens for Analysis 
The sample of choice is serum stored at 2-8°C for 5-7 days or stored at -20°C. 
2.2.5.3. Reagents Used 
2.2.5.3.1. The Q Fever IgG ELISA Test Kit (Panbio QFB01G). 
Contains:  
• C. burnetii Phase-II (Henzerling strain) Antigen Coated Microwells (12x8 wells). 
• Serum Diluent: Two bottles 50ml (pink) Tris buffered saline. Ready for use. 
• Positive Control: Red capped vial, 200µL of human serum. 
• Negative Control: Green capped vial, 200µL of human serum. 
• Cut-off Calibrator: Yellow capped vial, 400µL of human serum. 
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• Conjugate: 15ml (green) Horseradish peroxidase conjugate sheep anti-Hu IgG. 
 
2.2.5.3.2. The Q Fever IgM ELISA Test Kit (Panbio QFB01M)    
Contains:    
 C. burnetii Phase-II (Henzerling strain) Antigen Coated microwells (12x8 wells). 
 Serum Diluent IgM: One bottle 22ml (pink) Tris buffered saline. Ready for use. 
 Serum IgG Absorbent: 22ml (blue) goat anti-human IgG (precipitating antibody to 
remove competing IgG antibody and rheumatoid factor) 
 Positive Control: Black capped vial, 200µL of human serum. 
 Negative Control: White capped vial, 200µL of human serum. 
 Cut-off Calibrator: Orange capped vial, 400µL of human serum. 
 Conjugate: 15ml (yellow) Horseradish peroxidase conjugate sheep anti-Hu IgM. 
 Generic Reagents for both assays: 
 Substrate: Tetramethylbenzidine (TMB) 15ml with hydrogen peroxide. 
 Stop Solution: 15 ml of 1M Phosphoric Acid. 
 20X Wash Buffer Concentrate: 60 ml of phosphate buffered saline with 
detergent. Prepare a working solution by diluting the 20X solution to make up a 
final volume of 1200 ml with distilled water. Make up in Wash Bottle A and store 
the remaining portion in a reagent bottle at room temperature for future use.  
Label the bottle with the lot number and expiry date. 
Procedure: 
 Each test serum, control and cut-off calibrator must be diluted 1:100. Use a clean 
microtitre plate to prepare the initial dilutions.   
 NB: IgG and IgM dilution procedures are different. 
Q Fever IgG 
 Add 90µL of kit Serum Diluent to the required number of wells of a microtitre plate. 
 Add 10µL of each patient serum, controls or cut-off calibrator to give a 1:10 dilution.  
 Add 180µL of Serum Diluent to the required number wells of a microtitre plate. 
Using a multichannel pipette transfer 20µL from each well of the previous step to 
the Serum Diluent in the second ELISA plate to give a 1:100 dilution. 
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Q Fever IgM 
 Add 90µL of Serum Diluent to the required number of wells of a microtitre plate.   
 Add 10µL of each patient serum, controls or cut-off calibrator to give a 1:10 dilution.  
 Add 180µL of Serum Absorbent to the required number of wells of a microtitre plate.  
Using a multichannel pipette transfer 20µL from each well of the previous step to 
the Serum Absorbent in the ELISA plate to give a 1:100 dilution. 
General steps for both IgG and IgM ELISA 
1. Seal the wells, and incubate the plate for 30 minutes at 37°C. 
2. Wash the plate with working Wash Solution 6 times using wash procedure outlined 
below.  Turn the plate upside down and tap firmly on a paper towel to remove 
excess wash solution. 
3. Add 100µL of the appropriate IgG or IgM conjugate to each well. 
4. Reseal and incubate the plate for 30 minutes at 37°C. 
5. Wash the plate as described previously. 
6. Add 100µL of TMB substrate to each well. 
7. Reseal the plates; incubate for 10 minutes at room temperature.  
8. A blue colour will develop. 
9.  Add 100µL of stop solution to each well. The blue colour will change to yellow. 
10. Read each reaction in dual wavelength mode at 450nm and 620nm within 30 
minutes. 
Washing Procedure 
1. Discard contents of plate in appropriate waste container 
2.  Fill wells with wash buffer using a suitable squeeze bottle. (Avoid bubbling of wash 
buffer as this may reduce wash efficiency) 
3. Discard wash buffer from wells immediately 
4. Refill wells with wash buffer and discard immediately 
5. Repeat step 3 another 4 times (This will make a total of six washes) 
6. After the final wash, discard contents of wells and tap the plate on blotting paper to 
ensure all wash buffer is removed.  
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Reading Results 
The mean cut-off absorbance value is determined.  Those cut-off values lying more than 
10% outside the mean should not be used and the mean cut-off value must be 
recalculated. The cut-off is also corrected with the calibration factor noted on the 
specification sheet accompanying each kit (lot specific). 
   Cut-off value = Mean absorbance of calibrators x calibration factor. 
  Panbio units (PBU) = Sample Absorbance x 10 times Cut-off value 
Run Validity 
For an assay to be valid, the control samples must be within a range of predetermined 
values. Acceptable values for positive and negative controls, the cut-off calibrator and 
positive/cut-off ratio are provided in the specification sheet accompanying each kit.   
Result Interpretation 
The upper limit for negative results is 9 PBU. Test sera with less than 9 PBU are 
considered Non-Reactive for IgG or IgM antibodies to Q fever. 
The lower limit for positive results is 11 PBU.  Test sera with greater than 11 PBU are 
considered Reactive for IgG or IgM antibodies to Q fever. 
Sera tested for IgM, and IgG with values between 9 and 11 PBU, should be repeated as 
the result is deemed Equivocal (Table2.5). 
 
Table 2.5: Interpretation of Panbio ELISA kit results for test sera 
PBU Result Interpretation 
<9 Negative No detectable IgM antibody to Q Fever. 
9 - 11 Equivocal 
Presence or absence of detectable levels of 
IgG antibody to Q Fever cannot be determined. 
The test should be repeated. 
>11 Positive Detectable levels of IgM antibody to Q Fever. 
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2.2.5.4. Equipment and Apparatus Used in the Assay 
1. Wash bottles 
2. ELISA Plate Reader: Molecular Devices Spectramax 340PC384 plate reader 
3. 37°C Incubator 
4. Microtitre plate with 96 U bottom wells for serum dilutions 
5. ELISA plate sealers 
2.2.6. Performance Characteristics of the IFA and ELISA for IgG Antibody Detection  
The IFA and ELISA methods were used throughout this study to determine IgG 
seroprevalence to Coxiella. Therefore the performance characteristics of these assays 
were established. 
2.2.6.1. Serum Samples Used to Determine Performance Characteristics 
De-identified serum samples (n=2122) collected from patients with non-Q fever related 
infections were obtained from public and private pathology laboratories. Queensland 
Health Pathology Services – Central Laboratory at Herston, and the Toowoomba Hospital 
servicing the highest risk rural region in Queensland (postcode 4350)– provided serum 
samples collected between October 2008 and June 2009. De-identified sera were also 
obtained from a private pathology laboratory for previous investigation into allergies in 
children. These samples were collected from January to May, 2007 and from January to 
April 2008, and were used to determine the performance parameters of the IFA and 
ELISA.  
2.2.6.2. Evaluation of the IFA and ELISA Methods for Screening Human Sera 
Of the 2,122 specimens examined, there were 98 (4.6%) that were positive for Coxiella 
phase II IgG by both screening methods (IFA and Panbio ELISA) and 1997 (94.1%) 
samples that were not detected by either method. There were 27 (1.3%) discordant results 
(Table 2.6).  Further testing was performed on the 27 discordant results using the 
commercially available IFA (Focus Diagnostics, Cypress, USA). Of the 21 IFA positive, 
ELISA negative samples: 11 were confirmed to be positive. Of the 6 IFA negative/ELISA 
positive results, none were confirmed as positive (Table 2.7). This resulted in a total of 109 
positive specimens for further analysis: 98 with both screening assays positive, and 11 
positive following subsequent discrepant testing.  
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Table 2.6: Summary of results for IFA versus ELISA screening on 2122 serum samples, 
showing 27 discrepant results which are highlighted in red. 
Method Result IFA Detected IFA Not Detected 
ELISA Detected 98 6 
ELISA Not Detected 21 1997 
 
Table 2.7: Summary of the discordant results from serology screening and confirmation 
testing by commercial IFA assay as the reference standard showing 11 results confirmed 
as positive 
Test Results Discrepant Results Focus IFA Detected Result 
IFA Detected/ 
ELISA Not Detected 
21 11 
ELISA Detected/ 
IFA Not Detected 
6 0 
 
From the above the number of true positives was determined as 109, and the number of 
true negatives as 2013. Using this algorithm for defining positive and negative results, the 
performance characteristics of the IFA and ELISA were established and shown in Table 
2.8. 
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Table 2.8:  Performance parameters for the IFA (IMVS) and indirect ELISA assays used to 
determine the seroprevalence in human sera. * Positive Likelihood Ratio was determined 
 IFA (IMVS Method) ELISA 
Sensitivity 100% 96 – 100% 95.6% 90 -99% 
Specificity 99.5% 99 – 100% 99.7% 99 – 100% 
Positive Predictive Value 91.6% 85 – 96% 95.6% 90 - 99% 
Negative Predictive Value 100% 99 – 100% 99.7% 99 – 100% 
Positive Likelyhood Ratio* 202.3 109 – 375 385.9 160 - 927 
 
.    
These results showed that sensitivity and specificity of the two assays were highly 
comparable, and supported the results previously published by Herremans et al9. 
2.3. Significant Outcomes from this Chapter 
 The IFA and ELISA proved to be sensitive and specific methods for the detection of 
Coxiella antibodies 
 Both the assays have a high positive and negative predictor value, ensuring a high 
correlation with previous exposure to Coxiella 
 Due to the reliability and performance parameters met, these assays will be used 
throughout the studies for the detection of C.burnetii antibodies 
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3.1. Introduction 
3.1.1. Surveillance of Q Fever in Australia 
Since 1917, Australia has had a national notifiable disease surveillance system for 
monitoring infectious diseases, in which data were collected by individual states and 
territories under public health legislation.  It was the responsibility of the medical 
practitioners to notify the relevant health authorities of certain communicable diseases and 
other infectious agents.  The data were collated and results were distributed to medical 
professionals via medical journals such as the Medical Journal of Australia and the 
Commonwealth Departments’ Journal of Health along with the Commonwealth Year Book 
1. The National Notifiable Disease Surveillance System (NNDSS) was implemented in 
1990 under the Communicable Disease Network, Australia, in which more than 50 
communicable diseases were monitored.  This system, enforced under current Public 
Health legislation, requires that local health authorities notify the relevant State or Territory 
Health Departments.  This reporting system distributes patients’ de-identified records to 
the Australian Government Department of Health on a daily basis.  Subsequently, 
information is made available to the Commonwealth agencies via the Communicable 
Diseases Intelligence Journal and a fortnightly reports from the Communicable Diseases 
Network Australia (CDNA) (http://www.health.gov.au/cdnareport). 
There are many levels involved with disease surveillance within Australia.  The 
responsibility at a national level is to provide assistance in prevention and control of public 
health issues involving communicable diseases along with implementing strategic 
measures in the event of public health outbreaks and to minimise the impact of 
communicable disease transmission within the immediate region. 
For Q fever, Australia has been collecting data since 1952, focusing on gaining a more in-
depth understanding of the disease epidemiology and subsequent disease burden2 . The 
data are collected by the Communicable Disease Departments in each Australian state 
and territory. In Queensland, these data are collated and managed using the Notifiable 
Conditions System (NOCS), and compiled data are then provided to the NNDSS.  A 
national case definition has been developed to allow recognition of Q fever cases and its 
documentation (Table 3.1)3. 
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Table 3.1: Case definition and laboratory parameters used to diagnose Q fever3 
  
Q fever Case definition 
National definition from January 2004  
Only confirmed cases are notifiable. Confirmed cases require either laboratory 
definitive evidence or laboratory suggestive evidence together with clinical evidence.  
a. Laboratory definitive evidence  
o Detection of Coxiella burnetii by nucleic acid testing; or  
o Seroconversion or significant increase in antibody level to phase II 
antigens in paired sera tested in parallel in absence of recent Q fever 
vaccination.  
b. Laboratory suggestive evidence  
o Detection of specific IgM in the absence of recent Q fever vaccination.  
c. Clinical evidence  
o A clinically compatible disease. 
 
Q fever has a wide diversity in the presentation of symptoms, including infections which 
may be asymptomatic.  As a result, it is a disease that is underreported  in Australia  and 
the rest of the world 4,5. 
In Australia, the disease Q fever is most  frequently identified in patients residing in rural 
Queensland and northern New South Wales  who typically have contact with large 
ruminants 6.   The disease is of public health concern, with the potential to cause extensive 
outbreaks, as recently occurred in The Netherlands7.  Hence, surveillance for the disease 
is of utmost importance and should be continuous, with the results made available to 
veterinary and health professionals world-wide in order to reduce wide-spread disease and 
to be able to limit or at least control potential outbreaks.   
The continual collection of Q fever disease data in Australia via NOCS, has highlighted the 
importance of identifying and monitoring those at risk of contracting the disease, and 
hence provides valuable information for the initiation of extensive screening programs and 
vaccination strategies within Australia. These strategies led to the establishment of the 
National Q fever Management Program (NQFMP)8 in the year 2000, which was an 
Australian and world-first in the prevention of Q fever disease. 
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The NQFMP sought to raise education and awareness of those at risk of Q fever in high 
risk areas, along with providing medical staff with clinical and diagnostic background.  The 
program included extensive Q fever pathology screening of at risk subjects followed by 
vaccine administration, and was initiated in 2001 in Queensland South Australia, Victoria 
and Western Australia as stage 1. The second stage of the program, stage 2, commenced 
in 2002 in the Australian Capital Territory and New South Wales.  The Northern Territory 
reported very few cases, and opted out of the Federal Government program8. This 
program was funded nationally and was concluded at different times between June 2004 
and December 2006 in different jurisdictions6. It was designed to identify subjects at “high 
risk” through extensive analysis of the national notification data over time.  Such analysis 
highlighted that abattoir workers and farm workers were most at risk and should receive 
the vaccine immediately, and that veterinarians and other animal handlers (tanners, 
boners, butchers and shearers) should be offered the vaccine as a second stage to the 
program.  
3.1.2. Australian Demographics and Q Fever 
Australia has a total population of 23,625,600 inhabitants as of June 2014, and has one of 
the highest rates of Q fever disease globally, excluding outbreak episodes. Between 1954 
and 2014 Australia had over 20,000 clinically confirmed cases of Q fever reported to the 
national surveillance units, despite this being a vaccine preventable disease9 (Figure 3.1).  
Australia has three times as many Q fever cases as are reported in the European Union, 
and records more than six times the number of cases diagnosed in the United Kingdom6.  
In addition, Australia had the highest annual notification rate recorded in 1993 at 4.9 cases 
per 100,000 persons. However, a rapid decrease followed  the implementation of  the 
NQFMP in 2000, after which rates dropped by more than 50% in the subsequent years of 
2005-20066.     
Laboratory diagnosis of Q fever in patients in Australia has been ongoing since 1936 and 
results have been included on the national surveillance register for over 60 years.  There 
have been a number of notable outbreaks of Q fever recorded nationally during this time, 
highlighting once again the importance of the surveillance program (Table 3.2). 
 
  
 
 
7
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Figure 3.1:  Australian Q fever notifications for 1954 to 2014. These data show Q fever rates that are twice those reported in 
France, a country that invests a large amount of time and resources into Coxiella research52.   
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Table 3.2: Small and medium size outbreaks of Q fever in Australia 
 
3.1.3. Queensland Demographics and Q Fever 
Queensland has over 20% of Australia’s total population, and geographically is the second 
largest state in Australia with an area of 1,730,648 square kilometres. It is the third most 
populous state with over 4.56 million inhabitants as of 2013. This equates to a population 
density of 2.6 persons/km2 ,22.  South-East Queensland, including the Statistical Divisions 
(SDs) of Brisbane, Gold Coast, Sunshine Coast and West Moreton has 3 million 
inhabitants residing in this sector, which is approximately two-thirds of Queensland's 
population (Figure 3.2)23. Queensland is classified into 452 postcodes of which 293 are 
classified as “rural”. 81% of Queensland’s land is used for farming and agriculture24. 
Year                          Event Reference 
1957 An outbreak (52 cases) was reported in a meat-works in 
Adelaide, South Australia.  
Beech10 
1959 An outbreak of Q-fever in Queensland was associated with 
sheep contact.  
Derrick 11 
1969 An outbreak in a Brisbane "meat works" affected 7.9% of 
workers. 
McKelvie12 
1979 An outbreak (110 cases) was reported at an abattoir in 
Victoria.  
Buckley13 
1998 An outbreak (29 confirmed and 8 suspect cases) was reported 
at an abattoir in New South Wales.  
No Author14 
2004 An outbreak (9 confirmed and 6 suspect cases) was reported 
among farmers in South Australia.  
Gilroy15,16 
2005  An outbreak (5 cases) was reported among persons involved 
in calving activities, in New South Wales.  
Rodriguez17 
2006   An outbreak (4 cases) was reported among workers at a 
cosmetics factory.  
Wade18 
2006  An outbreak (27 cases) was reported in rural South Australia.  Turra19 
2007 An outbreak (5 cases confirmed, 1 possible fatal case) was 
associated with an abattoir in South Australia.  
ProMED20 
2013 An outbreak was reported among cats in a veterinary hospital.  Kopecny21 
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To date there are no extensive data on the rates of Q fever in Queensland in the literature, 
and although statistical data has been gathered, this has not been analysed and 
published. Two previous publications exist, presenting snap-shot data reviewing the 
national rates of Q fever disease over very short time periods. These data suggest that 
Queensland may contribute a large percentage of cases to the national disease figures 
6,25. 
 
Figure 3.2: Population density for Queensland at 201126 
3.1.3.1. Age Distribution of the Queensland Population 
Globally, Q fever has been reported primarily in adults and was rarely reported in children 
except in unique cases27. Also, Q fever disease is mainly diagnosed in abattoir workers,  
farmers and vets and hence the disease is associated with the age groups of the “working” 
population (20 to <60 year olds)28.   Australia has approximately 12,521,000 people in this 
working age group or 55% of the Australian population.   
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 In 2010, the average age group of Queenslanders was between 35 -39 years old with the 
median age at 36.2 years. The median age of Queensland males was 35.5 years and for 
Queensland females it was 36.9 years.  In Queensland, 54% of the population were aged 
20 to <60  years  as of 201229. Approximately 20% of Queensland’s population or 901,452 
persons are children under 15 years of age (Table 3.3).  
 
Table 3.3: Distribution of age groups in the Queensland population at 2014 29 
 
. 
Queensland 
Age group (years) Total Persons 
0–4 309 885 
5–9 297 766 
10–14 294 736 
15–19 305 448 
20–24 328 037 
25–29 332 950 
30–34 309 774 
35–39 313 356 
40–44 330 119 
45–49 309 744 
50–54 304 866 
55–59 268 547 
60–64 247 851 
65–69 205 768 
70–74 145 046 
75–79 104 437 
80–84 78 654 
85–89 48 094 
90–94 19 796 
95–99 4 594 
100 and over 591 
All ages 4 560 059 
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3.1.3.2. Queensland Population and Gender 
In 2012 the Australian population had a male to female ratio of 0.989:1 26, and in 
Queensland this ratio was 1:1, with the ratio only varying in the elderly age groups (Table 
3.4).  
Previous published data for Australia show that Q fever predominantly affects males6,25. 
An Australian review of cases between June 1962 and June 1981 showed that all but one 
of 111 consecutive Q fever cases occurred in males, and medical review showed that the 
single case reported in a woman may have originated outside Australia28,30. Of the 111 
cases reviewed, 93% of the infected males were abattoir workers.  During 1991-1994, the 
male to female ratio of Q fever disease  in the 20 to 50 year old age group, was 5:125. 
Based on these data the working age group referred to by many Q fever publications is 
gender specific and emphasizes Q fever as a disease that effects working age men in 
occupations involving contact with animals28. 
3.1.3.3. Queensland Primary Industries 
Previous notification data for Australia (2006)6 have shown that cases of Q fever have 
largely been diagnosed from patients in geographical locations with a high percentage of 
livestock usage, and where agriculture is the primary occupation. Queensland livestock is 
widely distributed and consists predominantly of cattle and sheep. In 2010, Australia had 
more than 2.4 million head of dairy cattle, over 25 million head of beef cattle, and over 68 
million head of sheep with total livestock commodities valued at AU $19,073 million31.   
Queensland has nearly three times the number of cattle, including dairy cattle, as it does 
sheep with the rural farming industry being  responsible for livestock commodities worth 
AU $4,653 million (Table 3.5) 31.   Grazing occupies approximately 82% of the total area of 
land usage, and Queensland is the leading beef-producing state in Australia with a large 
percentage of its population working both directly and indirectly in the livestock and or beef 
industries (Figure 3.3)32.   
Sheep farming has been one of Queensland’s main primary industries since the 1840’s. 
The current sheep belt covers an area of about 55 million hectares, with a large supply of 
lambs for the meat industry being raised on farms on the Darling Downs.     
 
 
 80 
 
 
Table 3.4: Queensland population by age and gender for 2014. 
 
 
 
 
 
 
 
 
 
 
 
Table 3.5: Queensland livestock distribution in 2010. 
Queensland Livestock 2009-2010 Total Numbers 
Sheep and lambs 3 622 141 
Dairy cattle 162 200 
Meat cattle 11 193 348 
Other livestock – Goats 49 141 
Queensland 
Age group (years) Females Males Ratio 
0–4 150 837 159 048 1.1 
5–9 144 600 153 166 1.1 
10–14 143 682 151 054 1.1 
15–19 149 288 156 160 1.0 
20–24 162 741 165 296 1.0 
25–29 165 016 167 934 1.0 
30–34 154 896 154 878 1.0 
35–39 157 713 155 643 1.0 
40–44 166 923 163 196 1.0 
45–49 156 430 153 314 1.0 
50–54 154 155 150 711 1.0 
55–59 135 291 133 256 1.0 
60–64 123 847 124 004 1.0 
65–69 102 461 103 307 1.0 
70–74 72 918 72 128 1.0 
75–79 54 981 49 456 0.9 
80–84 44 273 34 381 0.8 
85–89 29 659 18 435 0.6 
90–94 13 368 6 428 0.5 
95–99 3 409 1 185 0.3 
100+ 488 103 0.2 
All ages 2 286 976 2 273 083 1.0 
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3.1.4. Seasonal Conditions and Q Fever 
During any given season, Australia and Queensland experience a widely divergent 
weather pattern across the continent, consistent with desert, temperate and tropical 
conditions. Queensland’s average temperature over the past 10 years was 23.4 °C with an 
average annual rainfall of 656 mm over the state.   
 
Figure 3.3:  Geographical distribution of cattle  numbers in Queensland per property as at 
April 200832.  
(Blue and green indicate cattle numbers, red and orange are population densities). 
 
In dry areas of Queensland the weather phenomenon may also include the initiation of 
dust storms which carry dust particles, including bacteria, into the atmosphere. These may 
be carried over large distances33.  Atmospheric dust particles are between 0.001 - 40 µM 
in size, and settle at a rate depending on their size. Bacteria are between 0.3 – 60 µM and 
are considered to be medium sized particles which can take days to years to settle out of 
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the atmosphere34.  Dust storms may occur locally, or may be widely distributed to diverse 
geographical locations by favourable atmospheric conditions 35. 
Coxiella burnetii is known to infect humans via airborne transmission, and previous studies 
have detected C. burnetii DNA in inhalable dust samples, demonstrating that low levels of 
the bacterial DNA were present in inhalable sized fractions36. 
Australian data showed that Q fever may be acquired in any given month throughout the 
year, yet many studies report a correlation between the onset of disease with spring and 
the birthing of new animals37. The seasonal presentation of Q fever is still being studied 
globally, and research in France has examined  the correlation between wind and Q fever 
cases  in that country 38.  However, Australian cases recorded and reviewed from 
Townsville, highlighted increases in  notifications after seasonal rainfall and increasing 
animal populations following the wet season; hence the disease was thought to be 
associated with rainfall rather than the season of Spring and/or the birthing season39. 
3.1.5. Vaccination and Q Fever 
Q fever is a vaccine preventable disease, and there has been a commercially available 
vaccine in Australia from the Commonwealth Serum Laboratories (Victoria, Australia) 
since 1989.  The vaccine, Q Vax®, has been targeted at workers in high risk occupations, 
in particular those working in abattoirs, and has contributed to the reduction of Q fever 
cases nationally in workers in “at risk” occupations40.  The national financial impact of Q 
fever disease on the community was estimated (1993-1994) at AU$1million or 1700 weeks 
of lost work, with financial estimates of AU$3,800 – AU$ 7,000 per patient41.  The costs 
associated with an individual case of chronic Q fever have been estimated at AU$20,500, 
and in 1997 there were workers compensation claims paid of AU$1.1million dollars42. 
3.2. Specific Aims Addressed in this Chapter: 
There has been only limited examination of the incidence of Q fever in the Queensland 
population. These data are important in order to assess (i) the true incidence of disease 
over an extended period of time, (ii) the correlation with specific population groups, (iii) the 
identification of risk factors for infection, and (iv) the formulation of an effective vaccination 
strategy.  
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This chapter examines Q fever notification data collected for the Queensland population 
for the year 1984-2014. Specifically the analysis addressed the following: 
 The temporal distribution of Q fever among the Queensland population 
 Identifying the populations most at risk of infection 
 The spatial distribution of Q fever notifications within Queensland 
 Distribution of Q fever notification with gender and age groups 
 Q fever in children 
 Correlation between Q fever and Queensland weather patterns 
 Association between notifications and known risk factors 
 
3.3. Methods 
3.3.1. Data Used in the Analysis 
Notification data forwarded to the NOCS, Department of Health, Queensland, between 
1970 and 2014 were used in the analyses described in this Chapter. Notification data for Q 
fever have been collected since 1970; however,extensive data have only been collected 
since 1984. So far there has been no publication regarding the analysis of these data.  
These data included a unique identification number, demographic details such as time 
period for onset of disease, patient age, gender and geographical location of residence 
using the Australian Bureau of Statistics Local Areas (SLA) and postcodes.  Specific 
employment history and animal contact was requested by NOCs but was not always 
obtained or provided, or was frequently included as an “uncertain” category in the reporting 
of Q fever cases.  The data regarding employment and exposure risks have been included 
but are limited.   
3.3.2. Analysis of the Data 
The NOCS data were compared to national data previously published for Australia, which 
was limited in scope, and even less data have been generated and published for 
Queensland.  Data available for comparison have been restricted to snap-shots of either 
Australian notifications or discrete data generated from other states. 
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All Q fever notification data were based on laboratory confirmation of disease. There have 
been a number of different laboratory testing methods used over time to determine 
disease status, but details of these methods were not included in the data sets obtained 
and were not included in the analyses. 
3.4. Results 
3.4.1. Temporal Distribution of Q Fever Notifications 
From the years 1970 to 2014, 18,669 cases of Q fever were reported in Australia. For the 
same time period 6,797 cases, or 36.4% (95% Confidence Interval (CI) 35.7%-37.1%) of 
the total number of national cases, were recorded in the Queensland NOCS (Figure 3.4).  
During the last 31 years (1984-2014), a vaccine for Q fever has been available, and more 
comprehensive data collection has occurred. During this period Australia has recorded 
14,443 notifications, for which Queensland reported 6,794 cases or 47% (95% CI 46.2% to 
47.9%) of the total notifications.   
Notification data collected since 1970, show that three peaks of disease occurred in 
Australia in 1979-80 (which included an outbreak in Victoria of 110 cases), in 1993-94 
(during limited vaccine usage) and 2001-02 (when the NQFMP had already been 
implemented nationally). Comprehensive Queensland data were available from 1984 
onwards and on analysis showed coincident peaks for the years 1993 and 2001 with other 
Australian outbreaks. In 2001 the number of cases in Queensland totalled 444 or 65% of 
the national total, and occurred at a time when the Q fever vaccine had been available for 
10 years and recommended to the high risk groups in the community. 
3.4.2. Geographic Location 
Q fever notifications were recorded in both rural communities and urban cities of 
Queensland, and included data from 386 of the 452 postcode divisions in Queensland. 
This equates to more than 85% of the State’s regions. Figure 3.5 shows the geographical 
distribution of the 6,749 Q fever notifications across Queensland for the past 31 years from 
1984 to 2014. Metropolitan Brisbane, the capital of Queensland, with a central business 
postcode of 4000, recorded 128 notifications, being the 6th highest notification rate of the 
State. There were 69 postcodes that have recorded 50 notifications or more for the 31 
year period (Table 3.6).  The postcode/geographical region with the highest notification 
 85 
 
 
rate recorded was postcode 4350 with 337 notifications.  This corresponded to the regional 
city of Toowoomba in the District of the Darling Downs. The regions of Queensland with 
the second highest notifications recorded were postcodes 4470, 4455 and 4487 (Table 
3.6).These postcodes correspond to the district of South West Queensland and include the 
rural towns of Charleville, St George and Roma (Figure 3.6).   
 
Figure 3.4: Q fever notification data for Queensland and the rest of Australia from 1970-
2014. NB: Data was collected from other Australian States before 1970.  Queensland only 
began recording complete notification data in 1984 
 
A preferred method to directly compare infections or disease rates within communities is 
an estimation of number of infections per capita. However, the Australian Bureau of 
Statistics did not have specific population numbers for specific postcodes. It also did not 
have population numbers for every year in which Q fever notifications were collected. The 
population numbers were based on census years and these occur at 5 year intervals. 
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For this reason the notifications were expressed as a single whole number. This is the 
next best estimate of Q fever incidence, and in fact the only method possible with the data 
available. 
Table 3.6: Postcodes of Queensland notification data highlighting the regions with more 
than 50 notifications for the 31 year period (1984 to 2014). 
Postcode Notifications 
4350 337 
4470 179 
4455 166 
4487 159 
4370 147 
4000 128 
4570 126 
4305 116 
4285 115 
4700 114 
4421 106 
4390 95 
4207 93 
4352 93 
4490 92 
4610 85 
4816 75 
4701 73 
4472 72 
4810 70 
4872 70 
4870 69 
4465 66 
4702 66 
4306 61 
4102 57 
4343 57 
4405 57 
4740 57 
4800 55 
4605 54 
4730 54 
4883 52 
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Figure 3.5: Queensland map showing the distribution of Q fever notifications as a visual 
for 1984 to 2014 by postcode. 
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Figure 3.6: map pf Queensland showing visually Queensland’s postcodes with the highest 
notifications over a 31 year period (1984 to 2014) 
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3.4.3. Gender 
Although Q fever is usually associated with men working in “at risk” occupations, it is a 
disease that may also affect women.  In Queensland, meaningful data was only recorded 
from 1984 onwards and showed that the rate of infection varied markedly between the two 
genders (Table 3.7).  Over the period 1984-2014, there were a total of 6,794 notifications, 
5,417 (79.7%) from men and 1,370 (20.1%) notifications from women, with 7 (0.2%) 
notifications where the gender data was not provided.  This gave an overall ratio of 4.0:1 
(M:F) for all of the Queensland Q fever notifications.  Over this period (1984 to 2014), the 
annual ratio of male to female notifications has declined from 8.6:1 (Male 103: Female 12) 
in 1985 to a ratio of 2.4:1 (Male 114: Female 48) in 2008.   
From 1984 to 1990 the numbers of notifications for males and females remained similar, 
giving a range of M:F ratios from 8.6 – 6.0 (average = 6.8). However, from 1991 onwards 
the numbers of notifications for both males and females rose substantially, with a greater 
rise in the number of cases reported in females, resulting in a decrease in the M:F ratio 
between 1992 and 2002 (average = 4.4) (Figure 3.7). Since 2002, the numbers of 
notifications has declined in both males and females, giving a range of M:F ratios of 2.4 – 
4.5 (average = 2.9).  
The notable exceptions were the years 1997 and 2000, when the M:F ratios were 
considerably greater than the preceding and the subsequent year (Table 3.7). 
Interestingly, in 1997 the Q fever vaccine registry was introduced along with a large scale 
education program including the Q fever Information Kit for the Australian Meat Industry 
which specifically targeted men to heighten awareness of the disease, and 2000 saw the 
introduction of the NQFMP in Queensland, with a program of large scale vaccination of 
men in “at risk” occupations.  
Stage 1 of the NQFMP (2001-2002) coincided with record numbers of notification in 
females, nearly doubling those previously recorded. The average annual notification in 
women prior to the NQFMP in 2001 was 36.6 notifications, which increased by over 260% 
to an average of 95 cases per year in the first years of stage 1. Following the roll out of 
stage 2 of the NQFMP in 2002, which expanded the vaccination program to include 
farmers, their employees and unpaid family members working on farms, the number of 
notifications in both males and females began to decline (Table 3.7). This decline has 
been sustained with a M:F ratio of 2.6 in 2014. 
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Table 3.7: Annual Queensland Q fever notifications from 1984 to 2014 showing the 
distribution throughout the different genders. Numbers for each gender, ratios and total 
numbers are shown. 
Year Male Female Ratio (M:F) Total Number 
1984 36 12 3.0 48 
1985 103 12 8.6 115 
1986 169 25 6.8 199 
1987 135 19 7.1 154 
1988 135 19 7.1 154 
1989 142 23 6.2 165 
1990 185 31 6.0 216 
1991 240 39 6.2 279 
1992 250 52 4.8 302 
1993 329 75 4.4 405 
1994 230 46 5.0 276 
1995 143 33 4.3 176 
1996 120 40 3.0 160 
1997 208 34 6.1 242 
1998 195 52 3.8 247 
1999 235 57 4.1 292 
2000 338 54 6.3 392 
2001 347 96 3.6 443 
2002 262 95 2.8 358 
2003 174 49 3.6 223 
2004 116 43 2.7 159 
2005 123 33 3.7 156 
2006 140 31 4.5 171 
2007 126 51 2.5 177 
2008 114 48 2.4 162 
2009 95 36 2.6 131 
2010 108 43 2.5 151 
2011 118 46 2.6 164 
2012 146 49 3.0 195 
2013 183 60 3.1 243 
2014 172 67 2.6 239 
Grand Total 5417 1370 4.0 6794 
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Figure 3.7: Temporal distribution of Q fever notifications from 1984 to 2014 highlighting ratio between different genders over time 
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3.4.4. Q Fever and Age Distribution     
3.4.4.1. Queensland Data in the Australian Context 
Since the implementation of the National Notifiable Disease Surveillance System (NNDSS) 
in 1990 under the auspices of the Communicable Diseases Network Australia; limited data 
analyses has been performed and published linking national Q fever notifications with age 
for the general Australian population, nor has there been previous analysis of paediatric 
cases 43. However, the limited data available for Australian notifications have focused on 
short discrete time periods including 1991-1994, which covers post vaccine development, 
and the period 2006-2007, which is post implementation of the NQFMP44,45.   
In this study, the analysis of Queensland notifications for the same years (1991-1994), 
showed that the majority of Queensland cases, 76.5% (965 of 1261) were from subjects 
aged between 16-45 years of age (a 30 year age bracket).  This was a slightly younger 
age group than was identified in the national notifications (20-50 year olds; 70% of 
notifications)44,45.  Within the Queensland age groups, the highest numbers of total 
notifications were from 21-25 year olds, with 196 cases recorded, equating to 16% of the 
total Queensland notifications.  The average number of notifications for the 21-25 year 
olds in Queensland for 1991-1994 was 49, compared to national data which showed an 
average of 70 cases per year being reported from this same age group during the 1991-
1994 period.  
Analysis of the 2006-2007 Queensland notification data showed that the age range with 
the highest notifications occurred in 26-59 year age group, accounting for over 66% (252 
of 384) of the Queensland total notifications during this time. This was very similar to 
Australian national data of 69% (587 of 852) in this age bracket. Analysis of specific age 
groupings for 2006-2007 of Queensland data showed that the 46-50 year old age group 
had the highest number of recorded notifications, with 43 or 12% of the total notifications 
during this time period (Table 3.8).  The Australian data did not discriminate in 5 year 
brackets.  
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Table 3.8:  Queensland notifications for the two periods published 1991-1994 and 2006-
2007, showing age distribution  
 
Age Groups 
 
1991-1994 
Average  
Notification 
/year 
2006-2007 
Average  
Notification 
/year 
 
00-04 
4 1.3 2 2 
05-09 7 3.5 7 3.5 
10-14 10 2.5 8 4 
15-19 149 37.3 17 8.5 
20-24 204 51.0 26 13 
25-29 171 42.8 25 12.5 
30-34 170 42.5 25 12.5 
35-39 127 31.8 29 14.5 
40-44 121 30.3 39 19.5 
45-49 103 25.8 44 22 
50-54 63 15.8 41 20.5 
55-59 47 11.8 33 16.5 
60-64 34 8.5 23 11.5 
65-69 14 3.5 14 7 
70-74 10 2.5 8 4 
75-79 12 4.0 4 2 
80+ 15 5.0 3 1.5 
Grand Total 1262 315.5 348 174 
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The comparison between the two time periods analysed, 1991-1994 (post vaccine 
development) and 2006-2007 (post NQFMP implementation), showed a significant shift in 
age groups recording maximum numbers of notifications.  This was seen in both the 
published national data and the Queensland data44,45.   
3.4.4.2. Analysis of All Queensland Data (1984 – 2014) 
There has been no previous in depth analysis of Q fever notifications in Queensland. Data 
in this study showed notifications in all age groups over time with a total of 6,794 
notifications recorded over the 31 year period.  The average age of patients confirmed with 
Q fever infection was 38.8  years, with a median age of 38.0 years and an age range of <1  
months to 98 years old (Table 3.9).  The age group that had the most notifications were 
those aged between 40-45 years of age with 736 notifications (11% of the total number of 
notifications for the 31years analysed).  The age groups that had the least number of 
notifications were 0-4 year olds with a total of 26 notifications. 
Queensland has seen a clear shift in the age groups reporting Q fever notifications for the 
period 1984-2014 (Figure 3.8).  Prior to 2001 and the NQFMP, the majority of notifications 
occurred in the 15-39 year olds with >61% (2332 from 3822), with an average notification 
age of 35.1 years.  During the NQFMP implementation the age groups reporting the 
highest notifications were the 30-59 year olds, with 827 from 1334 notifications or >62% 
and an average of 42.1 years old.  The age groups showing the highest notifications post 
NQFMP, from 2006 onwards are the 35-64 year olds with 1026 from 1633 notifications, 
and an average age of 44.3 years.  Figure 3.8 shows the distribution of notifications over 
time with relation to the various age groups, highlighting a clear shift in the average age of 
Q fever notifications with time. 
Q fever notifications rates peaked between 1991-1994 with a total of 1261 notifications, 
and an average of 315.5 notifications per year during this time.  A second peak in 
notifications in Queensland was seen post vaccination program implementation, between 
2000 and 2002 with 1193 notifications being recorded and an average of 398 cases 
reported each year. 
These data show that Q fever primarily occurs in older age groups, but a significant 
number of cases were reported in children less than 16 years of age. This finding warrants 
more detailed analysis of notifications in children. 
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Table 3.9: All Queensland notification data for years 1984-2014, showing distribution of 
gender among the notifications and in relation to age groups 
 
Age Groups in 
years 
Females Males Ratio Unknown Total 
00-04 9 17 1.9 - 26 
05-09 18 34 1.9 - 52 
10-14 33 58 1.8 - 91 
15-19 83 513 6.2 - 596 
20-24 98 620 6.3 - 718 
25-29 102 581 5.7 - 683 
30-34 125 566 4.5 1 692 
35-39 139 562 4.0 1 702 
40-44 158 578 3.7 - 736 
45-49 159 506 3.2 - 665 
50-54 135 421 3.1 - 556 
55-59 122 374 3.1 - 496 
60-64 83 247 3.0 - 330 
65-69 54 156 2.9 - 210 
70-74 16 69 4.3 - 85 
75-79 17 50 2.9 - 67 
80+ 19 65 3.4 5 89 
      
Grand Total 1370 5417 4.0 7 6794 
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          Figure 3.8: Temporal Distribution of Q Fever Notifications in Age Groups for the 31 year period 1984-2014  
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3.4.4.3. Q Fever in the Paediatric Population 
In Queensland there were 235 reported cases of Q fever in children under 16 years of age 
over the study period 1984-2014.  The average age was 10.8 years, the median age was 
12.0 years (Figure 3.9), and the average number of cases reported per year was 7.6.  
 
Figure 3.9: Queensland paediatric notifications per age group (1984-2014) 
 
From the year 2000 the average annual number of children reported with Q fever has 
slightly increased from 6.1 cases in the period 1984-2000 to 8.7 cases in the period 2001-
2012. In 2001 and 2002, 19 and 18 paediatric cases were recorded respectively, and a 
single case was reported in 2010 (Figure 3.10).  
The average age of infection per year studied ranged from 5.5 years to 14.5 years. 
However, the number of notifications, when analysed per individual age group, showed 
that there was an increase in disease recorded with increase in age. The older children of 
10 years and above were responsible for 67 % (157 notifications) of the total number of Q 
fever infections recorded between 1984 and 2014 (Figure 3.10). 
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 Figure 3.10: Paediatric Q fever notifications for the years 1984 – 2014, shown in ages 
with the average age highlighted. 
 
The Q Vax® vaccine has not been licensed for use in children under 16 years old, and 
therefore does not influence these numbers of notifications.  During the implementation of 
the vaccine program in adults, there were 60 paediatric notifications during the 5 year 
period (2001-2005), resulting in an average of 14.5 paediatric cases identified each year of 
the campaign.  
3.4.4.4. Paediatric Q Fever Cases and Geographic Location 
The 235 paediatric notifications recorded were identified using postcodes and comprised 
85 geographical locations in Queensland (Figure 3.11).  The areas that recorded more 
than 4 notifications and their associated postcodes are shown in Table 3.10, and those 
areas in Queensland with more than 8 paediatric notifications are highlighted in Figure 
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3.12.  Most of the paediatric notifications were from the Darling Downs and South West 
districts of Queensland, similar to the adult cases. However, a substantial number of 
paediatric notifications were recorded from Brisbane metropolitan postcodes.  
 
Table 3.10: Queensland postcodes with paediatric Q fever notifications greater than 4 for 
the period 1984-2014. 
 
Postcode Notifications 
4285 4 
4468 4 
4478 4 
4700 4 
4870 4 
4000 5 
4350 5 
4455 5 
4610 5 
4305 6 
4570 6 
4406 7 
4490 7 
4421 8 
4465 10 
4470 10 
4487 11 
4390 13 
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Figure 3.11: Number of Queensland Q fever notifications shown per location (postcode). 
The marker colours shown are representative of the number of notifications per location.  
Legend:   Yellow = 4 notifications;    Grey = 5 notifications;    Fawn = 6 
notifications;  Aqua = 7 notifications;   Pink = 8 notifications;   Green = 10 
notifications;   Red = 13 notifications.
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Figure 3.12: Geospatial display of areas with more than 8 paediatric Q fever notifications 
mapped 
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3.4.4.5. Gender and Paediatric Q Fever Cases  
 Q fever notifications in the paediatric population for the total period between 1984 and 
2014 show an average male to female notification ratio of 2.3:1.  In Q fever notifications 
occurring in children under 6 years old, the gender ratio varied from 1:0 (<1year old) up to 
7:1 (6 year olds) with an average ratio over the 6 years of 1.9:1 (Male:Female).  The 
children aged between 6 and 15 showed an overall Male:Female ratio of 2.4:1, and were 
generally dominated by Q fever cases reported in boys, except for the 3 and 11 year olds, 
where there were more notifications from girls (Figure 3.13). As the children reached a 
working age of 15 years there was a substantial increase in Q fever notifications recorded 
from males. 
 
 
 Figure 3.13: Distribution of paediatric Q fever cases among the various ages for the years 
1984- 2014, showing the ratio of male to female notifications 
 
The increasing number of notifications in adolescent males is reflected in the <16 years 
total age group data collected between 1984 and 2014, which shows a preponderance of 
notifications from males for most years (Figure 3.14).  Only in 2007 and 2013, were there 
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more notifications reported in females than males. Interestingly there were 5 years with no 
reports of Q fever in girls at all, and thus ratios could not be calculated (Figure 3.14).  
 
Figure 3.14: Q fever notifications from children aged less than 16 years of age for the 
each of the 31 years analysed 1984-2014, along with the ratio of male to female 
notifications 
 
3.4.5. Seasonality of Q Fever Infection 
 Q fever notifications were recorded in all months of every year from 1984 to 2014.  On 
average, an increase in notifications was recorded for the months of March, April and May 
which corresponded to autumn in Queensland and spring in the Southern Hemisphere, 
and generally follows a period of increased rainfall during summer (Figure 3.15).  
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Figure 3.15: Seasonal breakdown of Q fever notifications for the years 1984-2014 
However, there was no statistical correlation between Q fever notifications and average 
annual rainfall for Queensland, (p value was >0.23 r(29) = 0.22) with only a slight decrease 
in the number of notifications recorded during a time of lower rainfall.  Queensland 
consistently records Q fever notifications more frequently and in higher numbers in the 
months preceding the state’s highest average rainfalls (Figure 3.16). 
Interestingly, increases in Q fever notifications were observed in the years of 1992-1994 
and in the years 2001-2003 which coincided with a significant decrease in average annual 
rainfall for the state, and Australia as a whole. These were periods of widespread drought 
with increased dust activity, during which the highest number of Q fever notifications were 
recorded (Figure 3.17).  
There was no correlation identified between notification data and recorded dust events in 
Queensland with p value = >0.73 r(29) =0.07.  Nor was there any significance calculated 
between Q fever notifications and average temperatures p value= >0.66 r(29) =0.08.   
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Figure 3.16:  Queensland notifications of Q fever and average monthly rainfall for the period 1984 to 2014 
● Summer; ● Autumn; ● Winter; ● Spring.     
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Figure 3.17: Queensland notifications and average rainfall for the years 1984-2014
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3.4.6. Identification of Risk Factors  
The collection of NOC data included questionnaires regarding 25 categories of potential 
exposure risks associated with the disease, Q fever. However, these data were not always 
complete or included in the information sent to the Queensland Department of Health.  
From the 6,794 notifications recorded in Queensland since 1984 to 2014, there were 6,312 
instances of risk identified, with some notifications identifying multiple risk factors, and 
more than 5% of all notifications were associated with a known risk factor for Q fever.  
Meat processing and abattoir environment exposure were two of the most documented 
risk factors, and were identified in 5.0% of Queensland Q fever cases for the 31 years 
analysed.  In all, 14% of all Q fever notifications had a risk factor documented (Table 3.11). 
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Table 3.11: Risk factors identified as part of the notification process associated with Q 
fever disease 
 Q FEVER RISK FACTORS 
IDENTIFIED 
A
T
 R
IS
K
 
N
O
T
 A
T
 R
IS
K
  
U
N
K
N
O
W
N
 
N
O
 R
E
C
O
R
D
 
G
R
A
N
D
 T
O
T
A
L
 
%
 A
T
 R
IS
K
  
%
 A
T
 R
IS
K
 
N
O
T
IF
IC
A
T
IO
N
S
 
At Risk  Q Fever 348 1066 118 5610 1184 29.4 5.1 
Abattoir Exposure 333 1010 109 5675 1119 29.7 5.0 
Visitor To Abattoir 75 213 17 6564 230 32.6 1.1 
Work Inside Abattoir 178 583 40 6171 623 28.6 2.6 
Inside Abattoir Duties 39 55 13 6726 68 57.4 0.6 
Other Exposure In Abattoir 35 84 5 6705 89 39.3 0.5 
Work In Grounds Abattoir 77 212 19 6563 231 33.3 1.1 
Contract Worker 74 201 16 6577 217 34.1 1.1 
Assist Observe Animal 
Birth 
334 1033 74 5687 1107 30.2 4.9 
Skinning Meat Process  337 1035 77 5682 1112 30.3 5.0 
Shooting Hunting 336 1037 74 5683 1111 30.2 4.9 
Work With Wool 339 1042 75 5677 1117 30.3 5.0 
Work In Shearing Shed 315 970 69 5755 1039 30.3 4.6 
Work In Wool Processing 308 967 67 5760 1034 29.8 4.5 
Work With Straw Animal 
Bedding 
338 1036 72 5686 1108 30.5 5.0 
Attend Saleyard Animal 
Show 
334 1034 68 5692 1102 30.3 4.9 
Work With Animal Manure  338 1037 71 5686 1108 30.5 5.0 
Live On Farm 74 88 11 6695 99 74.7 1.1 
Visit Farm 341 1037 84 5673 1121 30.4 5.0 
Launder Clothes Animal 
Worker 
306 966 71 5757 1037 29.5 4.5 
Exposed To Livestock 
Transport 
339 1041 74 5679 1115 30.4 5.0 
Consume Unpasteurised 
Milk  
341 1049 91 5654 1140 29.9 5.0 
Exposure To Paddock Dust  324 1035 90 5669 1125 28.8 4.8 
Live Work Within 1km 
Abattoir 
318 1026 90 5678 1116 28.5 4.7 
Live Work Within 300m 
Bush  
132 1247 21 5526 1268 10.4 1.9 
Totals 6312 20104 1516 148230 21620 14.5  
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3.5. Discussion 
Q fever disease in Australia continues to impact on rural communities and veterinarians 
despite the availability of an effective vaccine and the implementation of a large scale 
national vaccination campaign.  However, despite this awareness, both in Australia and 
the rest of the world,  there is a shared consensus that the disease is underreported and 
often misdiagnosed46.  
In Australia, over time, there has been an increase in Q fever notifications both nationally 
and in Queensland.  This has included the period of implementation of the national Q fever 
vaccine program. Interestingly, Queensland continues to record the highest proportion of 
notifications in Australia suggesting that either (i) a larger proportion of the workforce is 
engaged in risk-related employment, or (ii) there is increased laboratory testing and 
screening in Queensland compared to other Australian states which results in the 
identification of more cases. Alternatively, there may be other risk factors, not work related, 
that predispose Queensland residents to infection. 
The Queensland notification data supported previous observations that Q fever was 
widespread in rural populations.  There have been regions where notifications have been 
consistently recorded over time and these have been in areas of high concentrated beef 
production along with sheep and cattle rearing areas such as Goondiwindi, Roma, St 
George and Charleville. These were areas with increased numbers of people in direct 
occupational contact with farm animals.  Over time, Toowoomba has recorded the highest 
number of notifications for any specific geographical location in Queensland, yet it was not 
a location of great farming activity or where large numbers of livestock resided.  The 
population of Toowoomba were mainly employed in healthcare, retail and education (38%) 
with only 6% of the community working in the agricultural sector with an associated 
occupational risk of contracting Q fever.  However, Toowoomba has close proximity to 
cattle rearing areas, and is the main corridor for livestock transport for shipping centres in 
Brisbane and interstate.  In addition, there are a number of rural and metropolitan abattoirs 
that are supplied via livestock road trains passing through Toowoomba, and hence the 
dispersion of contaminated dust and the direct depositing of contaminated animal 
secretions may occur.  This may contribute to the high numbers of notifications recorded 
from this region. 
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A high rate of Q fever notification was also observed for the metropolitan area of Brisbane, 
with the 6th highest rate of notification. The risk factors associated with these infections 
were not clear, but are likely to involve factors other than those associated with close 
proximity to ruminants or employment. 
Queensland was responsible for over 50% of the national Q fever notified cases since the 
collection of Q fever data began in 1952, and continues to report cases from all over the 
state.  It recorded a continual increase over time in Q fever notifications, with the highest 
number of cases recorded during the implementation of the vaccine program.  This may 
have been the result of an increase in Q fever screening and a heightened awareness of 
the disease by medical practitioners and other health professionals.  In Queensland, there 
has been a decline in notifications and under-recognition of Q fever since the vaccine 
program ended in 2005 with the number of yearly average notifications decreasing. This 
may simply be a reflection of the lapse in awareness of the disease or as a direct impact of 
the effectiveness of the vaccine program.  The number of cases identified post Q fever 
vaccine program in Queensland were still high compared to national disease rates, 
illustrating that Queenslanders were still very much at risk of contracting the disease, and 
probably reflects the large number of Queenslanders in at risk occupations.  
Although Q fever occurred mainly in males, high levels of infection were recorded in 
females in the years 1997 and 2001. This coincided with the introduction of the Q fever 
vaccination program and the NQFMP respectively. These increases may have been due 
directly to a heightened awareness of the disease by health professionals and therefore a 
higher rate of diagnosis, or perhaps by the incursion of females into previously male 
dominated roles such as meat packing and processing. Also, it is possible that with 
increased vaccination, pre-vaccine screening identified cases that had not previously been 
detected and therefore added to the overall notification numbers. 
The notification data showed that Q fever disease affects all age groups including children 
and elderly.  However nationally, including in Queensland, over the last 20 years there has 
again been an upward shift in the average age groups reporting Q fever disease, and this 
coincided with the implementation of the national vaccine program.  The average age of 
persons identified as having Q fever in Queensland prior to the vaccine campaign in 2000 
was 36.6 years old.  This comprised the traditional working age group of 16-45 year olds, 
an age group that potentially had the highest occupational exposure risks. The average 
 111 
 
 
age of notification post implementation of the vaccine program was 43.4years and the 
group recording the highest notifications came from the 36-60 year olds. This may be due 
to an increase in awareness of Q fever among these age groups or it may reflect the 
number of cases of chronic Q fever being reported as a result of previously identified or 
asymptomatic, acute Q fever episodes and an ongoing Q fever sequelae. These data were 
consistent with previous observations of an increase in exposure to C.burnetii with an 
increase in age.  
The occurrence of Q fever has been reported in children in Australia and internationally. 
However, the awareness of Q fever in children is rare, and the disease is often not 
recognised and subsequently under-reported in this population, or reported as unusual 
case studies.  Queensland has reported some of the highest rates of Q fever disease in 
children in the world, excluding the recent outbreak in The Netherlands.  In Australia, rural 
children are often involved in farm duties including maintaining animals and pasture 
enclosures, and are often present at the birthing of farm and stock animals. As a result 
they are commonly exposed to the Coxiella bacteria. The increase in responsibilities and 
duties that commonly occur with increasing age for the children living on farms and rural 
properties is reflected in the increasing number of Q fever cases reported in children as 
they get older.  Also, for younger children, the potential to have secondary exposure to 
animal products and secretions from the parents or their work clothing and footwear, may 
account for the number of paediatric cases recorded from this age group in rural 
Queensland. To highlight this some clinical case studies were examined in Chapter 7. 
Potentially, any or a combination of these factors may help explain the higher rates of Q 
fever seen in Queensland among the paediatric population, than that recorded in other 
areas.   
In the Northern Hemisphere, Q fever disease primarily occurs in spring or the “birthing” 
season47. However, in Queensland and Australia as a whole, the majority of notifications 
occur in the autumn months, directly following large rain periods or the wet season.  This 
corresponded to the same global time period as spring in the Northern Hemisphere but did 
not correlate to the birthing seasons in Australia.  These data suggest that Q fever was a 
disease seen globally in the beginning of any given year and was not linked to the spring 
season. Queensland experiences its wet season in January and February or the season of 
summer, while in Europe the wet season begins in the same months during winter. This 
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suggested that Q fever is a disease that is influenced by rainfall.   With increased rainfall 
comes new vegetation and food supply for many animals, and perhaps this is the link 
between Q fever disease and climate.  
Even though no direct correlation was found between Q fever notification and annual 
rainfall patterns, it was interesting to observe that the two peak periods of Q fever disease 
occurred during drought conditions in 1992-1994 and 2001-2003. During these periods of 
drought, high levels of dust and dust storms were recorded in the country, and these may 
have contributed to the widespread dissemination of C.burnettii from rural areas to the 
country as a whole. Similar observations in soil dissemination have previously been 
reported in the USA48 .  
This extensive notification data analysis showed that there were many factors that 
influenced the occurrence of Q fever disease in Queensland. However, the data confirmed 
that Q fever infection was not exclusively confined to the rural population, and that other 
groups at risk included those in metropolitan areas, and children in both regions. So far, 
the true extent of exposure to C.burnetii by residents in Queensland has not been 
extensively tested, and requires further examination by a retrospective serological survey 
of the population to determine the true rate of exposure. Also, there is a need to determine 
other risk factors associated with infection, particularly those that are responsible for 
infections in metropolitan populations. These may include exposure to animals other than 
farm animals, such as domestic pets and native fauna, or perhaps environmental exposure 
through soil and dust particles49–51.  
Finally, Q fever may present with a wide range of clinical signs and symptoms. It is likely 
therefore that the disease is not recognised in areas and populations that are not normally 
considered to be at risk, particularly those in metropolitan locations. Also, the laboratory 
diagnosis of infection has traditionally been based on the immunofluorescent antibody 
assay which detects antibody developed following infection. This gives a retrospective 
diagnosis but may not be optimal to detect early acute infections. The newly evolving 
molecular diagnostic methods may provide an improvement in some areas of Q fever 
diagnosis and are being implemented more in the general screening for disease. Given 
this, it is possible therefore that the exposure rates described above based on notification 
data may in fact be under-reporting the true level of Q fever disease in Queensland, and 
by association in Australia. 
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3.6. Significant Outcomes from this Chapter 
 This was the first comprehensive study examining Q fever notifications in 
Queensland over an extended time period (1984 – 2014) 
 There was a higher notification rate of Q fever than expected in the urban 
population, who are traditionally considered to be at low risk of infection 
 Despite a national government funded vaccine program,  Q fever disease in 
Queensland still had one of the highest rates of notification in the world 
 There was evidence of a substantial rate of Q fever notifications among children in 
Queensland, indicating that the disease was not restricted to the at risk adult 
population 
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4.1. Introduction 
Epidemiological studies provide insights into the state of knowledge of particular infectious 
agents within defined populations. The study of disease and the impact a specific disease 
has on a population is often investigated using prevalence studies.  A cross sectional 
study of Coxiella burnetii exposure in the Queensland population using serological based 
methods and hence a seroprevalence study will help to ascertain the true exposure rate of 
Coxiella in this population and help to predict the potential disease burden for the 
community. 
Current epidemiological data published for Q fever is largely produced using serological 
methods1.  There are however, no standardised methods that have been established for 
sero-profiling of Q fever, and the methods used vary greatly and have different thresholds 
for determining positivity.  Early investigations employed micro-agglutination assays and or 
complement fixation tests which proved to be highly specific but lack the sensitivity 
associated with the newer techniques of ELISA and IFA screening.  These less sensitive 
techniques of micro-agglutination and complement fixation assays may result in an 
underestimation of the true prevalence of Coxiella throughout the community.  
Immunoassays measuring antibody levels such as the ELISA and IFA have a high level of 
sensitivity, and in the case of the ELISA this method can be automated for more accurate 
results2,3. 
C.burnetii is widely shed into the environment by infected animals via birth product, urine, 
faeces, and milk, and can also be transmitted via ticks which draw blood contaminated 
with Coxiella from an infected animal.  Both avian and mammalian species are able to 
become infected with Coxiella and hence are potential sources of Coxiella exposure to 
humans4.  These infected animals generally do not exhibit any signs or symptoms of 
disease, and it is only a subset of infected animals that may present with late abortions 
and reproductive difficulties5.  Traditionally Q fever infections in human have been widely 
associated with parturient animals and the exposure of humans to infectious birth 
products. 
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4.1.1. Prevalence of Q Fever in Humans 
Q fever cases and local epidemics have been reported around the globe, yet, despite the 
global prevalence of Coxiella  and Q fever disease, there have been very few large 
population-based studies investigating the seroepidemiology of this infection in humans4,6–
11.   Seroprevalence studies have been performed in both animals and humans to assess 
the potential infection rates, while other studies have been used to estimate disease 
burden within populations12.   Recently seroprevalence studies for Q fever have been 
performed following large outbreaks in The Netherlands and Germany. These highlight the 
potential risks associated with Q fever disease and illustrate the epidemiological 
inconsistencies associated with such outbreaks13. 
4.1.1.1. Global Prevalence of Q Fever 
Australia identified the first cases of Q fever14, and since then every country in the world 
has reported cases of Q fever with the exception of New Zealand4.  There have since been 
numerous outbreaks of Q fever globally with early reports from the United States of 
outbreaks in meat packing plants in Texas and Chicago in the late 1940’s15,16 and more 
recently in US troops returning from Afghanistan17. There were over 300 cases of Q fever 
reported in Canada as a result of secondary exposure to parturient cats which was 
identified as a single outbreak event18, and  Israel reported an acute Q fever outbreak in a 
school 19.  The United Kingdom has reported outbreaks of Q fever associated with sheep 
and the dispersion of Coxiella via wind20.  In addition, there have been many countries 
throughout Europe that have experienced outbreaks of Q fever including Switzerland21,22, 
Italy23 and Poland24. These outbreaks have highlighted the extent of Coxiella dispersion 
throughout the world and hence the different populations exposed to the disease. 
Four European countries have been associated with the largest outbreaks of Q fever since 
1982: The Netherlands, Germany, Bulgaria and France13.   These reports identified goats 
and sheep as the main sources of infection to humans, and highlighted that these animals 
were potential sources responsible for large community outbreaks. These investigations 
also identified that cattle do not play a major role in the dissemination of Coxiella into the 
environment within these countries, as abortions in cattle were less frequent and hence 
the transmission of Coxiella to humans from this source appeared to be limited5,13. The 
large scale outbreaks that occurred in The Netherlands, Germany, Bulgaria and France 
have initiated the need for further investigations into the extent of exposure that these 
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populations, and potentially other nations have to Coxiella.  To truly assess this extent of 
exposure in defined populations, seroprevalence studies have been performed in these 
countries.  
4.1.1.2.   Seroprevalence Studies 
Seroprevalence rates in the general population of 14% were reported for France and 2.4% 
for The Netherlands (Table 4.1).  Higher seroprevalence rates have been reported from 
these countries in “at risk” populations. These include reports from The Netherlands of up 
to 24%, 22% reported in Germany and up to 38% in Bulgaria. These populations were 
investigated after Q fever outbreaks and showed that whole communities were considered 
to be at risk of infection.  The true extent of exposure in these communities as a result of 
the outbreaks were assessed using seroprevalence studies 13.  Globally, seroprevalence 
of Q fever varies greatly. Different countries report different rates of disease with outbreaks 
occurring sporadically and not necessarily limited to large farming nations or at risk 
populations (Table 4.1).  The extent of exposure needs to be identified for individual 
countries, states, districts or provinces for a true assessment of exposure and to estimate 
the potential disease burden.  
4.1.1.3. Seroprevalence Studies in Australia  
Australia has on average, the highest, annual notifications of Q fever cases in the world25 
and yet there are very few epidemiology data available from this Q fever endemic country.  
Only limited seroprevalence studies have been performed in Australia, and as a result 
there are limited nationwide seroprevalence data regarding the true exposure rate of 
Coxiella in the Australian population. These studies have been restricted to small numbers 
and limited to only six of the eight states and territories. Only nine seroprevalence studies 
into Q fever exposure have been performed since the first study in 1980, which was more 
than thirty years after the disease was first described in Queensland. Until recently, these 
studies have focused on different “high risk” or “at risk” populations, including animal 
handlers, meat workers, abattoir workers and rural communities or populations, and 
reported seroprevalence rates from 7%-66% (Table 4.2)  Many of these studies have 
involved small cohorts and have been from very diverse geographical locations around 
Australia.  Also they were limited to adolescents and adults.  To date, there have been few 
comprehensive studies in Australia which assessed the general population for Coxiella 
exposure.   
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Table 4.1: Seroprevalence reported in different countries around the world over time. 
Published Country Seropositive Sample Positives Population Ages Author 
1986 Switzerland 7-32% 5446 381-1743 
following 
outbreak 
adults Dupuis21 
1995 England 19% 730 143 farming 10-70 Thomas26 
1995 Nova Scotia 15% 492 72 general 18-70 Marrie27 
2000 Taiwan 4.2% 616 26 general adults Ko28 
2001 Germany 22% 1651 51 
general 
(including 
outbreaks) 
adult Hellenbrand29 
2006 Barcelona 15% 216 33 general 00-91 Cardenosa30 
2006 E. Turkey 20% 92 18 cattle farmers adults Seyitoglu31 
2006 Cyprus 53% 583 307 general all Psaroulaki 32 
2008 Ankara 32% 601 194 general adults Kilic33 
2008 Ireland 13% 2394 306 general 12-64 McCaughey34 
2009 USA 3% 4437 133 general >20yrs Anderson35 
2010 
Northern 
Turkey 
12% 407 50 general >5yrs Gozalan36 
2012 Greece 62% 159 445 at risk adult Vranakis37 
2012 Greece 49% 493 242 general adult Vranakis37 
2012 Netherlands 12% 543 66 general adults Hogema38 
2013 Kenya 31% 246 76 - - Knobel39 
2013 Gambia 8.3% 796 66 general 
Childre
n<16 
Van der Hoek40 
2014 Bulgaria 18% 5207 937 at risk group adult Georgiev 41 
2014 France 14% 578 81 
following 
outbreak 
adult Georgiev 41 
2014 Netherlands 2.4% 5 654 136 general adult Georgiev 41 
2014 Germany 22% 255 56 
following 
outbreak 
adult Georgiev 41 
 
4.1.1.4. Seroprevalence in the Queensland Population 
Queensland reports, on average, 215 cases of Q fever a year compared to the national 
average of 467 cases, therefore over 46% of Australia’s laboratory confirmed cases of Q 
fever are contracted in Queensland. However, given the wider understanding that the 
disease is misdiagnosed or under-reported,   the true incidence of the disease may be 
underestimated along with the extent of true exposure in this population42.  
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The first published epidemiology study performed in Queensland was in Brisbane in 1980 
among meat workers as part of a retrospective study spanning 10 years from 1968 to 
1977. This showed an average incidence rate for Coxiella of 1% per annum, with an 
increase to 7.9% following a work-place related outbreak in 196943.  The first Queensland 
sero-prevalence study was performed on this population involving 139 meat workers 
showing a rate of 15.8% 43.   
Table 4.2: Results of seroprevalence rates reported in Australia 
Published Region 
Sero-
positive 
Sample 
(n) 
Positive 
(n) 
Population Ages Author 
1980 
Brisbane 
Queensland 
16% 139 22 meat workers adult McKelvie43 
1984 
Adelaide South 
Australia 
45% 1922 875 abattoir adults Marmion44 
1999 NSW 11% 829 89 abattoir adults Casolin45 
2000 NSW 27% 1417 394 cattle handlers adults Hutson46 
2001 
Central 
Queensland 
19% 265 49 
rural/ 
farming 
12-79 Taylor47 
2003 Kimberly WA 66% 59 39 
rural/ 
farming 
16-65 Mak48 
2005 Victoria 20% 9196 1859 abattoir  10-72 Greig49 
2010 
South West 
Queensland 
7% 447 29 rural <25yrs Parker50 
 
Central Queensland has high numbers of notifications of Q fever each year, and in 2001 
the Central Queensland Rural Division of General Practice undertook a large study and 
vaccination program for rural community residents.  The participants in this study were of 
adolescent or adult age, largely from a rural background, with the majority having resided 
on farms or worked with ruminants, thus having a potentially high level of exposure or risk 
associated with the acquisition of Q fever disease. This population had a seroprevalence  
of 18.5% 47.  
A recent study performed in a select population of under 25 year old subjects residing in 
South West Queensland, the geographical “hot spot” for Q fever in Australia,  highlighted 
the exposure in children and the younger rural population in potentially high risk 
communities, showing a rate of 7% from the 447 subjects investigated50. 
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Coxiella exposure in the general Queensland population remains largely unknown, and 
there is a distinct lack of knowledge regarding those populations considered not at risk and 
those residing in urban or metropolitan areas with low rates of Q fever notification.  Table 
4.2 shows the results of seroprevalence studies that have been conducted in Australia, 
highlighting the limited data that currently exists for a nation that has one of the highest 
rates of notification per capita. 
4.1.2. Seroprevalence in Animals  
Coxiellosis may occur in a variety of animal species throughout the world including 
mammals, birds, reptiles, amphibians, insects and fish51.  The transmission of Coxiella 
between animal species and within species, in particular between livestock, creates 
potential sources of infection for humans.  The level of potential risk of disease may be 
assessed by investigating the previous exposure rates in these animal species by use of 
seroprevalence studies. 
There are very limited data generated describing the seroprevalence of Coxiella in 
Australian animals.  The studies that have been performed are listed in Table 4.3 and 
highlight the need for further more extensive investigations in animal populations from 
regions with high Q fever notifications. 
4.1.2.1. Seroprevalence in Livestock 
4.1.2.1.1. Cattle 
In most countries cattle are one of the main sources of transmitting Coxiella to humans 
and causing Q fever disease. Correlations between the sero-positivity in cattle and 
humans has previously been established52, and there were varying seroprevalence rates 
from different countries and within different countries around the world depending on 
geographical location1. Rates varied from 6 % in Northern Ireland53, 7% in Spain54, up to 
11% in Iran55, 24% in Cyprus32, 26% in Korea, Bulgaria had 21% prevalence rate, 
Germany showed 19% among cattle while France had 15% within herd prevalence and  
up to 73% for between herd prevalence and The Netherlands reported 21% within herd 
rates and up to 37% for between herd prevalence13.  Australia had reported rates of <1% 
from cattle in Western Australia56, South Australian57, Victoria  and New South Wales58.  
Recently there has been a prevalence study of cattle in Central Queensland showing rates 
of 17%59. 
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Table 4.3: Animal seroprevalence studies performed in Australia 
State Species 
Sero-positive 
(%) 
(n) 
Year 
Published 
Author 
Queensland 
Dogs 21.8 201 
 
2011 
 
Cooper 59,77,81 
Cats 38.7 31 
Foxes 43.8 16 
Pigs 22 50 
Bandicoots 23.9 46 
Dingos 17.3 127 
Possums 10.7 56 
Cattle 16.8 308 
Macropods 20.8 500 2012 Cooper85 
Eastern 
Australia 
Cats 0-9 712 2015 Shapiro82 
Western 
Australia 
Cattle and 
Sheep 
0.5 379 
2009 Banazis56 
Kangaroos 33.5 343 
Kangaroos 24.3 1017 2011 Potter86 
Bandicoots 8.6 35 2011 Bennett87 
 
4.1.2.1.2. Sheep 
Small ruminants have also been regarded as potential sources of infection to humans as 
they carry Coxiella in birth products and their fleece60–62.  The prevalence rates in sheep 
also vary depending on geographical location.  Rates in sheep from various countries 
include 40% from Mexico63, 23% in Egypt64, 20% in Turkey with flocks having an 80% 
seroprevalence rate65, Cyprus reports 19% of sheep tested positive32, 12% in Ireland53 and 
Spain54and 3% in Albania66.  The four European countries investigated after large 
outbreaks showed up to 57% of sheep screened in Bulgaria were positive, 20% in France, 
9% in Germany and 4 % in The Netherlands13. 
In Australia there has only been one sero-survey conducted involving sheep co-residing 
with cattle in Western Australia, which has one of the lowest notification rates of Q fever in 
humans in Australia.  The rate detected among these sheep was 1%56.   
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4.1.2.1.3. Goats 
Goats may have persistent Coxiella infections and can shed the bacteria in milk, urine and 
faeces along with high bacterial loads in parturient animals1.  Goats have recently been 
associated with large outbreak of Q fever in The Netherlands67.  As with cattle and sheep 
the rates of exposure in goats globally, vary with geographical location.  Seroprevalence 
rates have been reported in Iran of 66%55, 49% of goats in Cyprus32, 35% seen in 
Mexico63, 17% reported in Egypt64, 9% in both Ireland53 and Spain54.  Following large 
outbreaks in Europe, Bulgaria reported up to 40% sero-positivity in goats, 88% was 
reported in France, 3% in Germany and 8% in The Netherlands. 
Australia also recorded an outbreak of Q fever in meat processors following exposure to 
feral goats during slaughtering68,69.  Following this outbreak a seroprevalence study of 
Coxiella in feral goats was performed, showing that 52% were positive for Coxiella-specific 
antibodies70.   
4.1.2.2. Domestic Pets  
It is well documented that Q fever disease is predominantly associated with large 
ruminants, however, there have been numerous cases and outbreaks that have been 
related to domestic pets including felines and canines71,72.  In the cases of Q fever disease 
where no direct ruminant contact can be recorded, it is thought that perhaps these 
domestic animals may be the reservoir of the disease and hence the sources of infection 
to humans in urban or non-rural environments. 
4.1.2.2.1. Canines  
Dogs have long been companion animals for humans as well as working animals to aid 
farmers, yet few seroprevalence studies in dogs have been performed throughout the 
world.  A French study showed that military dogs used in various countries had rates of 
12% when stationed in Senegal, 10% from France, 8% in the Ivory Coast and 5% in 
Guyana.  The dogs that resided in Martinique showed no exposure to Coxiella while 
residing there73. Slovakia showed rates of 12% among canines screened74 while a study in 
Sicily showed a rate of 8% 75.  A large study performed in New Zealand with over 12,500 
serum samples from dogs located in various geographical areas throughout New Zealand 
showed no seropositive samples.  This formed part of a major study into Q fever in New 
Zealand and is an important finding which seems to confirm the absence of Coxiella in that 
country 76. 
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Recently in 2011, Australia reported the first investigation into the seroprevalence in dogs, 
with a study performed in Townsville, one of Australia’s major beef/cattle producing 
regions and known for high notification of Q fever in humans. This study showed a rate of 
22% among domestic dogs from Townsville77 and hypothesised that dogs may be a 
potential source of transmission for Coxiella to humans. 
4.1.2.2.2. Felines 
Cats have been widely associated with outbreaks of Q fever throughout the world and 
have been responsible for causing Q fever disease in humans more commonly than dogs1.  
Seroprevalence studies have been initiated following such outbreaks to determine the 
extent of exposure in cats and to aid in predicting the potential risk of disease to humans.  
Japan reported rates of 14% among domestic cats, while stray cats had up to 42% 
seropositivity rates78. Canada, which has had several outbreaks of Q fever linked to 
domestic cats, reported 13% of cats screened had been exposed to Coxiella79. The United 
Kingdom recently reported 62% of cats screened for Coxiella antibodies were positive in 
2014 80. 
Australia has limited studies regarding cats and Coxiella. However, Australia has reported 
seroprevalence rates among feral cats trapped in Central Queensland of 39%81.  A recent 
study performed on feral, domestic, shelter and cattery felines from the east coast of 
Australia showed varying exposure rates from 0-9%.  The cattery felines had 9% exposure 
rates while the domestic pets had 1% and the other two groups had no seropositive results 
recorded82. These animals may play a significant role in the chain of transmission of 
Coxiella to other wildlife and domestic animals in the region. 
4.1.2.3. Native Animals  
4.1.2.3.1. Flying Foxes 
In Australia, flying foxes have been identified as a potential source of infection to humans 
or other animals for a large number of diseases, including Hendra virus and Lyssa virus. 
To date, there has only been one study investigating the prevalence of Coxiella in flying 
foxes in Australia.  This is the study described in Chapter 5 of this thesis and forms the 
basis of a publication on which the Chapter is based83. 
However, there have been no reports of seroepidemiology studies investigating Coxiella 
and flying foxes, but there was a report of Coxiella seroprevalence in Phyllostomus and 
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Molossus, both are genera of bats.  This study was in French Guiana and no antibodies 
were detected84.   
4.2. Specific Aims Addressed in This Chapter  
The previous chapter, examined the notification data for Q fever in Queensland, and 
showed that the disease was far more widespread than previous reports suggested. It was 
not just restricted to the rural population, but showed significant notification rates from both 
rural and urban populations. 
Also, it showed that, based on notification data, children in both rural and urban settings 
had a considerable rate of exposure to the disease. 
At the time of commencement of this study, there were very limited data regarding the 
seroprevalence of Q fever in the Queensland population. Also, acquisition of the disease 
was largely associated with animal contact, specifically ruminants with some limited 
evidence that native animals might be a source of infection.  
The study in this chapter therefore sought to address the following specific aims: 
 To assess the seroprevalence of Coxiella burnetii antibodies in serum samples 
collected from a generally healthy population in Queensland, and compare those 
from rural and urban populations, in order to assess the population with greater 
exposure. 
 To determine such seroprevalence in a subset of serum samples collected from 
children, to assess if children are at risk of contracting the disease. 
 To develop and apply competitive ELISA and IFA assays to investigate the 
seroprevalence in animal species. Competitive assays needed to be developed 
because specific anti-species conjugates were not available for many of the animals 
to be tested.   
 To determine the level of C.burnetii exposure in serum samples collected from a 
range of animals, including ruminants and farm animals, native animals and 
domestic pets, using the serological assays above. 
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4.3. Methods 
4.3.1. Serum Samples Collected 
4.3.1.1. Human Serum Samples  
The Queensland Q fever notification data reviewed in Chapter 3 highlighted that Q fever 
was predominantly a rural disease. This was taken into consideration and over-sampling of 
sera from rural areas was deliberately performed. The investigation into Q fever exposure 
in paediatric age-groups (children younger than 16 years of age), was sought to be better 
defined by over-sampling of sample numbers from this age-group also. Subjects in this 
age group are currently not eligible for vaccination in Australia. Sample demographics 
were collated and only sera from patients with a current Queensland residential postcode 
were included in the seroprevalence analysis.   
In the serum bank of 2122 serum samples described in Chapter 2 (section 2.2.5.1.) there 
were a total of 1988 serum samples from subjects residing in Queensland.  Geographical 
distribution was determined using the Bureau of Statistics Standard Geographical 
Classification System.  Statistical Subdivisions (SSD) were defined as socially and 
economically homogeneous regions characterized by identifiable links between the 
inhabitants88. Two distinct geographical populations were established based on patient’s 
postcodes and SSD.  SSD’s beginning with the code 305 were considered to be an 
“Urban” population and the rest of the patient population from Queensland was considered 
to be “Rural” 89.  When samples were collated based on postcodes, it was shown that 
there was a representative sample from each of the 39 Statistical Subdivisions within 
Queensland.   
Limited demographic data were available on each de-identified sample, being restricted to 
date of collection, date of birth, age, sex and postcode.  The age distribution amongst 
samples in the serum bank was 0 – 92 years of age, with an average age of 37.6 years 
and a median age of 37 years.   The paediatric populations were defined as patients being 
younger than 16 years of age.   
These 1988 samples were screened for Q fever phase I and II IgG antibodies to determine 
the seroprevalence of the Queensland population to C.burnetii.   
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4.3.1.2. Animal Samples  
A collection of canine and feline serum samples conveniently acquired from the University 
of Queensland, School of Veterinarian Science in 2011 was used in this study.  These 
samples were collected from animals presenting to the University of Queensland 
Veterinary Clinic located at the St Lucia and Gatton campuses. There were 628 serum 
samples obtained.  These samples did not have any clinical data attached.  There were 
470 dog sera of which 250 were male dogs of which 50% were de-sexed and 220 female 
sera of which 30% were de-sexed.  There were 158 serum samples obtained from cats in 
which 88 were from males with 72% being de-sexed males and 70 were from females with 
76% being de-sexed. 
Serum collected from flying foxes were also obtained from Queensland’s Centre for 
Emerging Infectious Diseases and Biosecurity.  These sera were included in the study as 
Coxiella DNA had previously been detected using molecular methods in pooled flying fox 
urine collected from colonies in close proximity to humans (Chapter 5 of this thesis)83.  
There were 50 of these serum samples included in this study. 
4.3.2. Laboratory testing 
Human serum samples were analysed using the standard IFA and ELISA methods as 
previously described with anti-human FITC or anti-human HRP as the detector (Chapter 2 
– sections 2.2.3. & 2.2.4.). For some animal species, species-specific conjugates were 
available, and sera from these animals were examined using the standard indirect IFA as 
applied to the human sera. However, for a significant number of animal species, such a 
species-specific conjugate was not available, and a competitive ELISA, and a competitive 
IFA method were developed to test the sera from these animals. 
4.3.2.1. Screening Methods for Human Serum Samples 
In Australia, Q fever testing is largely performed using serological methods, with only very 
few laboratories now introducing molecular techniques. The gold standard for Q fever 
screening is considered to be the immunofluorescence assay (IFA)4, which is used as a 
diagnostic screening tool for confirmation testing and a tool to determine past exposure.  
This assay is used widely due to its high sensitivity and specificity rates (Chapter 2 - 
section 2.2.5.2.)4,8,9. 
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In this study, serum samples were screened for Q fever IgG antibodies using two 
screening assays:  
(1) a modified, in-house IFA method (Institute of Medical and Veterinary Science - 
IMVS, Adelaide)90 The IFA method was able to measure all serological markers 
IgA, IgG, and IgM for both phase I and phase II of Coxiella. For this study, only 
phase II IgG antibodies were examined. A full description for the method has been 
described in Chapter 2 under General Methods (Section 2.2.3).  
(2) a commercially available ELISA method (ALERE Panbio Ltd, Brisbane, 
Queensland, Australia). The ELISA kit was able to detect IgG antibodies against 
phase II C.burnetii organisms only (Chapter 2 - Section 2.2.4). Results were 
recorded as positive, negative, and equivocal according to manufacturer’s 
instructions.  For the purpose of this study an equivocal result was repeated and if 
still equivocal it was recorded as a negative for the ELISA assay.  
A third assay was used for discrepant analysis of discordant results that occurred between 
the two screening assays. This was a commercially available IFA kit assay (Focus 
Diagnostics, Cypress, California, USA) and specimens were recorded as detected or not 
detected. The assay was performed as per the manufacturer’s instructions and had a 
documented sensitivity of 100% and specificity of 99% when compared to the IMVS IFA 
method and the complement fixation test (CFT). 
A specimen that was positive in the two screening assays was considered a true positive, 
and the commercial IFA was not performed. Where a specimen was positive in only one of 
the screening assays, the commercial IFA was performed and the result in this assay was 
considered the final result. 
4.3.2.2. Indirect IFA for Testing Animal Sera 
Sera collected from dogs and cats were screened using IFA slides prepared as before for 
human screening, using the Nine Mile strain of Coxiella. The IFA methodology employed 
was as previously described in Chapter 2 (Section 2.2.3.). The specific conjugates used 
were anti-dog IgG (H+L) - F(ab’)2 fragment-FITC (Sigma-Aldrich, St Louis, USA) for the 
detection of dog specific antibodies, and anti-Cat IgG (H+L), F(ab’)2 fragment-FITC 
(Sigma-Aldrich, St Louis, USA)  for cat antibody detection, both conjugates were used at a 
working concentration of 1:500.  
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4.3.2.3. Competitive ELISA for the Detection of Coxiella in Animal Sera 
4.3.2.3.1 Principle of the Competitive ELISA Method 
Indirect ELISA assays and species-specific conjugates to detect the antibodies of different 
animal species were not commercially available. As a result, a variation of the standard 
ELISA method was developed specifically for this study to detect Coxiella antibodies in 
animals; the competitive ELISA. The general principle of the competitive ELISA assay is 
shown in Figure 4.1. 
The central principal of the competitive ELISA is a competitive binding process executed 
by the animal sample antibody and a competitor antibody. The procedures of competitive 
ELISA are different in some respects compared with the indirect ELISA method described 
in Chapter 2 (section 2.2.4.) for the detection of Coxiella antibodies in human sera. 
A simplified list of the steps involved in the competitive ELISA is as follows: 
1. Primary animal serum is incubated in the ELISA plate which is coated with 
Coxiella substrate antigens. 
2. After removal of unbound animal antibodies by washing, the competitor antibody 
(e.g. anti-Coxiella mouse serum) is added to the 96-well ELISA plate and 
incubated. 
3. Unbound competitor antibody is removed by washing the plate. (The more anti-
Coxiella antibodies in the animal serum, the less competitor antibody will be able 
to bind to the antigen in the well, hence "competition.") 
4. An enzyme conjugated anti-competitor species antibody (e.g. anti-mouse HRP 
conjugate) is added, incubated and washed to remove unbound conjugate. 
5. A substrate is added, and the bound enzymes elicit a chromogenic signal. 
 
For competitive ELISA, the higher the sample antibody concentration, the weaker the 
eventual signal. The major advantage of a competitive ELISA is the ability to test serum 
samples from animal species for which a species-specific conjugate is not available. 
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4.3.2.3.2. Titration of Inhibitor Antibody 
Known positive sera from different animal species were tested in the competitive ELISA 
using the commercially available human ELISA screening kits.  Previously confirmed 
pooled human positive sera was used as the competitor antibody.  These initial trials 
proved to deliver a high background absorbance in the assay and it was determined that 
human serum was not acceptable for the use as a competitor in the competitive ELISA. 
Coxiella-positive mouse sera, provided by Dr Alana Cooper (James Cook University, 
Townsville) at high titre was then used as the competitor antibody in the competitive ELISA 
method. A checker board titration was performed to determine the optimal concentration of 
competing mouse sera to be used, with the appropriate anti-mouse conjugate.   
4.3.2.3.3. Optimisation of Reagents 
Q Fever Phase II IgG ELISA plates (ALERE Panbio Ltd, Brisbane, Queensland, Australia) 
were blocked with 10% skim milk at 37⁰C for one hour, and washed three times with wash 
buffer provided in the kit.  Positive mouse sera were diluted using kit dilution buffer from 
1:1 to 1:20,000 and 100µL was loaded into the plate (Figure 4.2), and incubated for 1 hour 
at 37⁰C.  The plate was washed three times using kit wash solution and 100µL of goat 
anti-mouse IgG specific HRP-conjugate (Sigma-Aldrich, Missouri, USA) diluted 1:100 to 
1:102,400 was loaded across the plate as per Figure 4.2. The plate was incubated at 37⁰C 
for one hour. The plate was then washed three times using kit wash provided. 100 µL of 
tetramethylbenzidine (TMB) substrate was added and incubated at room temperature in 
the dark for 30 minutes.  The substrate reaction was stopped by the addition of 100 µL of 
2M sulphuric acid, producing a final yellow colour. Optical densities in the plate were then 
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determined using the Molecular Devices Spectramax 340PC384 plate reader at 
wavelength 450nm. 
 
Figure 4.2: Configuration of ELISA plate for optimisation of competing antibodies and 
conjugate for the screening of animal sera to determine previous exposure to Coxiella 
antigens. 
Optimal results in the checkerboard titration of the competitor mouse sera and the anti- 
mouse conjugate was established as a dilution factor of 1:500 for the mouse serum, and a 
1:200 dilution of the conjugate (Figure 4.3).  These dilutions were subsequently used in the 
competitive ELISA.  
4.3.2.3.4. Determination of Assay Parameters 
The level of competition required for assigning positive and negative values was 
determined using known positive rabbit sera obtained from a commercial source (R-
Biopharm, Laboratory Diagnostics Pty Ltd, Kurnell NSW, Australia).  Dilutions of the rabbit 
sera were analysed using the IFA method described in Section 4.3.2.1 above with the 
substitution of anti-rabbit IgG fluorescein isothiocyanate (FITC) as a species-specific 
conjugate, and a dilution end point was determined.  Based on this, the rabbit serum was 
diluted from 1:100 to1:1000,000 (see Figure 4.4) and loaded onto the indirect ELISA plates 
as per the described method above. Rabbit-specific HRP-conjugated goat anti-rabbit IgG 
(Sigma-Aldrich, Missouri USA) was used in the ELISA as the detector.  
The end-point titre of positive rabbit sera determined to give an equivocal or negative 
result in the indirect ELISA was 1:50,000 (Figure 4.4). Titration of this antibody by IFA 
showed an end point of one titre higher at 1:100,000. 
 
 137 
 
 
 
Figure 4.3: Competitive ELISA mouse antibody and conjugate checkerboard titration. 
Optimal dilutions were determined. 
        Shows combination of anti-mouse antibody and conjugate dilution chosen for 
subsequent use in the competitive ELISA.  
The positive rabbit serum dilutions were then re-screened using the competitive ELISA 
assay with positive mouse sera used as a competitor antibody and detection of this 
antibody using HRP-conjugated goat anti-mouse IgG (Sigma-Aldrich, Missouri USA). 
Negative human and rabbit sera were also screened using the assay and gave identical 
results. As the supply of Coxiella-negative human sera was more plentiful, this was used 
as the negative control throughout the subsequent experiments. 
 Using the competitive ELISA, dilutions of positive rabbit serum ranging from 1:100 – 
1:10,000 which have been predetermined to be positive by indirect IFA, showed 
absorbance values of less than 2.0 OD’s  (Figure 4.5).  While negative human sera 
screened with the competitive ELISA gave absorbance values of >2.0 indicating no 
competition for binding to the antigen.   
From the results above, it was determined that the following conditions for optimal assay 
performance would be applied in the competitive ELISA used in this study: 
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 Test animal serum dilution of 1:10 
 Competitors mouse serum dilution of 1:500  
 Anti-mouse conjugate dilution of 1:500 
 
Figure 4.4: Positive rabbit serum dilutions in ELISA using species specific HRP-
conjugated anti-rabbit IgG to determine end point titre absorbance of a positive serum 
 
Figure 4.5: Positive rabbit serum dilutions in competitive ELISA using mouse sera as 
competitive antibody to determine cut off point titres absorbance 
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4.3.2.3.5. Calculation of Results 
Using the above parameters, it was determined that if the difference in OD between the 
negative sera and the test sera calculated as a percentage was 40% or above, then the 
sample was deemed positive.  
Calculation:       (OD Negative Serum  –  OD Test Sera) x100    =  % of Competition 
                                                 (OD Negative serum) 
 
Known positive and negative animal sera from different species were finally used to verify 
the competitive ELISA. Results are shown in Figure 4.6 and Table 4.4. 
4.3.2.3.6. Optimisation of the Competitive IFA Using Animal Sera 
The indirect IFA was performed using the same method previously described in the 
general methods in Chapter 2 (Section 2.3.3). The competitive IFA method used animal 
serum undiluted and diluted 1:5 in 3% Chicken yolk sac (IMVS Adelaide, South Australia). 
The 5µL of test serum was loaded to the slide and incubated for 30 minutes at 37ºC, 
washed 2 times for 5 minutes in PBS-tween, air dried, and 5µL of competitive mouse sera 
diluted 1:1000 was loaded. This was incubated for 20 minutes at 37 ºC. The sera were 
washed as before and slides air dried.  The slides were then loaded with 8µL of FITC 
conjugate diluted 1:500 in PBS with 1% Evans blue to each well and incubated for 30 
minutes at 37ºC before being washed for 5 minutes in 2x PBS-tween and air dried.  Slides 
were then mounted with coverslips and read using a fluorescent microscope as previously 
described. Figure 4.7 shows the results obtained in competitive IFA for positive and 
negative Coxiella animal serum. 
4.3.2.4. Screening Methods for Animal Serum 
Competitive ELISA:  Animal test sera were screened using the competitive ELISA method 
described above.  This method used the commercially available Panbio Coxiella ELISA 
plates from (ALERE Panbio Ltd, Brisbane, Queensland, Australia), which were coated with 
antigens derived from the Henzerling strain of Q fever.  These plates were deliberately 
chosen so that the substrate antigen used was the same as the indirect ELISA used to test 
human sera. This allowed a direct comparison of human seroprevalence rates with animal 
rates knowing there was no discrepancy’s due to different strain types of Coxiella as has 
been identified previously 91 .  
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Figure 4.6: Competitive ELISA plate image of positive and negative animal sera 
 
Table 4.4: Competitive ELISA optical densities at 450nm and the % of competition 
between test sera and detector sera. 
Column 1 Serum Sample Loaded 
OD 
450nm 
Colour 
% 
Competition  
Detector Antibody 
Human Positive (Titre:256) 0.086 Clear 97.0 
Mouse Detector (1:500) 
Human Positive (Titre:512) 0.095 Clear 96.7 
Human Positive (Titre:64) 1.159 Faint Yellow 59.7 
Human Equivocal 2.614 Yellow 9.0 
Human Negative 3.875 Yellow -34.8 
Rabbit Positive (1:10) 0.163 Clear 94.3 
Rabbit Positive (1:100) 0.101 Clear 96.5 
Rabbit Positive (1:1000) 1.737 Yellow 39.5 
Column 2 Serum Sample Loaded     
Human Positive(Titre:256) 0.072 Clear N/A 
No Detector (Diluent) 
Human Positive (Titre:512) 0.072 Clear N/A 
Human Positive (Titre:64) 0.035 Clear N/A 
Human Equivocal 0.076 Clear N/A 
Human Negative 0.058 Clear N/A 
Rabbit Positive (1:10) 0.055 Clear N/A 
Rabbit Positive (1:100) 0.054 Clear N/A 
Rabbit Positive (1:1000) 0.054 Clear N/A 
Column 3 Serum Sample Loaded     
Horse Positive 1.642 Faint Yellow 42.9 Mouse Detector (1:500) 
Horse Positive 0.047 Clear N/A No Detector (Diluent) 
Cat Equivocal 3.747 Yellow -30.4 Mouse Detector (1:500) 
Cat Equivocal 0.101 Clear N/A No Detector (Diluent) 
Mouse Positive 2.870 Yellow N/A Mouse Detector (1:500) 
Mouse Positive 2.893 Yellow N/A No Detector (Diluent) 
Diluent 2.960 Yellow N/A Mouse Detector (1:500) 
Diluent 0.058 Clear N/A No Detector (Diluent) 
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 C      D 
Figure 4.7: Competitive IFA Images taken under the Nikon Fluorescent Microscope  
A: Coxiella phase II antibody positive rabbit serum in competitive IFA with mouse detector 
serum  
B: Coxiella phase II antibody negative rabbit serum in competitive IFA with mouse 
detector serum 
C: Coxiella phase II antibody negative flying fox serum in competitive IFA with mouse 
detector serum  
D:  Coxiella phase II antibody positive flying fox serum in competitive IFA with mouse 
detector serum 
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Indirect IFA and Competitive IFA: The indirect IFA used to screen animal sera was the 
same method as described in Chapter 2 (section 2.2.3.) with the substitution of species-
specific FITC conjugates to detect antibodies. The competitive IFA was performed as 
described in section 4.2.2.2.5 above.  
4.3.3. Data Analysis 
Patient demographic data were analysed based on date of collection, date of birth/age, 
sex and postcode. Two distinct geographical populations were defined based on patients’ 
postcode sorted into the 39 statistical subdivisions (SSD) within Queensland. On analysis 
of the research data 95% confidence intervals were calculated using Stata 10 (Stata Corp, 
College Station, Texas, USA).  
4.4. Results  
 4.4.1. Seroprevalence of Q fever in Human Sera from Queensland 
Serum samples (N=1988) were screened for both Coxiella phase I and phase II IgG 
antibodies using the IFA method.  Of these, 103 were Q fever phase II IgG-positive, giving 
a seroprevalence in the total sample population of 5.2% (95% CI: 4.3%-6.2%).  
Examining the seroprevalence in 1182 serum samples collected from the rural population 
only, the prevalence rate was 5.3% (95% CI: 4.6%-6.6%), compared to a seroprevalence 
of 5.0% (95% CI: 3.7%-6.7%) in 806 serum samples from an exclusively urban population. 
 Of the 63 seropositive males identified, 36 (57%) were from rural Queensland, and from 
the 40 seropositive samples from females, 27 (68%) were from rural communities (Table 
4.5).   
1144 serum samples were collected from adults (older than 15 years), with 92 (8.0%) of 
these positive for Q fever IgG. 649 of these samples were collected from a rural population 
and showed a seropositivity of 8.8% (57/649). Similarly, the 495 samples from the urban 
adult population showed a seropositivity of 7.1% (35/495).  An increase in seropositivity 
with increasing age was noted in this sample population (Figure 4.8 and Table 4.5). 
Of the 103 positive samples above, 77 (75%) also had antibodies to Coxiella phase I. 
These results were detected from all age groups with 50/77 (64.9%) positive results from 
males, and 27/77 (35%) from females.  
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Figure 4.8: Distribution of seropositive results with age groups in rural and urban 
populations. 
 
In addition to the adult samples above, 844 samples were from children under the age of 
16. Of these paediatric samples, 533 (63.1%) were from children in rural communities and 
311 (36.8%) from those in urban settings. Of the 844 samples tested, 11 showed previous 
exposure to Q fever; 5 boys and 6 girls, giving a seroprevalence in the Queensland 
paediatric population of 1.3% (95% CI: 0.7%-2.3%).  
Six (6) seropositive children, 4 girls and 2 boys were from rural Queensland, and 5 
seropositive samples were from children living in urban locations, with 2 positive samples 
from girls and 3 from boys.  
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Table 4.5: Results and percentages of the Q fever sero-positives described by gender, 
location, and age-group. 
 
Sample 
(n) 
Seropositive 
(n, %, 95%CI) 
Sex   
Female 1020 40   3.9%  (95% CI 2.9-5.3) 
Male 968 63   6.5%  (95% CI 5.1-8.2) 
Location   
Metropolitan Brisbane 806 39   4.8%  (95% CI 4.0-6.0) 
Rural 1182 64   5.4%  (95% CI 4.4-6.4) 
Age-group   
0 to 15 844 11   1.3%  (95% CI 0.7- 2.3) 
16 to 39 371 17    4.6% (95% CI 2.9- 7.2) 
40 to 64 385 38   9.9% (95% CI 7.3- 13.3) 
65+ 388 37   9.5% (95% CI 7.0- 12.9) 
Total Sera 1988 103   5.2%  (95% CI 4.3-6.2) 
 
4.4.2. Seroprevalence of Q fever in Animals from Queensland 
Of the 628 animal sera that were screened for Coxiella phase II IgG antibodies in both the 
competitive ELISA assay and the IFA or competitive IFA, 14 samples were identified as 
positive.  This gave an overall seroprevalence amongst all the animals screened of 2.1% 
(95% CI = 1.0% - 3.1%).   
There was a higher seroprevalence recorded in the cat population of 2.5%, (4/158) (95%CI 
= 0.8% - 6.6%).  These four samples were positive in all three assays (the competitive 
ELISA and both the indirect ELISA and indirect IFA using species specific conjugates.  
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The dog sera showed and overall seroprevalence rate of 1.9 % (9/470; 95% CI = 1.0-
3.7%) using a combination of assays.  The IFA assay using species-specific anti-dog 
conjugate - FITC showed greater sensitivity and detected nine positive sera in dogs. There 
were 6/470 (1.3%; 95% CI = 0.5% - 2.8%) sero-positive samples detected among the dogs 
screened with the competitive ELISA.  
Analysis of the 50 flying fox sera returned one positive result by the competitive IFA 
(Figure 4.6).  This gave a seroprevalence among the flying foxes of 2.0% (95% CI = 0.1% 
- 16.7%).   
A summary of seroprevalence in animal sera and the assays used is shown in Table 4.6. 
 
Table 4.6: Seropositivity determined in animal sera from three species using Indirect IFA 
and competitive ELISA and IFA assays.  
  Seropositive Samples 
Species 
Number 
(n) 
Competitive 
ELISA (%) 
Species 
Specific IFA 
(%) 
Competitive 
IFA (%) 
Total (%) 
 Dog 470 6 (1.3) 9 (1.9) ND 9 (1.9) 
 Cat 158 4 (2.3) 4 (2.3) ND 4 (2.3) 
 Flying Fox 50 0 ND 1 (2.0) 1 (2.0) 
 Total  10 (1.5) 13 (2.1) 1 14 (2.1) 
ND- Not Done 
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4.5. Discussion  
It is known that Q fever infections in humans are acquired through the inhalation of 
contaminated particles released by infected animals in their products, and hence the 
disease is more frequently recorded in rural settings, where close contact with ruminant 
animals is common.   In 2006, Queensland reported a notification rate of 107 Q fever 
infections per 100,000 people, with the majority of these in South West Queensland, a 
rural area with a large agricultural base50. This fact was supported by notification data for 
the Queensland population in this study, which showed that the highest numbers of 
confirmed Q fever cases occurred in rural communities, with a ratio of 5.5:1.0 of rural to 
urban notified cases.  
However, this difference was not observed in the seroprevalence results for these two 
populations in this study. The seroprevalence of Q fever in rural samples tested was 5.3% 
which was very similar to the 5.0% for the urban population. These results were also at 
odds with other studies 6,92–96, and reflect a significant level of exposure in the urban 
Queensland population possibly without clinical manifestation, compared to more overt 
clinical disease described in the rural population.  This may be the consequence of 
heightened awareness of disease in the rural communities, with more Q fever laboratory 
testing being performed, thereby resulting in a greater notification rate. However, it may 
also be the result of the encroachment of urban housing at the outskirts of cities, utilising 
land previously used for rural (farming) purposes, in particular cattle grazing and abattoir 
sites. An additional possibility may be that Queensland cities are intermittently enveloped 
by dust storms originating in rural areas, containing Q fever bacteria on dust particles 
which may have resulted in further undiagnosed cases in urban areas 92.  
However, the current paradigm in Australia is that the vaccine is only made available to 
rural populations, or workers in high risk occupations as these are considered to be most 
at risk of exposure. The findings from this study clearly show that exposure to Coxiella is 
more widespread, and that it may be advisable to extend the vaccination program to 
include the population more generally. Before this may happen however, further studies 
must be conducted to assess the scope of risk factors for the general population. 
The notification data described in Chapter 3, and the observations made by others showing 
that males are more often diagnosed with Q fever than females7,97,98 was generally 
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supported by the results of the seroprevalence from this study.  This presumably is due to 
the fact that occupational exposure is the primary cause of infection and occurs 
predominantly in the male workforce. Although the seroprevalence data supported this 
finding, the ratio of male to female exposure to Q fever was less pronounced. This may be 
explained by an increasing need and interest from rural women to be involved in animal 
handling occupations that may have previously been performed by men, and hence 
increasing their risk of disease. Alternatively, perhaps women are exposed from 
contaminated material at a lower dose, carried by their male partners, and go on to develop 
an asymptomatic infection with the subsequent development of an immune response. 
The seroprevalence of 8.0% observed in the Queensland adult population was low 
compared to some other seroprevalence studies performed in Australia and overseas 
(Tables 4.1, 4.2) which showed values ranging from 3% to 66%.  However, most of these 
other studies were performed on “at risk” populations only, such as rural workers or a 
general population of adult age.  This study however, investigated samples taken from the 
general Queensland population which were not associated with outbreaks of the disease, 
and included subjects with a varying range of ages including children.   
There have been a limited number of previous seroprevalence studies that investigated Q 
fever in a paediatric population.  These previous studies have been limited by either small 
numbers of samples, and/or being drawn from a high risk population. The seroprevalence 
of 1.3% in the paediatric sample set tested here, reflected results reported by others in a 
recent study of children younger than 16 years of age from South West Queensland. These 
showed a seroprevalence rate of  2.5% from 237 samples examined50.  However, these 
children were known to reside in a high risk area11,50.   
Overall, the seroprevalence results in this study supported the hypothesis that currently the 
greatest risk of Q fever infection in Queensland is for males living or working in a rural 
environment. Although the seroprevalence in children was significantly lower than adults, of 
concern was the observation that the average annual notification rate of Q fever in 
Queensland children has increased nearly 4-fold over the last 7 years. The reasons for this 
are unclear but the introduction of the NQFMP may have increased awareness of the 
disease and the use of diagnostic screening. This highlights the need to closely examine 
public health policy which may prevent or limit the acquisition of Q fever in the paediatric 
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population, and vaccination for children and adolescents in high-risk settings should be 
strongly considered. 
In animals the disease process has not been as well-defined as in humans99. The 
presence of antibodies in animal sera cannot determine the infectious state of the animal, 
as antibody production may continue long after the animal was initially infected. Also, 
some animals shed the organism prior to the production and detection of antibodies, while 
other animals never show any seroconversion after exposure and infection99.   
The detection of antibodies in the companion animals screened in this study raised many 
questions regarding the levels of exposure and shedding that may be occurring from this 
potential source of infection.  The seroprevalence among dogs was 1.9% from the 470 
companion animals screened.  This was within the various seroprevalence rates reported 
in other countries throughout the world, however, compared to data reported by Cooper et 
al (Townsville, Australia)  in 201177, this was a very conservative rate. This may simply be 
related to the geographical location, or perhaps differences in sampling or test methods.  
The animals screened in the study described in this Chapter resided in South East 
Queensland and the animals investigated by Cooper et al77 were from Central Northern 
Queensland, particularly Townsville, which is an area that reports high numbers of Q fever 
notifications. Differences in the seroprevalence rates reported may also be due to different 
strains of Coxiella used as substrate antigens in the assays used to screen for antibodies, 
resulting in differences in test results.  To address this potential limitation, this study 
specifically used the commercially available kit, which used the Henzerling strain in the 
preparation of antigen coating on the ELISA plates, thus ensuring that the most consistent 
results were obtained.  
The 2% antibody detection rate observed among cats from South East Queensland, was 
again within the range of seroprevalence rates reported from other countries (Table 4.3).   
Cats, particularly domesticated and parturient cats, are known reservoirs of infection and 
may be responsible for transmission of the bacteria to humans, as illustrated by outbreaks 
of Q fever involving many individuals, which have been directly linked to cats71,100.  Recent 
studies performed in New South Wales, Australia, identified that 1% of domestic 
companion animals (dogs and cats) were seropositive for Coxiella antibodies (Table 4.3). 
The seroprevalence results above showed that cats carry evidence of a significant level of 
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exposure, and cats may be the cause of an increasing rate of spread of the disease to 
humans,  
These seroprevalence results have illustrated that domestic cats and dogs have a 
substantial level of exposure to C.burnetii and therefore may pose a potential threat of 
infection to their owners and to the communities in which they reside.  Also, cats may 
travel some distance within a 24 hour period, enhancing the potential for spread of 
Coxiella over a greater area.   
Finally, the evidence showing that flying foxes have also been exposed to Coxiella is a 
significant finding. Flying foxes are very mobile, sometimes flying hundreds of kilometres 
per night. Therefore, if these animals are a reservoir for Coxiella infection, this will have a 
significant implication for the wider spread of Q fever disease, not only for humans, but 
also other animals, particularly farm animals and native fauna.  
4.6. Significant Outcomes from this Chapter 
The results of this study showed: 
 This was the first study to show that the seroprevalence for Coxiella in the human 
urban population was comparable to the rural population of Queensland.   
 Similarly, the findings showed that children residing in Queensland are an 
emerging group at risk of Q fever infection. 
 The demonstration that flying foxes may be a potential reservoir of Coxiella was 
novel, and warrants further investigation to assess the potential for these animals 
to be a source of widespread infection. 
  A competitive ELISA was developed to test for the presence of Coxiella antibodies 
in animals. This assay may be used in future studies to conduct a further, more 
comprehensive, survey of Coxiella seroprevalence in animals, particularly native 
fauna.  
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5.1 Introduction 
Q fever disease is a worldwide zoonosis with the infectious agent having been detected in 
every country with the exception of New Zealand1.  The distribution of Coxiella is 
widespread throughout the entire animal kingdom with detections in many species2.  
However, large domestic ruminants are the main reservoirs of infection to humans3.  
Queensland notification data shown in Chapter 3 were consistent with data reported 
around the world showing that Q fever notifications were recorded predominantly in rural 
regions and in those subjects that were exposed to large ruminants.  However, the 
seroprevalence data generated for the Queensland population in Chapter 4 showed a 
different pattern of exposure to that observed in the notification data reported in Chapter 3. 
These data showed that Q fever exposure occurred at the same rates in rural communities 
as it did in urban settings, and implied that there may be other sources of  Coxiella burnetii 
infection4. 
5.1.1. Animal Infections 
Coxiella infects animals asymptomatically, often residing persistently within the host’s 
macrophages. Female animals frequently have chronic infection and harbour high 
bacterial loads in their reproductive organs, including the mammary glands and the uterus.   
There have been reports of abortions and still births associated with Coxiella infection, as 
well as animals born with low birth weight and failure to thrive.  Animals with high loads of 
Coxiella in birth products and the products of conception expel the bacteria along with the 
offspring and birthing products directly into the environment.  Concentrations of the 
organisms expelled have been reported as high as 109 Coxiella organisms per gram of 
placenta 2.  Therefore the risk of infection to humans is especially high in large facilities 
housing ruminants, such as barns, dairies, abattoirs and their surrounding areas.  
 Furthermore, Coxiella organisms are extremely hardy and able to withstand harsh 
conditions for long periods of time.  The result is that they can survive for several months 
in areas which have had animals residing 5.   
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5.1.2. Transmission to Humans  
5.1.2.1. Ruminants as a Source of Infection 
The common route of transmission associated with infections in animal handlers or 
subjects with direct animal contact is through the inhalation of contaminated aerosols or 
direct contact with contaminated material.  However, there are many infections that occur 
in humans residing in low risk communities such as in urban settings or where no animal 
contact has been reported.  The primary source for the dispersal of Coxiella bacteria to 
these areas of low risk is thought to be wind, and the transportation of infected animals 
through these areas.  Both of these modes of Q fever transmission have been implicated 
in previous outbreaks of disease6–9.   
5.1.2.2. Ticks as a Source of Infection 
Part of the natural route of transmission for Coxiella to animals includes the transmission 
via ticks, which may act as a reservoir for the bacteria2.  Ticks harbour Coxiella in their 
digestive tract and expel the organism via faecal excrement.  Tick faeces contains high 
loads of the bacteria,  which is responsible for contaminating the skin and wool of the host 
on which ticks have been feeding10.  In addition, ticks may be the source of infection for 
native and domestic animals. Coxiella has been isolated from many tick species around 
the world. In Australia Coxiella has been detected in ticks removed from a variety of native 
animals which were widely distributed geographically11.   
5.1.3. Human Infections 
Q fever infections in humans may present as a variety of clinical syndromes and are 
classified as either acute or chronic. Acute Q fever infections may be asymptomatic or 
present as a self-limiting febrile illness such as pneumonia or hepatitis12–14. Chronic Q 
fever disease follows an acute episode resulting most commonly in endocarditis or may 
manifest as a chronic hepatitis or osteomyelitis; with the latter commonly present in 
paediatric infections3,15,16.  Initially infection may be subclinical or asymptomatic in patients 
where there is no direct contact with large ruminants, and often in these cases the patient 
can go undiagnosed and untreated until a time when a diagnosis of chronic Q fever is 
made17,18.  This may be one of the explanations why the disease is considered to be 
under-diagnosed in areas considered to be of low risk.  Yet recent seroprevalence data 
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show a significant level of exposure in these low risk communities, which warrants further 
investigation. 
The risk of contracting Q fever in a rural setting has been extensively reported worldwide 
and has been recently investigated in Australia.  Direct correlations between animal 
handlers contracting Q fever from large ruminants has been identified and well 
documented10,19–22.  Publications have identified many species of animals from around the 
world as being hosts for Coxiella2,10. There have been few prevalence studies from 
Australian remote and urban areas that have shown  that a number of animal hosts, both 
domestic and native; have been exposed to Coxiella, with these animals producing 
detectable antibodies.21,23–26.   
5.1.4. Presence of Coxiella in the Environment 
Coxiella is shed directly into the environment from infected animals and is highly stable for 
many months and even years27.  The Netherland has recently endured an exceptionally 
large epidemic with over 4,000 cases of Q fever reported from 2007 to 2010.  This 
outbreak was the result of infected pregnant goats in local surrounding goat farms 
shedding billions of organisms into the environment.  With less than 10 organisms required 
to seed infection in humans, the dispersal of Coxiella via various transmission routes 
resulted in many people being exposed and contracting Q fever 28–30.  It was established 
that those residing within a 5 kilometre radius were at greatest risk of contracting Q fever 
from the infected goat farms, and was directly related to the dust generated from these 
farms31.  It also highlighted that Q fever infection was due to the dispersion via wind and 
the movement of contaminated bedding of animals shedding Coxiella. In Australia, the 
majority of the country is arid and often windy which is perfect for the formation of dust.  
Australia has been recognized and often referred to as the Southern Hemisphere’s largest 
source of dust, with the central Australian basin, which expands into the Northern Territory 
and South Australia, spanning much of inland Queensland and New South Wales.  
Australia is the globe’s eighth largest source of atmospheric dust32,33. 
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5.2. Specific Aims Addressed in this Chapter 
The results in chapters 3 and 4 indicated a discrepancy between notification rates and 
evidence of previous exposure to Q fever in the Queensland urban population.  Chapter 4 
showed evidence of Coxiella exposure in animals including domestic pets.  This evidence 
points to a more widespread source of Coxiella infection for humans, which is mostly likely 
associated with environmental exposure. 
Specifically this addressed the following: 
 An examination by PCR of a diverse range of samples from a large number of 
animal species to determine the presence of C.burnetii DNA. 
 To examine soil and dust samples collected from various geographic locations in 
Queensland for the presence of C.burnetii DNA, and identify these as possible 
sources of infection. 
5.3. Materials and Methods: 
5.3.1. Samples 
It is hypothesised that environmental exposure plays a large role in the dissemination of 
Coxiella burnetii in the community. To determine the potential source of exposure for 
humans in Queensland, different sample banks of environmental samples were examined.  
The species sample types tested in this study are shown in Table 5.1. 
5.3.1.1. Blood, Urine and Milk Samples 
In total, 515 blood samples were collected from 20 different animal species residing in 91 
different geographical locations. 704 urine samples from 10 animal species in 90 locations, 
submitted for investigations not including Q fever, were conveniently obtained from private 
animal pathology providers.  There were 7 milk samples collected from bovines kept on a 
farm property at Gatton, Queensland. 
In addition, 90 DNA extracts from flying fox urine were obtained from the Queensland 
Centre for Emerging Infectious Diseases, Biosecurity Queensland. These samples were 
collected via large tarpaulin urine collection pools set up directly under flying fox colonies.  
The colonies were from Cedar Grove, Slacks Creek and the Gold Coast, in South East 
Queensland. These samples were specifically collected for the screening of Hendra virus 
and were negative for this virus by molecular testing. 
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Table 5.1: Species sample types collected for C.burnetii investigation.  * Ticks were 
removed from 2 species. Ɨ Urine was obtained as DNA extracts from pooled collections. 
Species Specimen Collected 
 Total Samples Blood Faeces Milk Ticks* Urine 
Avian 1 1 - - - - 
Bilby 1 1 - - - - 
Bovine 12 4 - 7 - 1 
Canine 614 201 - - 40 373 
Caprine 1 1 - - - - 
Dolphin 2 2 - - - - 
Donkey 1 1 - - - - 
Elephant 2 2 - - - - 
Equine 126 112 - - - 14 
Feline 319 132 - - - 187 
Ferret 1 1 - - - - 
Flying-Foxes 90Ɨ - - - - 90Ɨ 
Kangaroo 3 3 - - - - 
Koala 99 26 43 - - 30 
Lemur 2 2 - - - - 
Porcine 7 7 - - - - 
Possum 9 1 - - 5 3 
Quoll 1 1 - - - - 
Reptile 3 3 - - - - 
Tiger 9 7 - - - 2 
Wallaby 5 - 4 - - 1 
Wombat 10 7 - - - 3 
Total 1318 515 47 7 45 704 
 
5.3.1.2. Faecal Samples 
Faecal samples (N=47) were collected from 43 koalas and 4 wallabies, residing in South 
East Queensland.  These samples were obtained by Australia Zoo between October 2010 
and December 2011 from animals brought to the clinic for trauma or treatment of injury.  
5.3.1.3. Animal Ticks 
This sample pool included ticks removed from domestic and native animals presented to a 
local Brisbane veterinary surgery in December 2011. There were 45 ticks from 5 possums 
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and 40 canines. All ticks were classified as Ixodeos holocyclus, commonly known as 
“paralysis ticks”. 
5.3.1.4. Soil and Dust Samples 
Approximately 50 grams of soil was collected from 151 locations throughout South East 
Queensland. These included a random collection from local Brisbane residences, and 
direct sampling from highway surrounds taken by cattle trucks in the Darling Downs, South 
West Queensland, which is considered to be the Q fever “hot spot” in Australia. These 
samples were collected from January 2011 through to October 2011 and were from 78 
geographical locations. 
Dust samples were provided by DustWatch Northern Atmospheric Environment Research 
Centre, Griffith University, Nathan, Queensland. Atmospheric dust collection involved the 
use of high volume air samplers (HVS) and monitors that were maintained and operated 
by selected Dust Watchers throughout Queensland.  The HVS instrument is able to trap 
the total suspended sediment onto a glass fibre filter paper (Whatman GF/A) with a 
nominal pore size of 1.6 µm.  A total of 72 dust samples collected at 2 geographical 
locations between 1988 and 2009 were tested for Coxiella.  These collection points were 
(1) South East Queensland; 35 samples from 20 dust events, and (2) Charleville with 37 
samples from 2 dust events. 
In addition, swab samples of dust collected from 50 domestic vacuum cleaners in 32 
geographical locations of Queensland were also tested.  These samples were collected by 
local residents between January 2011 and October 2011.  
5.3.2. Laboratory Testing 
5.3.2.1. DNA extraction:   
Nucleic acids were extracted from the various samples using commercially available kits. 
Before DNA extraction, equine herpes virus (EHV) was added to each of the different 
sample types to examine the efficiency and reproducibility of the various extraction 
processes by monitoring real-time PCR Cycle Threshold (CT) values. Nucleic acid was 
then extracted using the methods below for each sample type34,35. 
Animal blood, milk and urine samples were extracted using the DNeasy Blood and Tissue 
kits (Qiagen, Brisbane, Australia) as per the manufacturer’s instructions.  Briefly, 200µL of 
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sample was spiked with EHV before processing with a final dilution of DNA in 100uL of 
water. 
5.3.2.1.1. Flying Fox Urine   
Pooled flying fox urine was extracted using the automated KingFisher Duo Prime 
Purification System by ThermoScientific (Thermo Fisher Scientific, USA), in conjunction 
with the KingFisher Cell and Tissue DNA extraction kits (Thermo Fisher Scientific, USA) as 
per the manufacturer’s instructions. 
5.3.2.1.2. Faecal Samples  
Faecal samples were extracted using the Mini stool kit (Qiagen, Brisbane, Australia) 
following the manufacturer’s recommendations. Briefly, one pellet of faecal sample 
(approximately 1.5-2.0 g) was added to ASL buffer for cell lysis at 95°C. Inhibitors were 
removed by absorption using the kit InhibitEX tablets followed by centrifugation. The DNA 
in the supernatant was then extracted using the QIAmp spin columns as described in the 
kit insert and DNA was eluted in a 100uL volume of water. 
5.3.2.1.3. Tick Samples   
Tick samples were extracted using the DNeasy Blood and Tissue kits (Qiagen, Brisbane, 
Australia).  Ticks were placed on glass slides and engorged blood and tissue was released 
with a scalpel blade.  These were added to 200µL of tissue lysis buffer containing 20µL of 
proteinase K and incubated overnight at 56°C on a mechanical rocker at low speed.  The 
samples were then treated with the same extraction kit and method as the blood, milk and 
urine samples above. 
5.3.2.1.4. Soil Samples   
Nucleic acids in soil samples were extracted as previously described 36,37.  Soil samples 
were pre-treated prior to DNA extraction. Briefly, 5g of soil was mixed with phosphate 
buffered saline (PBS) and put on a mechanical rocker at room temperature for one hour. 
Samples were centrifuged for 5 minutes at 123g and the supernatant was retained and 
further centrifuged at 20,000g to pellet cellular material.  The pellet was resuspended in 
1ml of PBS and used in the DNA extraction protocol previously described with the QIAamp 
DNA Stool kit (Qiagen, Brisbane, Australia). 
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5.3.2.1.5. Dust Samples  
Dust collected on Whatman glass fibre filter paper was placed in sterile tubes containing 
5ml of sterile water. These were incubated at room temperature on a mechanical rocker 
overnight to release bacterial particles.  Briefly, 200µL of the dust suspension was 
processed with the DNeasy Blood and Tissue kits (Qiagen, Brisbane, Australia) using the 
manufacturer’s method for blood extraction.  The DNA extract was collected in a final 
volume of 100 µL of water for PCR. 
Dust swabs were processed as previously described by Kersh et el 37. Swabs were placed 
in 1.0ml of sterile PBS and vortexed.  A volume of 200µL was processed using the 
QIAamp DNA Stool kit (QIAGEN Australia) as per the previously published protocol. DNA 
was eluted in 100µL of water for PCR. 
5.3.2.2. Real Time PCR Method 
Real-time PCR for C.burnetii was performed targeting the repetitive IS1111 gene and the 
outer membrane protein com1 gene as previously described in Chapter 2 (section 2.2.2.1).   
EHV real-time PCR was described in Chapter 2 (section 2.2.2.2) of this thesis and was 
performed on all extracted samples.   
5.4. Results 
5.4.1. Animal Samples 
Screening by real-time PCR showed a total of 85 of 1318 animal samples were positive by 
either gene target, giving an overall incidence of 6.2% (CI 5.0%-7.5%).  Positive results 
were confined to 6 of 22 different animal species, from 28 different geographical locations 
throughout Queensland. Table 5.2 shows C. burnetii PCR results for the 6 different 
species with positive results and the various samples types screened.  
Of the 515 whole blood samples from 20 different species, 34 (6.6%; CI 4.8%-9.1%) 
samples had a positive PCR result in either gene target tested.  Of these 14 (2.7%; CI 
1.6%-4.5%) were positive for both targets leaving 20, (3.9%; CI 2.5%-5.9%) that were 
positive in a single Coxiella gene target. These were 18 extra IS1111 detection and 2 extra 
detections by the com1 target.  These detections comprised 5 different species residing in 
16 different locations.   
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Table 5.2: Positive PCR detections within a variety of sample types from individual animal 
species. Only those species recording a positive result are shown. 
Species 
Total  Samples 
Screened 
Species 
Detection Rate 
Specimen types 
Faecal Urine Blood Ticks 
Avian 1 100% 0 0 1 0 
Flying 
Fox 
90 7.8% 0 7 0 0 
Canine 574 5.6% 0 26 3 3 
Equine 127 11.8% 0 1 14 0 
Feline 319 7.8% 0 12 13 0 
Koala 99 5.1% 1 1 3 0 
TOTAL 1210  1 47 34 3 
 
In urine samples, 40 of 614 (6.5%; CI 4.8%-8.8%) were PCR positive for the IS1111 gene 
target. In addition, 28 (4.6%; CI 3.2%-6.5%) of these were positive with the second com1 
target.  These were collected from 4 species in 12 various Queensland locations.  There 
was additional testing on DNA samples from 90 pooled flying fox’s urine which showed 7 
(7.8%; CI= 3.8%-15.2%) were positive. Detections occurred as single target detections, 
with the IS1111 gene target giving one positive result and the com1 target identifying 6 
positives.  There were no detections among the 7 milk samples screened. 
Only one koala faecal sample of the 43 koala faecal samples tested was positive for 
Coxiella DNA (2.1%; CI 0.5%-10.9%) in the IS1111 gene target only.  None of the 4 
wallaby samples had detectable Coxiella DNA.  Of the 45 tick samples tested, 3 had 
detectable Coxiella DNA.  This was distributed with 2 ticks having detections in both 
IS1111 and com1 genes and an additional detection in the com1 gene.  This was a 6.7% 
(CI 2.4%-18.0%) detection rate among the ticks removed from metropolitan/urban animals. 
(Table 5.3). 
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Table 5.3: Table of different sample types collected from various animals and the numbers 
tested. Dual targets IS1111 and com1 were used and the numbers expressed as 
percentages. 
Sample 
Total 
Number 
Locations  
Postcodes 
PCR Detections 
Either Target IS1111 com1 
Blood 515 91 34 (6.6%) 32 16 
Urine 704 90 47 (6.8%) 41 34 
Faeces 47 2 1 (2.1%) 1 0 
Ticks 45 1 3 (6.7%) 2 3 
Milk 7 1 0 - - 
Soil 151 78 3 (2.0%) 3 2 
Dust 
(filters) 
72 2 5 (6.9%) 5 1 
Dust 
(swabs) 
50 32 1 (2%) 1 1 
 
Detection of C.burnetii occurred in animals sampled from 28 different locations within 
South East Queensland. The highest incidence, 18.5% (CI of 10.4%-30.9%), was in a 
semi-rural location in South East Queensland (postcode 4285; south west of Brisbane) 
followed by 8.8% (CI of 4.9%-15.4%) in the Gold Coast hinterland (postcode 4211). 
Samples from a nearby urban location (postcode 4127; Springwood, south of Brisbane) 
showed an incidence of 8.3% (CI of 4.2% - 14.1%).  
5.4.2. Soil and Dust Samples 
Of the 151 soil samples collected from South East Queensland, 3 (2.0%; CI 0.7% - 5.7%) 
contained detectable levels of Coxiella DNA.   Two of these were positive by both PCR 
targets, with an additional detection in the IS1111 gene target. The positive samples were 
collected from urban areas where there were no large ruminant animals residing.   
 The 72 dust samples collected by the HVS showed that 5, (6.9%; CI 3.1%- 15.2%) of the 
samples had detectable Coxiella DNA present.  These detections occurred in the IS1111 
gene with one sample having a dual detection with the com1 gene.  There were 2 positive 
samples collected from Brisbane and 3 from Charleville.  These positive dust samples 
were collected between 2001 and 2005.  There was a single detection (2.0%; CI 0.5%-
10.4%), of Coxiella DNA from the household vacuum cleaner swabs.  This sample had 
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detectable DNA in both the IS1111 and com1 gene targets.  This positive swab sample 
was obtained from Taigum (postcode 4018), close to the Brisbane CBD which is a semi-
rural area that now has high density housing on its boundaries. 
Table 5.4: Summary table of results for PCR testing of C.burnetii in soil and dust samples 
collected in Queensland from specific postcodes. 
Sample 
Total 
Number 
Different Locations  
(Postcodes) 
Detections 
   Either Target IS1111 com1 
Soil 151 78 3 (2.0%) 3 2 
Dust  
(HSV filters) 
72 2 5 (6.9%) 5 1 
Dust (swabs) 50 32 1 (2%) 1 1 
 
5.5. Discussion 
Traditionally, the acquisition of Q fever has been linked to close contact with ruminants. 
However, recent reports from Australia show that the number of cases of Q fever lacking 
any known direct contact with any animal is increasing 17,18,38. Furthermore, 
seroprevalence studies in Australia have highlighted the significant increase of exposure to 
Coxiella in supposably “low risk” communities and geographical locations 4,26,39. 
This study sought to identify potential sources for Coxiella exposure to humans in 
Queensland, and found an overall incidence of 6.2% (CI 5.0%-7.5%) amongst the 1318 
animal samples screened. Also, detections in environmental samples ranged from 2 to 
6.9% (CI =0.5%-15.2). Overall C.burnetii DNA was identified in all sample types tested 
from a variety of species residing in different geographical location throughout 
Queensland.   
The high prevalence (6.7%) of Coxiella found in the urine of domestic animals (cats 6.4% 
and dogs 6.9%) suggested that pets may play a significant role in the transmission of 
Coxiella in the domestic non-rural setting. Perhaps a likely pathway may be the spread of 
Coxiella-contaminated urine into the environment by these animals, followed by transfer to 
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the susceptible host through direct contact or aerosolation of contaminated soil or dust 
through gardening or mowing. The high rate of carriage in domestic dogs has been 
confirmed by seroprevalence studies  showing that 22% of dogs were previously exposed 
to Coxiella, again highlighting the potential risk to animal owners and those who have 
contact with the animals 25.  
Parturient cats have been identified as the primary source of isolated outbreaks of Q fever  
on a number of occasions 40,41. However, the results of this study highlighted the potential 
for humans to be exposed to C.burnetii not only via parturient animals and their birth 
products, but also to healthy animals performing normal activities.   
Screening of 122 native animals showed that 4.1% (CI 1.8%-9.2%) had detectable 
Coxiella DNA, in blood, urine or faeces, suggesting these animals as a potential source of 
infection. However, the predominant species with detectable organisms were koalas 
(5.1%).  These were the only species tested in significant numbers, and the prevalence in 
other native animals is likely to increase with a larger sample population.  This is 
supported by the findings in pooled flying fox urine samples (N=90) which showed that 
7.8% were positive for Coxiella DNA, suggesting that flying fox urine may be another 
source of transmission to either native or domestic animals and humans. Analogous to the 
current theory of Hendra virus transmission from flying foxes to horses, in this study 11.8% 
of 126 horses tested were positive for Coxiella DNA. These animals resided in close 
proximity to established flying fox roosts. 
It is postulated that ticks may be another source of bacterial transmission particularly 
amongst the native animal population. However, there is still considerable uncertainty if 
ticks themselves are infected or merely reflect the positive status of animals from which 
they derived their blood meal. In this study 45 ticks removed from both domestic and 
native animals were screened for Coxiella by PCR, showing a detection rate of 6.7%, with 
those removed from dogs having the greater detection rate (7.5%).  Ticks shed high loads 
of bacteria in their faeces and saliva and may be another potential  source for direct 
human exposure to Coxiella 42.   
Although Q fever disease in Queensland is frequently reported in rural communities, there 
has been a significant increase in detection of the disease in urban populations where no 
direct animal to patient contact can be identified 4,17. This is supported by the similarity in 
seroprevalence status between rural and urban populations reported in Chapter 4 of this 
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thesis. These observations cannot be attributed to animal spread alone, and other 
environmental factors clearly need to be considered. 
The inhalation of contaminated aerosols and dust particles as the source of human 
infection has also previously been reported 6,20,43–45, and a recent study in the USA 
described 24% of soil samples contained detectable Coxiella DNA 37.  This contrasted with 
the results of this study in which only 2% of soil samples had a detectable level of the Q 
fever organism.  These differences may just reflect sampling difference related to different 
geographic locations, or perhaps the differences in stock density and population density 
and distribution in the USA compared to a much sparser Australia. The samples in this 
study that did have detectable levels of Coxiella DNA were from “low risk areas” and 
coincided with positive samples collected from animals in the same region.    
During dry weather cycles, soil is frequently dispersed as dust, and hence dust may be an 
important mechanism for the dispersal of Coxiella organisms to both rural and urban 
regions as previously suggested by Kersh et el37. Examination of dust samples using HVS 
and domestic vacuum cleaners showed the presence of Coxiella DNA with an overall 
detection rate of 4.9%. The direct sampling of dust via HSV gave a 6.9% detection rate, 
representing positive results from both “high and low” risk areas.  This confirms that 
contaminated dust is a likely source of exposure to Coxiella in “low risk areas” and is 
perhaps responsible for asymptomatic disease and the development of high 
seroprevalence among low risk communities. 
This study specifically targeted samples from Queensland because of the high 
seroprevalence described previously in areas that were considered low risk 4.  There were 
many publications, using serological methods, that have reported that both domestic and 
native animals have significant exposure rates to Coxiella, yet the presence of the bacteria 
in these animals has not been widely studied.  This study was the first to investigate a 
diverse range of sample types collected from a variety of animal species identifying those 
as potential vectors in the transmission of Q fever to humans. In addition, data for soil and 
dust highlighted the important role these may play in the dispersal of Coxiella, not only as 
a source of infection for humans, but also as part of the transmission cycle in animals.  
This may help to explain the significantly high exposure rate in low risk populations which 
do not have direct animal contact.  
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5.6. Significant Outcomes from this Chapter 
 Coxiella burnetii was detected in a range of animals and ticks in South East 
Queensland. 
 Importantly, bacterial DNA was present in domestic dogs and cats, identifying these 
animals as a potential source of infection. 
 This is the first study which has identified flying foxes as harbourers of Coxiella, 
which has significant implications for the wider spread of the bacteria in the 
community.   
 Another unique finding by this study was the presence of Coxiella in environmental 
dust and soil samples collected in Australia. 
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6.1. Introduction 
Q fever was first discovered at the Royal Brisbane and Women’s hospital at Herston, 
Queensland in 1936 by Edward Derrick. He investigated a febrile illness in nine abattoir 
workers and was successfully able to transfer the infectious agent (Coxiella burnetii), via 
blood samples from the infected workers to guinea pigs and replicate the disease in the 
animal model1.  Further investigation by Frank Macfarlane-Burnet found that blood from 
the infected tissue of the inoculated guinea pigs was able to agglutinate when mixed with 
blood from convalescing patients, and so the beginning of a laboratory diagnostic system 
in which to identify and confirm the disease Q fever, began2. 
6.1.1. Bacteria 
C.burnetii is an intracellular, pathogenic, gram negative coccobacilli, which was renamed 
from the order of Ricketsiales to the more genetically related order of Legionallales in 
recent years.  The intracellular nature of the organism decreases the utility of traditional 
microbiological methods, such as isolating the bacteria by culture, which can be used to 
identify an acute infection.  The extreme infective nature of C.burnetii also poses an 
occupational hazard to diagnostic laboratory staff and hence traditional microbiology 
methods are not readily employed to determine infection in humans. C.burnetii is the only 
intracellular, pathogenic bacteria able to reside and replicate inside a phagosome, while 
evading the innate and adaptive immune response of its host. This in turn decreases the 
effectiveness of diagnostic tools, such as serology, for laboratory confirmation of the 
presence of the organism3.   
6.1.2. Variants 
This organism has a complex life cycle and is able to exist in two distinct forms, a small 
cell variant (SCV) which is the extracellular, survival form that is able to withstand harsh 
environmental conditions such as heat, desiccation and UV radiation4.  The SCV invades a 
host generally by the inhalation of the organism from the environment. The host 
macrophages are able to engulf the bacteria, which lead to transformation of the SCV to 
the large cell variant (LCV).  The LCV is metabolically different and has different surface 
proteins to the SCV.   Also Coxiella is biphasic, meaning that it has the ability to alter its 
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antigenic properties and structural lipopolysaccharide molecules resulting in two distinct 
serological variants, phase I and phase II5,6. It is these distinct phases that elicit a different 
antibody response in the infected host, which forms the basis of immunological testing and 
laboratory confirmation of infection1,2.  
6.1.3. Diagnostic Methods 
Usually, the microbiological diagnosis of Q fever relies upon serology, and the most 
commonly used serological techniques to determine disease status in patients with acute 
Q fever include the complement fixation testing (CFT), immunofluorescence assays (IFA) 
and enzyme linked immunosorbant assays (ELISA)7.  However, although highly reliable, 
serology provides only indirect evidence of infection, and antibodies are absent in the early 
phases of the disease. Recent advances in technology have allowed for the use of specific 
molecular techniques such as PCR to play a role in the diagnosis of Q fever, particularly in 
early acute infection8. However, the utility of molecular detection methods in the diagnosis 
of acute Q fever has not been widely tested.  
Q fever disease can be either acute or chronic and may be asymptomatic or present with a 
variety of clinical manifestations including, fevers, chills, severe headaches, pneumonia, 
hepatitis, osteomyelitis and fatigue syndromes9.  There is a strong belief that the true 
numbers of Q fever cases are under-diagnosed and hence under-reported in many 
countries10. This is supported by the findings in previous chapters of this thesis which 
highlight a difference between Q fever case notifications (Chapter 3) and the exposure 
rates of Coxiella in the Queensland population as determined in the seroprevalence study 
shown in Chapter 4.  Many countries, including Australia, only report clinical cases of Q 
fever disease after a laboratory confirmation has been obtained. However, accurately 
identifying cases of Q fever clinically presents a diagnostic dilemma due to the widely 
varying clinical presentations of the disease10,11.  The initial infection with C.burnetii will 
only produce symptoms in approximately half of the patients infected, with about 2-5 % of 
these patients going on to develop chronic Q fever12,13. Regardless of the clinical 
manifestation of a C.burnetii infection and disease severity, seroconversion will occur in 
most cases.  It is this immune response, produced by the different immunoglobulin subsets 
as a direct result of exposure to the two distinct phases of C.burnetii, that has allowed for 
differentiation and clinical diagnoses of both acute and chronic Q fever disease and hence 
lead to appropriate treatment and management of the distinctly different disease states14.  
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Acute Q fever in humans occurs approximately 14-21 days after initial inhalation of 
organisms, resulting in the presentation of immediate clinical signs of infection.  These 
may include severe fevers reaching peaks as high as 40 °C and lasting for extended 
periods if untreated. Fatigue, myalgia and headaches are also commonly reported from 
patients15 (see Appendix 6.1 at the end of this Chapter).  It is any, or combinations of these 
symptoms that complicate clinical diagnosis, as many of these manifestations occur in a 
variety of other respiratory illnesses, such as influenza. This contributes to the 
misdiagnosis and under- reporting of Q fever infections16.   
After initial exposure to the virulent phase I of the organism in the host, the bacteria in this 
phase continue to metabolise and multiply within the macrophage until modifications occur 
to the structural lipopolysaccharide (LPS). This results in an antigenic shift to form phase 
II, which is an avirulent form of the bacteria. This phase II is highly antigenic and one to 
which the host cells mount a specific immune response 17.  It is by the indirect 
measurement of the immune response and the production of phase-specific antibodies 
that Q fever disease diagnosis may occur. 
First infection with C.burnetii results in bacteraemia during which the bacteria may be 
isolated from the blood, followed by the induction of a specific immunoglobulin M (IgM) 
response against phase II antigen epitopes expressed on the cell surface. IgM antibodies 
may be detected as soon as seven days after onset of symptoms.  The specific 
immunoglobulin G (IgG) response, directed against phase II of the organism, occurs 
approximately seven days post exposure, and reaches a peak level at 3 – 4 weeks post 
infection.  The development of antibodies directed against phase I organisms may also be 
detected during the acute phase, but these are at notably lower titres (Figure 6.1).  
Chronic Q fever is a secondary disease that occurs in 2-5 % of patients who have suffered 
acute infections.  This form of the disease transpires months or even years after initial 
infection, and may persist for years. It may result in death of the patient, depending on the 
manifestation of the disease, before a definitive diagnosis can be made.  Serological 
methods have been employed over time to identify cases of chronic Q fever, which were 
characterised by an increase in phase I antibodies.  Typically, the heart is the organ most 
commonly affected during chronic Q fever resulting in endocarditis.  This is generally 
associated with patients who have an underlying heart valve defect, or in patients who are 
immunocompromised. During chronic Q fever infection, bacteria multiplying within the host 
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macrophages produce a permanent state of rickettsemia and induce production of 
elevated levels of antibodies to phase I in the host.  Clinically this low-level, persistent 
infection with C.burnetii produces an array of nonspecific symptoms, which in turn may 
delay a definitive diagnosis and appropriate treatment, resulting in increased morbidity and 
mortality8.   With the introduction of PCR, chronic Q fever diagnosis has become more 
sensitive and specific. However, the sample of choice is heart valve tissue which requires 
invasive cardio surgery for the patient. The initiation of such a procedure depends on 
clinical awareness by medical experts that Q fever may be involved; otherwise laboratory 
investigation still remains problematic 
 
  Acute Infection     Chronic Infection 
 
Figure 6.1: Temporal serological profiles for immunoglobulins A, G and M in acute and 
chronic Q fever in humans. The interval for PCR and culture positivity is shown early in 
acute infection. 
In Queensland and the rest of Australia, strict guidelines have been established to 
accurately confirm cases of Q fever.  The Queensland Health Communicable Diseases 
branch, together with the Public Health Laboratory Network, has specific clinical case 
definitions by which practitioners are able to notify the NOCS departments of Q fever 
cases. Clinical evidence of the disease is required for reporting cases but in the absence 
of laboratory confirmation, this alone is not sufficient for notification of the disease.   It is a 
requirement by the Communicable Disease Control Units of Queensland Health 
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(Queensland Government) that all Q fever cases be confirmed by definitive laboratory 
evidence18.  
Despite the many advances in serological test methods over the past decade, the accurate 
diagnosis of Q fever by serology is often still problematical. The reference (“gold 
standard”) method for acute Q fever diagnosis remains the IFA despite the number of 
different “in house” and commercial ELISA assays and the advances in molecular methods 
including strain typing and nucleic acid detection19. However, the knowledge of C.burnetii 
biology and its pathogenesis remains limited, and particularly the reasons that the disease 
is under-diagnosed need to be explored.   
6.2. Specific Aims Addressed in this Chapter  
The overall aim of this study was to determine if the current diagnostic algorithm 
employing serological tests only for the laboratory confirmation of acute Q fever in 
Queensland was adequate, or perhaps failed to diagnose early infections, and therefore 
contributed to the perceived under-reporting of disease as may be inferred from previous 
data. 
Also, the diagnosis of Q fever may not be considered in some patients with general non-
specific symptoms, or may be clinically diagnosed as a different disease. This study will 
also examine samples from patients with laboratory investigations not including Q fever, 
yet presenting with similar clinical symptoms. This will provide a measure of the potential 
rate of under-reporting that may result in cases where a definitive laboratory diagnosis was 
not made.  
Specifically the aims for this study were: 
 To compare the clinical utility of serological methods (IFA IgM and ELISA IgM) and 
the molecular method of PCR as tools to diagnose acute Q fever infections, and 
determine the optimal diagnostic algorithm for their use.  
 Use PCR to examine the presence of C.burnetii in various sample types collected 
from patients with similar clinical presentations as Q fever, such as respiratory 
illness, flulike illnesses and hepatitis. 
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 Investigate serum samples submitted for the investigation of pyrexia of unknown 
origin (PUO), atypical pneumonia, and respiratory infections in order to establish 
undiagnosed Q fever disease status in these patient populations  
 
6.3. Methods 
6.3.1. Diagnostic Assays  
To determine if assay sensitivity might be a causative factor for the under-reporting of 
acute Q fever in Queensland, three assays were applied to investigate potential assay 
sensitivity issues. These were: 
1. IgM phase II Immunofluorescence assay (IFA): this assay is considered the “gold 
standard” for the diagnosis of acute Q fever in Australia. 
2. Commercially available Q Fever phase II IgM ELISA Test: Panbio EQFB01M; 
Panbio ELISA Assays (Alere, Australia). This assay is widely used by many 
laboratories in Australia. 
3. PCR for the detection of C.burnetii DNA using dual gene targets for the IS1111 
gene and the outer membrane protein com1 gene20. PCR is not routinely used in 
Queensland to diagnose Q fever infections. 
 
The principles of these three methods have previously been described in detail in Chapter 
2 (General Materials and Methods). 
The widely considered “gold standard” laboratory method for diagnosing acute Q fever is 
serology, with the immunofluorescence assay (IFA) for the detection of IgM antibodies 
currently regarded as the reference method for acute Q fever screening 21.   The set of 
samples described in section 6.3.2. below were screened for IgM antibodies using the 
recommended  IgM phase II IFA method (Chapter 2; section 2.2.3.6.) and the 
commercially available IgM ELISA method above (Chapter 2; section 2.2.4.3.2.), and 
compared with PCR for their ability to diagnose acute Q fever disease.   
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6.3.2. Samples Screened 
6.3.2.1. Serum Samples Submitted for the Diagnosis of Acute Q Fever Infection 
This study used a sample set of sera that was obtained from Queensland Health over a 
three-year period. This included samples submitted from years 2008, 2009 and 2011.  
These samples were submitted to Queensland Health for the specific investigation of 
acute Q fever disease.   
There were 275 serum samples that were collected and stored; from this a 200uL aliquot 
of serum was extracted for nucleic acid testing.  These samples were selected randomly 
from a larger serum pool available at the Pathology Queensland laboratory, and had been 
submitted for the investigation of Q fever. Demographic data were available for all of these 
samples.   
The samples were collected from 100 females and 175 males, and comprised an age 
range of 0.4 - 87.3 years, with a mean age of 47.0 years and a median age of 47.5 years.  
The females were 12.1 - 87.3 years of age with an average age of 46.9 years and the 
median age 46.5 years. The male population selected had an age range of 0.4 - 83.0 
years with the average age being 47.1 years and a median age of 47.7 years.  There were 
nine samples from patients under 16 years of age.  The age range for these was 0.4 - 15.5 
years with an average age of 11.2 years and the median age of 12 years. The paediatric 
samples screened were from 7 males and 2 females.   
The postcode with the most requests for Q fever disease investigation was 4816, which 
was Townsville, with 10 requests, and the surrounding areas of Townsville had 16 
requests for Q fever testing.  The region with the second highest number of requests for Q 
fever was 4880, Mareeba, in the northern tropical hinterland.  The surrounding areas 
including Cairns had 13 requests.  
The clinical notes at the time of sample collection were examined.  The most frequently 
occurring clinical symptoms were fever/temperature in 39 patients, headaches in 11, 
pneumonia in 9,  “flu-like illness” in 9, PUO in  9, myalgia in 8 patients. 
From clinical notes provided, nine patients were considered to be in a high risk group (ie: 
animal contact or employment risk).  Of the 275 samples, 15 patients had a clinical follow-
 188 
 
 
up for Q fever investigation or for the development of chronic Q fever, and 97 patients had 
nothing recorded in the clinical history or clinical notes. 
6.3.2.2. Bronchoalveolar Lavage Samples 
A set of bronchoalveolar lavage (BAL) samples were collected from 100 patents in 2006 
for the investigation of a lower respiratory disease etiological agent.  This sample type 
represents a direct sampling of the lung cell surface, and hence any foreign material 
causing respiratory disease can be collected. Also, alveolar macrophages are found lining 
the airways, and these cells are responsible for engulfing C.burnetii, if inhaled, so BAL are 
an ideal sample type to detect Coxiella in the lung.   
These samples were obtained from patients aged 0.2 – 82.6 years of age, with a mean 
age of 39.3 and a median age of 48.3 years.  The samples were from 42 females and 58 
males, all presenting with respiratory disease. Included in the 100 samples were BAL from 
13 transplant recipients who were all receiving immunosuppressive treatment. According 
to the clinical notes recorded on sample submission, there were nine patients who 
recorded a cough, two patients with a febrile illness and one patient with “flu like illness”. 
6.3.2.3. Respiratory Samples for Flu-Like Illness 
 Q fever is a disease with clinical manifestations that may mimic “flu like illness”.  Clinical 
presentation may include high fevers, chills, sweats and headaches.  With seasonal 
outbreaks and continually circulating newly emerging strains of influenza both globally and 
nationally, “flu like illness” is readily identified in Queensland. However, often these 
patients are clinically diagnosed without laboratory confirmation. Considering that some of 
these infections may be manifestation of Q fever infection that are not correctly diagnosed, 
a sample set submitted for laboratory confirmation of respiratory viral illnesses, including 
“flu like illness”, was included in this study for testing of C.burnetii. These samples were 
negative for infectious agents by all previous laboratory investigations.  
A total of 1385 samples were collected and submitted to Queensland Health Pathology 
Departments for the PCR diagnosis of viral respiratory disease during the year 2008.  
These included 708 nasal pharyngeal aspirates, 21 lavages, 631 throat swabs, 4 tissue 
samples and 21 nasal washings.  The samples were from body sites including the 
bronchial tract, lung, nasal cavity and throat. The samples were collected from patients 
aged 0-95 years with a mean age of 21.6 years and a median age of 4 years.  There were 
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840 samples from children under the age of 16 years. There were approximately 80 
samples from each month of the year with the exception of February, March and April 
which had at least 157 samples.   
These samples were examined in this study for C.burnetii DNA using previously described 
methods (Chapter 2 – section 2.2.2.1).   
6.3.2.4. Samples for the Diagnosis of Atypical Pneumonia 
Atypical pneumonia is commonly reported in patients diagnosed with acute Q fever22.  In 
Queensland however, patient serum samples submitted to a pathology provider with the 
specific request for the investigation of “atypical pneumonia” or “atypical serology” do not 
have C.burnetii included in the investigation. In Queensland laboratories, the current 
“atypical pneumonia” screen only includes Mycoplasma pneumoniae, Legionella 
pneumoniae and Chlamydia pneumoniae.  Yet in the literature, it is commonly reported 
that the most common cases of atypical pneumonia are caused by three zoonotic 
pathogens, Chlamydia psittaci (psittacosis), Francisella tularensis (tularemia), and Coxiella 
burnetii (Q fever) 22.   
There were 374 serum samples collected from Pathology Queensland during the month of 
April 2009.  These samples were submitted for the specific test request of “atypical 
serology” or “atypical pneumonia testing” and were only screened for Mycoplasma 
pneumoniae, Legionella pneumoniae and Chlamydia pneumoniae. 
These samples were from patients aged 1 to 95 years of age, with the average age of 49 
years and a median age of 51 years.  Of the 374 samples, there were 44 samples from 
children under the age of 16 years of age. These 374 samples were tested for the 
presence of Coxiella DNA by PCR. 
 6.3.2.5. Extraction of Coxiella DNA from Samples for PCR Analysis 
For BAL and respiratory samples, nucleic acids were extracted from 200µL of original 
sample using the Magna Pure automated extractor (Roche Diagnostics, Australia), 
according to the manufacturer’s instructions.  The DNA was eluted in a final volume of 
50µL and stored at -20°C. 
The nucleic acids from serum samples submitted for the diagnosis of atypical pneumonia 
were processed by aliquoting 200µL of sample into a sample preparation plate for 
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extraction using the Reagent Pack VX (Qiagen Brisbane, Australia) in the QIAxtractor 
(Qiagen Brisbane, Australia) as per the manufacturer’s instructions for the extraction of 
DNA and RNA. The DNA was eluted in a final volume of 50µL and stored at -20°C. 
 
6.4. Results 
6.4.1. Comparison of Serological Assays and PCR for the Diagnosis of Acute Q 
Fever 
Of the 275 samples tested there were a total of 59 (21.5%) patients that had a positive 
result in any of the screening assays for acute Q fever markers (Table 6.1).  There were 
34 patients that were PCR positive in either gene target and 33 patients that had positive 
IgM serology markers for acute disease. 23 samples were positive by PCR only, with 2 
samples only detected by ELISA and 3 by IFA only.  
Table 6.1: Positive results for each of the three assays employed in testing 275 serum 
samples submitted for acute Q fever. 
Assay No Positive % of Positives 
PCR 34 58% 
IFA (IgM) 25 43% 
ELISA IgM) 23 39% 
TOTAL Positives detected 59 21.5% (59/275) 
 
PCR was able to detect the greatest number of patients with acute Q fever. The ELISA 
and IFA detected similar numbers of acute Q fever infections with 23 and 25 detections 
respectively.  
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When compared to the “gold standard” IFA method, the ELISA showed a sensitivity of 
64% and a specificity of 97%, which was in concordance with that reported by Herremans 
et al. for the detection of Coxiella IgM antibodies23. These values compared to a sensitivity 
for PCR of 24% and specificity of 89% (Table 6.2). 
 
Table 6.2: Comparison of diagnostic methods (sensitivity and specificity) for acute 
infection using IFA as the reference Gold Standard (* GS) 
  Serology Molecular Performance* 
 
Total 
Detected 
IFA (GS*) 
Detected 
ELISA  
Detected 
PCR 
Detected 
Sensitivity 
% 
Specificity 
% 
Assay  Results 
IFA IgM 
(*GS) 
25 25 16 6 - - 
ELISA 
(IgM) 
23 16 23 5 64 97 
PCR 34 6 5 34 24 89 
 
However, the PCR did not detect many of the patients that were positive by IFA or ELISA.  
Yet PCR detected 23 positive patients that were not detected by the serological methods. 
These PCR positive results were primarily from patients with early, acute infections.   
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Figure 6.2: A scatter graph showing positive detections for Coxiella DNA by PCR (), and 
positive IgM antibody detections by IFA () and ELISA (). Positive results are displayed 
by reactivity in the assay used with real-time PCR results shown as Ct value, and the 
results of IFA as fluorescence intensity (+1 to +4), and ELISA as the OD of the colour 
reaction at 450 nm. 
 6.4.2. Analysis of Bronchoalveolar Lavage (BAL) Samples 
Only one of the 100 BAL samples tested positive for Coxiella DNA (Figure 6.3). The 
patient sample was identified as a BAL washing from a 48 year old male who was 
admitted to hospital post renal transplantation.  The patient had a history of lingual lung 
lesions and complained of left pleural pain.  He was investigated for respiratory viruses 
including influenza virus A and B, parainfluenza viruses 1, 2 and 3, adenovirus, human 
metapneumovirus, herpes simplex virus 1 and 2, cytomegalovirus and also for 
Pneumocystis jiroveci using PCR. Results for all these were negative and a diagnosis was 
not recorded in this case.  
On examination of this sample with the Coxiella dual target PCR, it showed a positive 
result for the com1 gene only, producing a CT value of 40.7.  This patient resided in 
Toowoomba, postcode 4350, which is an area of high Q fever notification (Chapter 3). 
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Figure 6.3: Qiagen RotorGene real-time PCR results for bronchoalveolar lavage samples 
screened using dual targets com1 and IS1111 genes. 
6.4.3. Results for Samples Submitted for the Investigation of Respiratory Disease  
Of the 1385 respiratory samples tested, there were 12 (0.9%) PCR positive results using 
the com1 and IS1111 gene target.  Three samples were positive by the com1 assay only, 
and 9 samples were detected by both targets. Limited clinical data were available for these 
12 patients, but 2 samples were collected from children. One child was less than 12 
months old and the other was 7 years old. None of these patients showed any evidence in 
their clinical histories of follow-up laboratory investigations, and a diagnosis of Q fever was 
not recorded. 
6.4.4. Samples for the Investigation of Atypical Pneumonia  
374 serum samples were screened for acute markers of Q fever infection, including the 
dual gene target PCR and IgM serological markers with both the IFA and the ELISA.  Nine 
patients (2.4%) were identified as having one or more marker positive for Q fever.   
The PCR detected six patients with Q fever in the com1 gene only, with CT values 
between 36 and 40 (Figure 6.4). None of these samples gave a positive PCR result with 
the IS1111 target. The IS1111 target was expected to be more sensitive as there are 
Positive Control 1e-
4  
BAL 
#32  
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multiple copies in the bacterial genome. However, the results above may reflect the 
susceptibility of the assay to strain variation as previously described by Cooper et 
al(Cooper, 2011).  
` 
Figure 6.4: Qiagen RotorGene real-time PCR results for atypical pneumonia   samples 
screened using com1 genes targets. 
The serology methods identified six patients as having acute Q fever serology markers 
(Table 6.3).  The IFA phase II IgM was positive in all six patients and positive serology 
results in the ELISA phase II IgM were seen in three patients.  There were only 3 patients 
with a positive serology marker and a positive PCR result.  
 Table 6.3: Distribution of positive results for acute Q fever in serum samples submitted for 
the investigation of atypical pneumonia. 
 TOTAL PCR + IFA + ELISA + 
PCR Positive 6 6 3 0 
IFA IgM 
Positive 
6 3 6 3 
ELISA IgM 
Positive 
3 0 3 3 
 195 
 
 
Out of the 374 patient sera tested for atypical pneumonia only 3 were subsequently 
investigated for Q fever.  These three patients showed positive results in all three assays 
above, including PCR, and their clinical histories showed that they had positive results for 
the Q fever serology markers on follow up laboratory testing as part of their clinical 
investigation (Table 6.4). Consequently, these three patients had a definitive diagnosis of 
acute Q fever recorded and were treated accordingly.   
There was one case of atypical pneumonia in which Q fever was considered after the 
initial negative laboratory results. Here Q fever serology was included in secondary follow 
up testing using the ELISA IgM commercial kit.  This returned a negative result, and no 
further Q fever serology was requested.   
There were five cases of atypical pneumonia where routine Q fever screening was not 
performed as part of secondary follow up testing.  This study found three cases that were 
identified as acute Q fever using PCR and two with positive IgM serology.  
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Table 6.4:  Atypical pneumonia sample investigation, including testing, patient history and 
demographics. o/s = overseas. 
 
IFA 
phase 
II IgM 
PCR 
Result 
ELISA 
phase II 
IgM 
History Follow Up Age Postcode 
DET DET DET Pneumonia 
QF invest 
requested  
IFA IgM 
phase I  IFA 
titre>1280 
43.9 4888 
DET DET Equivocal Pneumonia 
QF serology 
request IgM 
Positive 
33.8 4305 
DET DET DET 
Embolism, ACS, 
pneumonia, myco-
neg,  
QF serology 
request IgM 
Positive 
64.9 4610 
NDT DET NDT 
 n/a  F/up resp NPA 
BP-neg RSV-POS 
Myco-neg 
Nil – QF not 
repeated 
2.0 4502 
NDT DET NDT 
Pneumonia Myco 
80 f/up Myco-160 
Chlamydia 200 IgA 
Nil – QF not 
repeated 
41.9 4160 
DET NDT NDT 
Viral illness Q fever 
serol-neg,myco-
neg,f/up-nil 
Nil – QF not 
repeated 
22.5 4029 
DET NDT NDT Cough, vomiting 
Nil - Pos 
Mycoplasma 
22.4 4680 
NDT DET NDT 
Febrile illness 40°C 
temps  
Nil – QF not 
repeated 
75.5 4680 
Weak 
DET 
NDT NDT 
Atypical pneumonia 
Myco,leg,chlamydia 
-neg,  
QF-serology 
negative 
69.4 o/s 
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6.5. Discussion 
Q fever is an important disease particularly in rural Queensland.  Chapter 3 of this thesis 
highlighted that notifications are based on laboratory findings as the Australian national 
notifiable diseases case definition for Q fever requires only confirmed cases to be 
reported.  Currently in Queensland, a confirmed case requires definitive laboratory 
evidence in the form of positive nucleic acid detection via molecular methods for Coxiella 
burnetii or a positive serological results for an acute marker, this can be demonstrated 
presence of IgM antibody, or either a seroconversion or a significant increase in IgG 
antibody titre to phase II antigens.   These scenarios must occur in the absence of a recent 
Q fever vaccination24. 
In Queensland pathology laboratories today, the method widely employed for the 
diagnosis of Q fever is serology. The method of choice is ELISA even though the 
immunofluorecent assay is still considered to be the most sensitive method for diagnosing 
Q fever using serum samples23. The commercially available ELISA from Alere Panbio 
(Brisbane, Australia) is widely used by Australian laboratories as an initial screening 
method for acute Q fever, as it is very cost effective, has the capacity for screening large 
numbers of specimens, and can be fully automated reducing the subjectivity associated 
with IFA.  
 The evaluation of the IgM ELISA in this Chapter showed a specificity of 97% but a 
sensitivity of 64% when compared to the IgM IFA.  This is similar to the findings by a large 
international study evaluating the different diagnostic methods, which showed that ELISA 
methods for the detection of IgM phase II as acute markers of Q fever diseases had a 
sensitivity of 60%23.  This is an important result from this study, because the current 
regime for initial testing of acute Q fever in Queensland diagnostic laboratories employ the 
ELISA method only. Clearly, this has a significant impact on the identification of acute Q 
fever cases in Queensland, and may be the cause of under-reporting of the disease as 
reflected in the discrepancy between notification rates and seroprevalence (Chapters 3 
and 4). 
The differences in the specificity results may be related to the substrate antigens used in 
the ELISA and IFA assays. Different strains of Coxiella may be used in preparing the 
antigens to which antibodies are measured, and this may affect the sensitivity observed 
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between assays.  The Alere Panbio kit used in Queensland has been prepared using the 
Henzerling strain of Coxiella, whereas the IFA assay was prepared using the Nine Mile 
strain of Coxiella.   
The reason Q fever infections have been diagnosed by serology is mainly due to the fact 
the organism is fastidious to grow and is an occupational hazard for laboratory staff. 
Recently molecular methods have replaced serological techniques for diagnosing many 
bacterial and viral agents causing disease in humans.   
PCR provides a rapid and accurate method for detecting Coxiella DNA as a marker of 
acute Q fever infection.  This has a distinct advantage over serological methods, which are 
often negative during the early phase of the disease, and ideally require examination of 
paired sera taken 14 days apart to confirm antibody conversion. 
At first glance the sensitivity of PCR compared to the gold standard IFA, is poor with only 
24% concordance. However, as this study has shown PCR is a more effective tool for the 
early diagnosis of Q fever when the antibody response is still developing and below the 
level of detection with serological testing. 
The PCR detected 23 cases of acute Q fever that were not diagnosed by serological 
methods. These were predominantly in samples that were collected early following the 
presentation of symptoms. Although these results could possibly be attributed to false 
positive reaction in the PCR, in 11 cases, where further confirmation was available in 
clinical histories or by presence of Q fever-specific symptoms, serology, or further 
molecular confirmation, the diagnosis was deemed to be correct.  
Early diagnosis and accurate recognition provides a better outcome for the patient, in 
terms of treatment and may reduce possible Q fever-associated sequelae including 
chronic Q fever and chronic Q fever fatigue syndrome. This study was conducted on 
randomly selected samples, and therefore was an observational analysis of a random 
population. However, it demonstrated that most of the patients in the cohort with 
suspected acute Q fever, presented to clinical staff early enough in their illness to enable 
the detection of Coxiella DNA before the detection of IgM antibodies. Therefore it would 
seem highly advantageous for the effective clinical management of patients with Q fever, 
that PCR be introduced to complement serological testing, particularly in those patients 
that present within the first 2-3 weeks after the onset of symptoms. 
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Thus, the results of this study support an improved diagnostic strategy for the early 
diagnosis of acute Q fever in patients with clinical manifestations suggestive of the 
disease. Namely: 
1. For serum specimens collected in the first 2 weeks of infection, both PCR and 
serology should be performed;  
2. From weeks 3 to 4 after onset, serology should be performed first and PCR should 
be reserved for seronegative specimens;  
3. For serum specimens collected later than 4 weeks after the onset of symptoms, 
serology but not PCR should be used as diagnostic test. 
Also, the diagnosis of Q fever using PCR may be more effective if the samples collected 
are more appropriate for the infectious agent; that is, if the samples were to be more 
representative of the cell types or tissues that are directly infected during the primary 
phase of disease.  For example, the bacteria are initially engulfed by macrophages in the 
respiratory tract15,26, therefore it may be more appropriate to sample macrophages and 
perform PCR directly on these infected cells rather than measuring DNA from the 
breakdown of the bacteria in the blood.   
Examining a range of specimens submitted for the laboratory examination for infectious 
agents other that Coxiella, yet presenting with similar symptoms, provided a valuable 
insight in the possible level of under-recognised Q fever that may occur in the Queensland 
population.  
Bronchoalveolar lavage samples collected in this study provided and excellent sample set 
to interrogate cellular components of the lung epithelial lining for the presence of Coxiella.  
These samples were specifically collected for the investigation of an etiological agent 
causing respiratory disease in this cohort of patients.  The results showed that one patient 
was positive for Q fever using PCR, confirming that this was the cause of infection. 
Although this was only a small sample set, it did indicate that Coxiella should be 
considered as a cause of respiratory disease, particularly in cases where another 
diagnosis is not provided.   
In this same context, samples collected for the investigation of a “flulike illness” were 
examined for Q fever using PCR, and showed that 0.9% of these were positive. Although 
this is not considered to be high prevalence, it is of similar magnitude as other recognised 
 200 
 
 
respiratory pathogens such as influenza C and parainfluenza 4.  Again, the patients 
making up this sample cohort were not considered to be infected with Coxiella, and the 
inclusion of an appropriate test to diagnose this may have improved clinical management, 
or perhaps may have prevented possible clinical complications such as the development 
of chronic Q fever and chronic Q fever fatigue syndrome.  
The most common symptoms of Q fever presentation are those that are commonly 
associated with atypical pneumonia.  For this reason a sample population from patients 
with this presentation and request for atypical pneumonia investigation were included in 
this study. Currently, testing algorithms in Queensland do not offer Q fever serology as 
part of initial screening when a request for atypical serology/pneumonia investigation is 
made.    
Atypical pneumonia is often community acquired, and the aetiological agent is largely 
unknown.  A study into community acquired pneumonia in Australian adults has shown 
that the most common agents responsible are respiratory viruses (15%), Streptococcus 
pneumoniae (14%), Mycoplasma pneumoniae (9%), Haemophilus influenzae (5%), 
Legionella species (3%) and Chlamydophila (Chlamydia) species (2%) 27, making up 
approximately 48% of atypical pneumonia diagnoses. This still leaves a large percentage 
of patients with pneumonia for which there has been no definitive diagnosis. Atypical 
pneumonia is considered to be the result of exposure to zoonotic infectious agents, and in 
Queensland, Q fever has been the zoonotic disease with the highest number of 
notifications over the last five years. Therefore it seemed highly likely that Coxiella may be 
an important agent of atypical pneumonia.  
This study showed that 2.4% of the atypical pneumonia patients with a specific request for 
atypical investigations were positive for Q fever, yet this test was not included as part of 
the routine testing regime in Queensland.  Over the past 5 years in Queensland Health 
laboratories there have been 13,338 request for the specific investigation of atypical 
pneumonia, an average of 2, 668 requests per year.  For the same time frame there have 
been 16,938 requests for the investigation of Q fever disease and from this there were 
2,011 cases (12%) identified using the ELISA screening method.  If atypical pneumonia 
investigation were to include Q fever screening as a first line screening option, this could 
have potentially identified another 2.4% or 320 cases of Q fever over the five years. This 
data has only been generated from Queensland Health patient populations and has not 
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taken into consideration the testing occurring in other pathology providers in Queensland. 
This is notwithstanding the number of extra cases that would be identified if PCR were to 
be included in the diagnostic algorithm as discussed above. 
In summary, the results presented here showed the current diagnostic protocol that is 
applied in Queensland is adequate to detect the majority of Q fever cases. However, 
significant improvement in the detection rate could result if routine PCR testing were to be 
included in the laboratory investigative pathway, and if there were greater clinical 
awareness that Coxiella should be considered in the presentation of respiratory illness, 
especially, atypical pneumonia.   
6.6. Significant Outcomes from this Chapter 
 The results of this chapter confirmed that using the current diagnostic algorithm, a 
substantial number of Q fever infections remain undiagnosed, and that the current 
diagnostic paradigm must be re-examined. 
 Use of IFA testing is recommended in preference to the Alere (Panbio) ELISA kit, 
which is used extensively throughout Australia. This will provide improved sensitivity 
in the diagnosis of acute Q fever infection. 
 Although PCR is not widely applied in the diagnosis of acute Q fever, its inclusion in 
diagnostic protocols is highly recommended, especially for the detection of early Q 
fever infections. 
 Clinical awareness of Coxiella as a pathogen involved in the wider presentation of 
respiratory disease must be improved, so that Q fever may be considered as a 
diagnosis in patients presenting with respiratory symptoms especially atypical 
pneumonia. 
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6.8. Appendix 6.1: Clinical manifestations that may be presented as a result of Q fever infection 
 Acute Chronic Post -Q fever fatigue syndrome 
Origin inhalation  or ingestion of bacteria persistent low level  infection with Coxiella post-acute or post-chronic Infection 
Cell Target macrophages organs - heart valve, liver, lungs, bone organs – muscles, lungs general health 
Incubation 
period 
7 - 60 days weeks - years post initial exposure weeks Months Years 
Disease Manifestation Symptom Manifestation Symptom Manifestation Symptom 
 asymptomatic none 
endocarditis 
cardiac valve failure 
chronic QFS 
prolonged malaise 
 
"flu" like illness 
high fevers (up to 40°C) vegetations fever 
 severe headache heart failure myalgia 
 general malaise   arthralgia 
 myalgia   night sweats 
 chills and/or sweats   osteomyelitis   
atypical 
pneumonia 
non-productive cough acute pneumonia chronic 
pneumonia 
fever osteoarthritis  
      
chest pain   productive  cough    
respiratory distress   wheezing  spontaneous abortion 
fever   night sweats   
consolidation   chest pain  vascular grafts 
infections 
    breathlessness   
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APPENDIX 6.1 (continued): Clinical manifestations that may be presented as a result of Q fever infection 
 Acute Chronic Post -Q fever fatigue syndrome 
Origin inhalation  or ingestion of bacteria 
persistent low level  infection with 
Coxiella 
post-acute or post-chronic Infection 
Cell Target macrophages organs - heart valve, liver, lungs, bone organs – muscles, lungs general health 
Incubation period 7 - 60 days weeks - years post initial exposure weeks months years 
 Manifestation Symptom Manifestation Symptom Manifestation Symptom 
hepatitis hepatomegaly chronic hepatitis  hepatomegaly   
 granuloma formation   
granulomatous 
hepatitis 
  
 jaundice      
       
myocarditis chest pain fatigue  generalised malaise   
 fever   anorexia   
    night sweats   
       
cutaneous 
infections 
maculopapular or pruritic 
rash 
osteoarticular 
disease 
osteomyelitis      
 erythema nodosum  osteoarthritis    
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APPENDIX 6.1 (continued): Clinical manifestations that may be presented as a result of Q fever infection 
 Acute Chronic Post -Q fever fatigue syndrome 
Origin inhalation  or ingestion of bacteria persistent low level  infection with coxiella post-acute or post-chronic infection 
Cell Target macrophages organs - heart valve, liver, lungs, bone organs – muscles, lungs general health 
Incubation period 7 - 60 days weeks - years post initial exposure weeks months years 
 Manifestation Symptom Manifestation Symptom Manifestation Symptom 
neurological 
disease 
meningoencephalitis 
infections during 
pregnancy 
spontaneous abortion    
 meningitis      
 encephalitis vascular disease 
vascular grafts 
infections 
   
 cerebellitis      
 neuritis      
 Guillain-Barre  syndrome      
 myelitis      
 peripheral neuropathy      
 extrapyramidal  disease      
hemophagocytosis uremic syndrome      
 anemia      
 rhabdomyolisis      
 bone marrow necrosis      
renal disease glomerulonephritis      
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Chapter 7 
 
 
Clinical Case Studies of Q fever from 
Queensland 
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2015-210808 
Tozer SJ, Lambert SB, Sloots TP and Nissen MD. Multiple Presentation of Q Fever in Six 
Family Members from Rural Queensland, Australia. BMC Clinical Pathology – Case 
Reports. Manuscript in Preparation 
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7.1. Introduction 
So far in this study, evidence has shown that although notifications of Q fever were 
predominantly centred on rural communities, significant levels of disease were also 
reported in urban populations. The fact that Q fever also may occur in those populations 
that are considered as “low risk” was supported by the evidence of the seroprevalence 
study described in Chapter 4, which showed that urban populations had similar levels of 
exposure as those in rural settings, further suggesting that infected subjects had 
asymptomatic infections, or failed to be correctly considered for the laboratory 
investigation of Q fever. 
Furthermore, Q fever is widely considered to be an occupational illness of adults in close, 
direct contact with ruminant animals in a rural environment. Therefore, it is not often 
considered when seeking preliminary diagnosis for a febrile illness, especially in children.  
Also, children may present with less defined symptoms than adults, and Q fever disease 
may not be considered as part of the clinical diagnosis for children presenting with acute 
symptoms1.  Q fever infections occurring in children, in general are rarely reported, 
probably  misdiagnosed and hence infections are potentially under-reported in this 
population 1,2.   
The documented acquisition of Q fever infection in humans is through inhalation of 
contaminated aerosols via the respiratory route3.  Aerosols may be contaminated by the 
products of parturient animals, including birthing products, and the dispersion of these into 
the environment 4.  The bacteria can remain highly stable and infectious in the 
environment for months and perhaps years and are able to withstand  many harsh 
environmental conditions3.  Other routes of transmission include the ingestion of 
contaminated dairy products containing C.burnetii and transmission from ticks that are 
infected with the bacteria5.  There have been isolated cases of human to human 
transmission in the performance of an autopsy on a Q fever patient, in bone marrow 
transplant recipients and one sexually transmitted case6.  However, these modes of 
transmission are very rare7. 
Other studies, including the findings in Chapter 5 of this thesis, have identified domestic 
pets as a potential source of infection.  Epidemics have been reported in Nova Scotian 
(Canada) communities which were linked to one single parturient cat that resulted in more 
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than 30 cases of Q fever8.  Recently, urban veterinary surgeries have also been 
associated with small Q fever outbreaks.  In Sydney, two separate veterinary clinics 
recorded an outbreak of Q fever amongst the staff working within the surgery.  One clinic 
performed an emergency feline caesarean, which was determined to be the source of Q 
fever infection for 9 of 20 staff employed at the clinic.  Eight of the staff members were 
present the day of the caesarean but the 9th patient contracted the disease 24 hours later 
through simply handling equipment used in the caesarean procedure the previous day.  
Under the current vaccination guidelines, the veterinarian was the only person vaccinated 
and hence did not contract Q fever9.  The second episode also occurred in a Sydney 
veterinary clinic where a moribund bitch dog underwent an emergency caesarean section.  
The birth resulted in all the pups being delivered still-born.   
There were three nurses present during the birthing episode who aided in the procedures, 
and one nurse cared for the dog at home during three weeks of convalescence. Four 
weeks post-caesarean two of the nurses presented with a flu-like illness while the third 
nurse was hospitalised six weeks later with pericarditis and pericardial effusion along with 
fevers and rigors.  All three nurses tested positive for Q fever serology and the dog was 
also serologically positive and hence identified as the source of infection. Again, the 
veterinarian who performed the procedure had been vaccinated against Q fever and did 
not produce any symptoms10.  These outbreaks highlight the potential for companion 
animals to transmit Q fever to humans in urban settings. 
Previous data from studies performed as part of this thesis identified a number of 
Queensland animals that have the potential to transmit C.burnetii to humans11.  Among 
these were companion animals in particular cats and dogs, along with native animals, that 
co-reside in suburbia with humans.  A significant find in this study was the detection of 
C.burnetii DNA in pooled flying fox urine and “bat spat” from colonies around Brisbane.  
These animals have the potential to spread the bacteria anywhere along their flight path to 
the feeding grounds of other animals.  Also, Australian native animals such as the 
possums, bandicoots, grey kangaroos and other macropods have been identified as 
harbouring C.burnetii and hence pose yet another potential source of infection to humans, 
especially as suburbia begins to encroach into native animal habitats12 .  There is also the 
potential for any animal to become infected with C.burnetii from different tick species that 
are found throughout Australia13.  In Chapter 5, it was shown that ticks removed from both 
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domestic and native animals in Brisbane may be positive for C.burnetii DNA, highlighting 
the potential for any animal to become  a carrier of Q fever and shed the bacteria into the 
human environment11. 
7.2. Specific Aims of This Chapter 
The study in this chapter sought to examine cases of Q fever that fell outside the normal 
paradigm associated with traditional methods of contracting the disease, or those with an 
unusual clinical presentation.  In particular: 
 It highlights the complexity associated with recognising Q fever infections and that 
direct animal contact is not a prerequisite for the acquisition of C.burnetii and Q 
fever disease.    
 It also demonstrates the potential for transmission in families, including infection of 
children from their parents or siblings 
 And demonstrates the clinical severity and complications that may occur as a result 
of infection.  
7.3. Methods 
7.3.1. Clinical Cases Examined 
Unusual presentations of patients with Q fever were identified by the Director of the 
Infectious Management & Prevention Service at the Royal Children’s Hospital-Brisbane, 
Associate Professor Michael Nissen, and Senior Staff Specialist in Infectious Diseases, Dr 
Marion Woods at the Royal Brisbane and Women’s Hospital. The cases analysed were all 
from rural Queensland and involved children younger than 16 years of age with unusual 
clinical histories in which Q fever was the definitive diagnosis, and one adult case.  
Specifically these were: 
1. Three cases of Q fever in children four years old or younger were the primary focus 
of infection. 
2. One family case investigation initiated by Q fever disease in a thirteen year old girl 
involving both parents and three siblings. 
3. One severe adult case in a 28 year old female which was contracted through 
presumed occupational exposure in Central Queensland, but for whom a definitive 
source of infection was not identified.  
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The majority of these cases had no history of direct animal contact and hence Q fever was 
not initially considered for diagnostic investigation, and excluded as a possible cause of 
disease.  Those cases which had a recorded history of animal contact had no direct 
contact with ruminants, and again were considered outside the established paradigm 
associated with classical Q fever acquisition. 
The cases presented here serve as an illustration of issues that may lead to the under-
recognition of Q fever in populations that are considered at “low risk”, highlighting the need 
for greater vigilance in considering unusual sources of Q fever infection.   
 7.3.2.   Method of Clinical Case Review 
Clinical charts from patients admitted to the Royal Children’s Hospital, Brisbane, or the 
Royal Brisbane and Women’s Hospital with a clinical diagnosis of Q fever were reviewed 
with data collated from the clinical notes and patient histories.  Pathology results were 
reviewed and recorded along with any specialist reports and clinical requests from 
referring doctors and GPs. All abbreviations, including medical, used in the description of 
case analysis were standardised and are shown in Table 7.1. 
 
Table 7.1: Medical abbreviations used in this Chapter. 
Medical Abbreviations 
Abbreviation Full term Abbreviation Full term 
GP General practitioner IV Intravenous 
LFTs Liver function Tests PUO Pyrexia of unknown origin 
E/LFTs 
Electrolytes and liver 
function tests 
CFT Complement fixation test 
M/C/S 
Microscopy, culture 
and sensitivity 
BFV Barmah Forest virus 
CRP C-reactive protein CMV Cytomegalovirus 
FBC Full blood count HCV Hepatitis C virus 
WBC White blood cells  EBV Epstein Barr virus 
RBC Red blood cell QF PCR 
Q fever polymerase chain 
reaction test 
IgA Immunoglobulin A RRV Ross River virus 
IgG Immunoglobulin G IFA Immunofluorescence assay 
IgM Immunoglobulin M ELISA 
Enzyme-linked immunosorbant 
assay 
tAB Total antibodies HBV Hepatitis B virus 
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7.4. Clinical Case Presentations 
7.4.1. Case No 1: Four Year Old Female from Goondiwindi 
7.4.1.1. Clinical Presentation 
A four year old female child residing in Goondiwindi developed fevers and lethargy over six 
days before presenting to a General Practitioner in the town.  The child had previously 
been in good health.   
Day 1:  On presentation at the GP clinic the child was alert but pale, febrile with a 
temperature of 39.0⁰C. No rash was detected, and the clinical examination was within 
normal including; ears, nose, throat, chest and abdomen. As a follow up a chest x-ray was 
requested, this was also normal.  Blood work revealed a lymphocytopaenia along with a 
thrombocytopenia, E/LFTs were abnormal and the biochemical screen showed a low iron 
level.  Microscopy of urine was normal and blood cultures were negative.  Serology 
investigations were ordered and included CMV, BFV, RRV and Q fever. The child 
deteriorated overnight with temperatures peaking at 40.7°C and associated rigors.   
Day 2: The child represented at the GP with a temperature of 37.6°C, very pale and 
lethargic, with no rash and no organomegaly. The E/LFTs were still abnormally raised and 
an provisional diagnosis of a viral infection or Q fever was proposed.  The child was sent 
home and returned 3 days later for GP review and serology results.    
Day 5:  On review, the child remained pale and lethargic with body temperatures 
remaining elevated at night. No rash was detected. FBC was normal as were E/LFTs. Q 
fever was finally diagnosed based on the results of serology (Table 7.2). Treatment with 
Rulide D tablets (roxithromycin – Sanofi Pharmaceuticals) was commenced and follow up 
serology was requested in 10 days.  
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Table 7.2: Case 1 - Results of laboratory investigation for patient in Case 1. 
 
7.4.1.2. Summary of Laboratory Investigations 
The results of serology performed at first presentation showed an equivocal Q fever IgM 
result for Q fever Phase II antigens. The diagnosis of Q fever was confirmed by increasing 
levels of Q fever IgM antibody and the presence of Q fever IgG antibodies in the second 
blood sample taken 4 days later. Unfortunately the results from follow up serology taken 
10 days after discharge from hospital were not available. Two positive IgM antibody 
detections, to unrelated viruses (BFV and EBV), had the potential in this case to confound 
the interpretation of results, were it not for the clear seroconversion to Q fever antibody 
positivity demonstrated between the two samples collected at different times. 
7.4.1.3. Case History 
A detailed history revealed that the child lived on a large cattle property.  The father of the 
child had recently been diagnosed with acute Q fever and the child's three siblings were 
also unwell with similar symptoms. This case, almost certainly, is an infection as a result 
from exposure to a parental contact. However, it is unknown whether the infection was 
caused by direct personal contact through aerosolised Q fever organisms from the infected 
father, or by or by transference of infected material acquired by the father during his 
Date of Collection Serology Test Result 
05 August 2002 CMV IgM Negative 
 BFV IgM Negative 
 EBV IgM Negative 
 Q Fever Phase II IgM Equivocal 
   
09 August 2002 CMV IgM Negative 
 BFV IgM Equivocal 
 EBV IgM Positive 
 RRV IgM Negative 
 Q Fever Phase II IgM Positive 
 Q Fever Phase II IgG Positive 
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occupational activities to the child. Also previous close contact, although not identified on 
review, could not be discounted. To resolve this molecular typing of the Coxiella isolates would 
be highly desirable, but unfortunately, as these studies in the thesis were based on case 
reviews, no samples were available on which molecular typing could be performed 
7.4.2. Case No 2: Three Year Old Boy from Goondiwindi 
7.4.2.1. Clinical Presentation of the 3 Year Old Boy 
A previously well three year old boy from Goondiwindi presented to a local General 
Medical Practitioner’s clinic with a 10 day illness. 
Day 1: He presented with a fever, cough and headaches.  The GP diagnosed a lower 
respiratory tract infection with a pleural effusion was treated with oral amoxicillin without 
improvement. He became increasingly unwell and was admitted to Goondiwindi Hospital 
two days later. 
Day 3: On admission to hospital the boy was febrile and dehydrated. A chest x-ray was 
performed.  He was treated with IV fluids and administered IV ceftriaxone for presumptive 
pneumonia.   A specialist examination found him to be febrile with 97% oxygen saturation 
levels, alert and active with no respiratory distress. His right lung had reduced air entry and 
his abdomen was distended with a large right upper quadrant mass. The boy was then 
transferred to Toowoomba Hospital. 
Day 4:  At Toowoomba Hospital, further investigations were requested including another 
chest x-ray and pathology blood tests.  The repeat chest x-ray showed a large right pleural 
effusion while ultrasound examination of the chest confirmed a large right effusion and a 
smaller left effusion.  Ascites was also detected by abdominal ultrasound, however,the 
liver and kidneys appeared normal. Pathology testing including FBC, E/LFTs and blood 
cultures were performed by a private pathology provider.  The FBC revealed a low platelet 
count and reactive lymphocytes. The child had a markedly elevated C reactive protein 
(CRP), a low serum iron with elevated E/LFTs, and normal urine M/C/S. Given the 
seriousness of his condition, the boy was transferred to the Royal Children’s Hospital 
(RCH) in Brisbane, Queensland. 
Day 6:  On presentation at the RCH, further blood samples were taken for LFTs and 
serology screening for other infectious agents including;  Mycoplasma pneumoniae, CMV, 
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EBV, HBV, Toxoplasma gondii, Q fever, Leptospira spp. and respiratory viruses including; 
RSV, influenza A and B, parainfluenzae 1 & 3 and adenovirus.  A third x-ray revealed a 
lung consolidation of the right middle and lower lobes, with a left pleural effusion and 
ascites.  An repeat ultrasound examination showed an enlarged liver.   
The results of Q fever serology detected phase II IgM antibodies and an IFA phase I IgM 
antibodies at a titre of >1280. The M. pneumoniae total antibody titre was 320. Blood 
cultures were subsequently reported as negative.  These results confirmed a diagnosis of 
acute Q fever infection. The IV ceftriaxone was ceased and treatment with oral doxycycline 
was commenced. The results of serological investigations are shown in Table 7.3. Given 
these results, a subsequent clinical review of other close family members was instigated.   
7.4.2.2. Clinical Review of Family Members 
Further follow up of the boy’s family revealed that his grandmother had been suffering with 
pneumonia, which was subsequently diagnosed as due to M. pneumoniae. The boy had 
visited her prior to becoming unwell. Also, it was found that the boy’s mother had also 
been unwell with fevers and had been hospitalised in Toowoomba as well prior to his 
presentation to the RCH. 
Table 7.3: Pathology results of patient described in Case2 
Date of Collection Serology Test Result 
16 July 2003 CMV IgM and IgG Negative 
 BFV IgM and IgG Negative 
 EBV IgM and IgG Negative 
 Mycoplasma total AB 160 
 HBV IgM Negative 
 HBC IgM Negative 
 Toxoplasma IgM and IgG Negative 
 Serovars Leptospiorosis Negative 
 Respiratory Virus Panel PCR Negative 
 Q Fever Phase II IgM  (ELISA) Positive 
 Q Fever Phase II IgG (ELISA) Positive 
 Q Fever IFA Phase II IgG 80 
 Q Fever IFA Phase II IgM >1280 
 Brucella IgM and IgG Negative 
   
06 August 2003 Q Fever Phase II IgM  (ELISA) Positive 
 Q Fever Phase II IgG (ELISA) Positive 
 Q Fever IFA Phase II IgG 320 
 Q Fever IFA Phase II IgM >1280 
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.7.4.2.3. Clinical Presentation of the Mother 
The boy’s mother, a 31 year old female, had been unwell for 10 days prior to the child 
falling ill and was herself admitted to Toowoomba hospital with a severe acute community 
acquired pneumonia and hepatitis.  She had suffered severe headaches, fevers, rigors, 
photophobia, meningism, myalgia, nausea, vomiting and complained of a nocturnal cough.  
Her chest x-ray showed consolidation of the right lung. A lumber puncture was performed 
with no WBCs present and normal cerebrospinal biochemistry glucose and protein 
concentrations. A FBC revealed low platelet and WBC counts. An atypical pneumonia 
screen revealed a M. pneumoniae antibody titre of 320 and negative serology results for Q 
fever antibodies. She was commence IV antibiotics. She remained febrile, with worsening 
headaches intensifying with movement, neck pain, photophobia, nausea and persistent 
lung consolidation over the next three days. Her symptoms slowly began to improve on 
days 4, 5 and 6, however, headaches remained as did the lung effusion. Her FBC 
improved with the WBC count increasing, but she remained febrile.  IV therapy was 
ceased after day 6 (a total of 96 hrs), She was now afebrile and much improved with only 
mild headaches and discharged after a 9 day in hospital, and 3 days prior to her son 
becoming unwell.   
As a result of the clinical review initiated by her son’s diagnosis, she was retested for Q 
fever antibodies, 9 days after being discharged from hospital (Table 7.4). Her serology 
results confirmed a diagnosis of acute Q fever and she was treated with oral doxycycline.  
7.4.2.4 Summary of Laboratory Investigations 
The serology results for this three year old boy confirmed a definitive diagnosis of acute Q 
fever, with Q fever phase II antibodies for IgM and IgG detected by IFA and ELISA testing. 
There was additional evidence of a previous infection to M. pneumoniae. Follow up 
serology confirmed diagnosis of Q fever with increasingly antibody titres. Interestingly, his 
mother was also previously diagnosed with Mycoplasma infection, supported by her 
elevated Mycoplasma total antibody titres, and like her son was consistent with her 
acquiring this infection from her mother (the boy's grandmother) who was previously also 
diagnosed with Mycoplasma pneumonia.  Retrospective antibody testing on the mother 
indicated a resolving acute Q fever infection.   
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Table 7.4: Case 2- Pathology results for the mother. *NB: Some of these tests were 
performed retrospectively  
Date of 
Collection 
Serology Test Result 
02 July 2003 * Mycoplasma tAB <40 
 Q Fever Phase II IgM  (ELISA) Negative 
 Q Fever Phase II IgG (ELISA) Negative 
   
11 July 2003 * Mycoplasma total AB 320 
 Mycoplasma IgM  Positive 
   
17 July 2003  Mycoplasma total AB 320 
 Q Fever Phase II IgM  (ELISA) Positive 
 Q Fever Phase II IgG (ELISA) Negative 
 Q Fever IFA Phase II IgG 40 
 Q Fever IFA Phase II IgM >1280 
   
06 August 2003 Mycoplasma total AB 40 
 Q Fever Phase II IgM  (ELISA) Positive 
 Q Fever Phase II IgG (ELISA) Positive 
 Q Fever IFA Phase II IgG >1280 
 Q Fever IFA Phase II IgM >1280 
 
7.4.2.5. Case History 
The mother was questioned regarding recent animal contact after the positive diagnosis of 
Q fever was made for her son. She clearly recalled aiding in the delivery of a calf by the 
roadside some weeks before becoming unwell.  Her son was present at the time, but 
remained in the car during the birthing.  The mother and child had a lengthy drive home. 
Given this new evidence, it seems likely that the boy was infected as a result of being in 
close proximity to his mother who presumably carried Coxiella infected birth products on 
her person.  It is also possible that the grandmother may have been suffering from acute Q 
fever as a result of being transported in the same vehicle following the event or by 
personal contact with her infected daughter. Unfortunately no serology testing for Q fever 
antibodies was performed on the maternal grandmother to investigate this hypothesis. 
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7.4.3. Case No 3: A Four Year Old Boy from Nanango 
7.4.3.1. Clinical Presentation of the 4 Year Old Boy 
This child had a complex past history of congenital heart disease and Klippel-Feil 
syndrome.  He had an unresolving acute illness which was not responding to medical 
treatment and had no definitive diagnosis.  His symptoms included fever, diarrhoea, 
cough, tachypnoea, hepatomegaly, intermittent swelling in the left scrotum, and a 
nonspecific erythematous macular rash on the limbs and trunk. In addition he had had 
been febrile for 14 days and had abnormal E/LFTs and with thrombocytopenia on FBC. 
Day 1:  The boy was admitted to the Toowoomba Hospital and treated with oral antibiotics 
which included penicillin and amoxicillin for 7 days.  He remained febrile and lethargic and 
an enlarged liver was palpated on abdominal examination.  The child’s FBC showed 
thrombocytopenia but was otherwise normal. His treatment progressed to IV antibiotics.  
Two days into the admission, he continued to have spiking fevers and developed rigors 
and seizures. His platelet count continued to plummet, and he was treated with serum 
immunoglobulins over the next 12 hours.  His E/LFTs remained abnormal and blood 
cultures remained negative. The boy was transferred to the RCH-Brisbane where he was 
further assessed.   
Day 8:  At RCH, he presented as alert and afebrile with a clear chest. An echocardiogram 
was reported as normal with no evidence of endocarditis. On examination, he had a 
petechial rash, hepatomegaly and mild ascites.  His treatment was continued with IV 
antibiotics.  Bloods were drawn for serology and urine collected for M/C/S.  That night he 
became febrile with temperature reaching 38.2⁰C overnight. The existing treatment 
continued. 
Day 9:  Overnight his fevers again returned, peaking at 37.9°C. There was no evidence of 
pneumonia with a clear chest auscultation.  Previous serology testing had detected Q 
fever IgM antibodies, but this was dismissed as a false positive result due to possible 
cross reaction with a viral IgM antibody response.  Further bloods were drawn with follow 
up Q fever serology tests requested.  A clinical diagnosis of acute Q fever was made 
based on a decreasing Q Fever CFT titre (Table 7.5) and a suggestive clinical history that 
included high fevers, headaches, minor LFTs abnormalities and the acute respiratory 
illness prior to hospitalisation. As a result, treatment was altered to IV ciprofloxacin and 
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rifampicin. To seek a definitive diagnosis, the presence of C. burnetii DNA in the blood by 
specific PCR was sought.  PCR testing demonstrated the presence of C.burnetii DNA in all 
previously collected blood samples confirming a diagnosis of acute Q fever infection. 
Following the detection of Q fever DNA in blood, retrospective Q fever serology testing 
revealed the presence of IgM antibodies with increasing levels of IgG, which was a further 
confirmation of acute Q fever (Table 7.6). 
Table 7.5: Case 3 – Summary of pathology results 
Date of Collection Serology Test Result 
05 December 2000 CMV IgM and IgG Negative 
 EBV IgM Negative 
 Toxoplasma IgM and IgG Negative 
 Toxoplasma IgM and IgG Negative 
 Serovars Leptospiorosis Negative 
 Mycoplasma pneumonae total Ab Negative 
 Q Fever Phase II IgM  (ELISA) Positive 
 Q Fever Phase II IgG (ELISA) Negative 
 Q Fever total Ab (CFT) 128 
 Rickettsia serology IgG Negative 
   
07 December 2000 Brucella IgM and IgG Negative 
   
12 December 2000 Bartonella IgM and IgG Negative 
 Q Fever Phase II IgM  (ELISA) Positive 
 Q Fever Phase II IgG (ELISA) Negative 
 Q Fever total Ab (CFT) 64 
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Table 7.6: Case 3 – Summary of retrospective Q fever serology results 
 
Q Fever IFA Serology 
 
 Phase I Phase II 
Date IgG IgM IgA Total Ab IgG IgM 
Total 
Ab 
7 December 2000 ND ND - 128 128 512 >128 
12 December 
2000 
ND 80 - >128 512 512 >128 
10 January 2001 ND 320 - >128 512 128 >128 
5 April 2001 64 128 - >128 2048 ND >128 
25 July 2001 128 128 - >128 2048 ND >128 
14 March 2006 640 - 160 >512 >1280 ND 512 
12 October 2010 320 - ND 64 >1280 ND 128 
 
7.4.3.2. Summary of Serological Results 
The serological profile based on retrospective testing for this child shows a classical 
pattern of phase II IgM and IgG Q fever antibodies developing over time consistent with 
acute Q fever infection.  This child had an underlying congenital heart condition putting him 
at risk of developing chronic Q fever infection. He was hence monitored at regular intervals 
for the development of chronic Q fever infection. Over a ten year period this boy showed 
clear evidence of the development of chronic Q fever infection with the detection of Q fever 
phase I IgA antibodies, which is considered a marker of chronic infection, together with 
increasing titres of Q fever phase I IgG and total Q fever antibodies. This child therefore 
continues to be clinically monitored for chronic Q fever infection together with his 
congenital heart condition.  
7.4.3.3. Review of Clinical Case and Contact Tracing 
In consultation with the boy’s mother, possible sources of Q fever exposure were 
discussed.  He came from rural environment. The family had a domestic cat and exposure 
to farm animals was identified as a possible source.  There was no evidence of contact 
with ticks, and there was no previous history of overseas travel identified.  The boy’s 
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mother was a veterinaryy surgeon and recalls attending the delivery of a stillborn goat kid 
six weeks prior to her son being hospitalised with Q fever.  She vividly recalled returning 
home from the delivery with blood and products from the birth on her overalls and boots.  
The boy had greeted her by embracing and then sitting in her lap while she was still 
dressed in her work clothes. This indirect contact is considered the most likely the original 
source of his infection. 
As part of the NQFMP for occupations at risk, the mother had been vaccinated, but her 
son and the rest of the family were not considered “at risk” and therefore not included in 
the vaccination program. 
7.4.4. Case No 4: An Entire Family from Cunnamulla 
The case study presented here was of particular interest, as it involved multiple family 
members. Family member 1, an eleven year old girl, presented with febrile illness which 
remained undiagnosed. Only on the diagnosis of acute Q fever in her sibling was a 
retrospective diagnosis of Q fever infection made in this girl. Subsequently, the infection 
was found to involve her other siblings, and parents. These cases are here presented and 
examined. 
7.4.4.1. The First Case: An Eleven Year Old Girl – Family Member 1 
An eleven year old female had been unwell for several days with symptoms including 
nausea, a cough which produced clear to white sputum and a tender abdomen.  She had 
presented to her local GP on six previous occasions with no definitive diagnosis. 
An eleven year old female had been unwell for several days with symptoms of nausea, a 
cough productive of clear to white sputum and a tender abdomen.  She had presented to 
her local GP on six previous occasions with no definitive diagnosis. 
Day 1:  The girl was afebrile when presenting 3 days after her sixth GP visit at her local 
regional hospital. She was noted to have mild dehydration, a clear chest on examination 
and soft yet tender abdomen. She was admitted to hospital and treated with IV antibiotics, 
IV fluids and oral paracetamol. Urine was obtained for a M/C/S and bloods were drawn for 
laboratory investigations.  During that afternoon and evening she became febrile with 
temperatures reaching 39.8⁰C.  She remained febrile for the next 24 hours and Q fever 
serology was added to the pathology requests. 
 223 
 
 
Day 2:  A FBC showed elevated lymphocytes and her urine was negative for pathogens.  
She remained febrile and was continued on IV antibiotics.  Over the next twenty-four hours 
her fevers peaked at 40.0⁰C and she had nausea with vomiting. A chest x-ray was clear.  
Treatment was changed to IV ceftriaxone while awaiting the results of Q fever serology. A 
further FBC showed an elevated WBC count with low platelets and RBC count. 
Days 3-5:  The patient continued to be febrile and continued to complain of nausea.  
Temperatures intermittently peaked at 38.0⁰C. She remained on IV ceftriaxone and IV 
fluids and Q fever serology remained negative.  She was discharged 6 days after 
admission, afebrile but with no definitive diagnosis being made. 
7.4.4.2. Serology Testing 
Retrospective Q fever serology testing was requested three weeks after hospitalisation of 
this girl. This decision was based on positive Q fever serology results obtained for her 
sibling who became ill subsequent to this case.  The retrospective serology results showed 
seroconversion to Q fever antibodies, thereby confirming the diagnosis. The results are 
shown in Table 7.7. 
Table 7.7: Case 4 – Summary of pathology results for family member 1 
Date of Collection Serology Test Result 
3 April 2002 Q Fever Phase II IgM  (ELISA) Negative 
 Q Fever Phase II IgG (ELISA) Negative 
   
6 April 2002 CMV IgM Negative 
 EBV IgM Negative 
 BFV IgM Negative 
 Brucella IgG Negative 
   
24 April 002 Q Fever Phase II IgM  (ELISA) Reactive 
 Q Fever Phase II IgG (ELISA) Reactive 
 Q Fever Phase I Total Ab <8 
 Q Fever Phase II Total Ab 256 
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7.4.4.3.   Family Member 2: An Eight Year Old Male Sibling of Family Member 1  
Family member 2 was an eight year old boy and brother of family member 1. He presented 
to the same hospital where his sister had been an inpatient for six days.  He was afebrile 
with nausea and vomiting, but had a clear chest and soft abdomen on examination.  He 
had a past medical history of upper respiratory tract infections. 
He had blood taken for routine laboratory investigations. His FBC showed 
thrombocytopaenia and all cell types were also below normal limits. His LFT’s were 
elevated and a urine sample submitted for M/C/S showed no growth for pathogens.  The 
boy became febrile overnight with temperatures reaching 40⁰C.  Treatment was 
commenced including IV gentamicin and IV fluids. The boy remained febrile for the next 48 
hours, while his chest remained clear to auscultation. 
Subsequent blood samples were taken and on the fifth day of hospitalisation serology 
showed a seroconversion for Q fever antibodies (Table 7.8). He remained febrile 
throughout with temperatures up to 38.4⁰C.  The boy’s treatment was altered to include IV 
doxycycline. His 11 year old sibling previously admitted to the same hospital (Family 
member 1 above), still remained negative for Q fever serology. 
Table 7.8: Case 4 – Summary of pathology results for family member 2. 
Date of Collection Serology Test Result 
7 April 2002 Q Fever Phase II IgM  (ELISA) Negative 
 Q Fever Phase II IgG (ELISA) Negative 
 CMV IgM Negative 
 EBV IgM Negative 
 BFV IgM Negative 
 Brucella IgG Negative 
   
10 April 2002 Q Fever Phase II IgM  (ELISA) Reactive 
 Q Fever Phase II IgG (ELISA) Non-Reactive 
 Q Fever Phase I Total Ab <8 
 Q Fever Phase II Total Ab <8 
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7.4.4.4. Family Member 3: A Thirteen Year Old Female Sibling of Family Members 1 and 2 
A female teenage sibling of the two children previously described became unwell 6 days 
after the onset of symptoms of the first family member.  She presented with a similar 
febrile illness as her brother and sister with high fevers with no obvious focus.  She was 
admitted to the local regional hospital for 5 days where she was treated with IV antibiotics.  
She remained febrile during the afternoons and evenings with temperatures reaching 
39.3°C. She was generally unwell and complained of lethargy, but did not suffer nausea or 
vomiting. Because one of her siblings was diagnosed with Q fever (Family member 2) she 
was started on doxycycline as part of her clinical management.  She continued to have 
fevers overnight with source unclear. Q fever serology was requested.  Her chest was 
clear on examination.  Treatment was changed to IV ceftriaxone as fevers were not 
subsiding. She became afebrile 24 hours later and was discharged. Her Q fever serology 
remained negative while she was an inpatient (Table 7.9).   
Table 7.9: Case 4 – Summary of pathology results for family member 3 
Date of Collection Serology Test Result 
10 April 2002 Q Fever Phase II IgM  (ELISA) Negative 
 Q Fever Phase II IgG (ELISA) Negative 
   
24 April 2002 Q Fever Phase II IgM  (ELISA) Reactive 
 Q Fever Phase II IgG (ELISA) Reactive 
 Q Fever Phase I Total Ab <8 
 Q Fever Phase II Total Ab >512 
   
7.4.4.5. Family Member 4: The 31 Year Old Mother of the Three Siblings  
The 31 year old mother of the children became unwell 14 days after her first child (Family 
member 1) presented with first symptoms.  She presented to hospital with symptoms 
similar to her hospitalised children, including; fever, cough and a clear chest on 
auscultation.  She however, complained of severe headaches. A FBC was requested 
showing a neutrocytopaenia. She too was admitted to hospital and continued to have 
fevers and headaches. She was treated with IV antibiotics and fluids with blood samples 
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drawn for Q fever serology (Table 7.10). She remained in hospital for a further 3 days and 
was discharged with oral medication and with convalescent Q fever serology requested.  
 
Table 7.10: Case 4 – Summary of pathology results for family member 4 
Date of Collection Serology Test Result 
13 April 2002 Q Fever Phase II IgM  (ELISA) Negative 
 Q Fever Phase II IgG (ELISA) Negative 
   
29 April 2002 Q Fever Phase II IgM  (ELISA) Reactive 
 Q Fever Phase II IgG (ELISA) Equivocal 
 Q Fever Phase I Total Ab <8 
 Q Fever Phase II Total Ab >512 
7.4.4.6. Family Member 5: A Four Year Old Female Sibling of Hospitalised Children and 
Daughter to the Hospitalised Mother  
This child had presented to the local GP with fever and nausea and milder symptoms 
similar to those displayed by her other siblings, including fever and nausea.  She was not 
admitted to hospital but did have blood samples taken for Q fever serology. The results of 
serology testing for this child are shown in Table 7.11. 
Table 7.11:  Case 4 – Summary of pathology results for family member 5 
Date of Collection Serology Test Result 
29 April 2002 Q Fever Phase II IgM  (ELISA) Negative 
 Q Fever Phase II IgG (ELISA) Reactive 
 Q Fever Phase I Total Ab <8 
 Q Fever Phase II Total Ab 64 
 
7.4.4.7. Summary of Serological Results 
The infections described in these patients were definitively diagnosed using Q fever 
serology. A consistent pattern of Q fever IgM positivity with the development of IgG and 
phase II total antibodies (CFT) was evident in all cases. 
 227 
 
 
7.4.4.8. Review of Clinical Case History 
Family member 6 was the father of the children and the husband of the 31year-old female 
(Figure 7.1). He recalled feeling unwell and having mild symptoms of fever and headaches 
following the kidding of goats on his property, 6 weeks prior to the display of symptoms in 
family member 1, his 11 year old daughter. He was not previously vaccinated against Q 
fever. It was presumed his mild symptoms were consistent with existing low level immunity 
as the result of constant exposure to C.burnetii in his working environment. It is likely that 
the infection in other family members was the consequence of either direct or indirect 
contact with infected material from the goats.  
A timeline of symptoms and hospitalisation of family members 1-4 who were hospitalised 
is shown on Figure 7.2. 
 
Figure 7.1: Case 4 - Family relationship of clinical cases 
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Figure 7.2:  Case 4 – Timeline of clinical presentation and medical history for the four 
family members hospitalized (in days) 
7.4.5. Case No 5: A 28 Year Old Female Park Ranger from Central Queensland 
7.4.5.1. Clinical Presentation 
A previous fit and well 28 year old female with no significant past medical history 
developed a mild influenza like illness associated with headaches. She presented to a 
local GP clinic in Rockhampton, Queensland, and was prescribed oral Tamiflu 
(oseltamivir) with amoxicillin/clavulanic acid.  Over the next eight days, her condition 
worsened with the development of nausea, vomiting and generalised abdominal pain. 
Day 1:   She presented to the local regional hospital and was admitted.  On presentation, 
she was febrile with a temperature of 37.8°C.  She developed acute kidney failure, 
profound hyperbilirubinemia, mucosal bleeding without any other major haemorrhage 
being detected. She became hypotensive with haemodynamic instability requiring 8 litres 
of IV crystalloid fluids. She was ventilated for seven days. Blood samples were taken and 
showed an abnormal LFTs, thrombocytopenia and disseminated intravascular coagulation.  
She had negative blood culture results and was treated with IV ampicillin and gentamicin. 
She was stabilised and transferred to the tertiary intensive care unit at the RBWH. 
Day 8:   During the transfer she went into vasodilatory shock. On arrival at the RBWH 
there was evidence of mucosal bleeding but no petechial rash. She had unremarkable 
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respiratory and cardiac signs and there were no signs of meningitis or neurological 
disorders.  The initial differential diagnosis included the possibility of scrub typhus infection 
due to the severity of her illness and extensive evidence of mite bites. This was also 
supported by the likely mite exposure during the performance of her occupation as a Park 
Ranger, as well as to native animal faeces which may have contained Rickettsia spp. A 
treatment regime with doxycycline was commenced.  Her platelet count remained low and 
she underwent a blood transfusion. She rapidly developed progressive respiratory failure 
and was intubated and ventilated for seven days.  Investigations of her blood including 
extensive serology testing, confirmed Q fever infection and treatment was altered to IV 
vancomycin and IV ciprofloxacin. Q fever serology results are shown in Table 7.12.  
She remained in hospital for a total of six weeks, of which three weeks were spent in 
intensive care for the treatment of vasodilatory shock with fluid resuscitation. She was 
febrile throughout her hospitalisation with temperatures greater than 38.5⁰C and she 
continually complained of headaches. She slowly recovered on the treatment regime with 
the normalization of LFTs and her thrombocytopenia. 
7.4.5.2. Summary of Serological Results 
The antibody profile for this patient showed increasing levels of phase II IgM and IgG as 
the disease progressed. On resolution of the infection phase I IgG became positive with 
maximum antibodies approximately 7 months after the first evidence of infection. IgA 
antibodies to phase I and II were not detected. Also, at the second sampling timepoint 
(23/4/2011) the IFA IgG result was positive, yet the ELISA IgG result for this sample was 
negative, demonstrating that the IFA was more sensitive than the ELISA as previously 
noted in Chapter 6 (6.3 Discussion) 
7.4.5.3. Case History and Contact Tracing 
Follow up investigation regarding potential sources of Q fever exposure revealed that, as 
part of her occupation as a wildlife park ranger, she would regularly remove kangaroo and 
wallaby carcasses that resulted from road kill. Her last contact with such animals had been 
3 weeks prior to her onset of symptoms. Also, three of her work colleagues had been 
previously unwell with self-limiting influenza-like illnesses.
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Table 7.12:  Case 5 - Coxiella burnetii serology results.  
 
Results are expressed as reciprocal titres, reactive, negative, or equivocal. Screening tests included ELISA assay for IgG and IgM 
antibodies to the phase II antigens of C.burnetii, and specific immunofluorescence (IFA) testing for Q fever phase I antibodies IgG 
and IgA and phase II antibodies IgG, IgM, and IgA. *PCR for C.burnetii was positive on two blood collections taken 13.7 hours apart
Q Fever Tests 21/4/2011 23/4/2011 30/4/2011 1/6/2011 21/9/2011 17/11/2011 
IFA Phase I IgG <10 <10 10 80 ≥1280 ≥1280 
IFA Phase I IgA - - - 10 10 10 
IFA Phase II IgG <10 160 ≥1280 ≥1280 ≥1280 ≥1280 
IFA Phase II IgM 40 320 ≥1280 ≥1280 80 160 
IFA Phase II IgA - - - 10 <10 <10 
ELISA Phase II IgG Negative Negative REACTIVE REACTIVE REACTIVE REACTIVE 
ELISA Phase II IgM REACTIVE REACTIVE REACTIVE REACTIVE EQUIVOCAL Negative 
PCR blood DETECTED* - - - - - 
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7.5. Discussion 
Although Q fever disease was described over 60 years ago in Queensland, the 
presentation of this infection still appears to be poorly recognised, with many cases missed 
or misdiagnosed. This is more than likely because the initial symptoms of Q fever are non-
specific and mimic many other infections. The cases presented in this Chapter 
emphasised the utility of supplemental Q fever serology testing and the importance of 
detailed patient histories when diagnosing Q fever infections. Moreover, in the majority of 
cases it was Q fever-specific antibody testing that confirmed a clinical diagnosis, because 
PCR is not widely used and is not available in regional Queensland laboratories. 
As previously indicated, the population considered most at risk are rural farmers, abattoir 
workers, veterinary surgeons, and large ruminant handlers. As a result of this all these 
occupational groups were included in the National Vaccination program. However, the 
majority of clinical cases presented here were in children and an adult considered to be at 
low risk of infection. These patients were all resident in rural Queensland, contributing to 
the high rate of notifications previously reported from this sector. 
Clearly the cases presented here demonstrate that Q fever can be a very serious disease 
in children and highlight the complexity associated with its clinical recognition and 
diagnosis. Often a diagnosis of Q fever in children is not considered and therefore the 
disease is under-recognised and under-reported as an unidentified cause of some febrile 
illness.   
The children presented in these case studies resided in traditional high risk communities, 
but consideration of the high risk was only associated with adults directly handing large 
ruminants.  With the rollout of the NQFMP the majority of at risk workers have been 
targeted and vaccinated, but the children have not been included in this program.   
However, children in rural Queensland are at risk of acquiring Q fever, because they are 
often expected to assist on the farm or rural property on a regular basis with daily contact 
and exposure to animals and animal products. Yet there is no vaccination program 
available to them, nor have they been considered from exclusion from the properties 
during extremely high risk activity such as in times of calving, lambing or kidding.  Children 
are commonly present at these activities and generally encouraged to help with the 
birthing, caring for and maintenance of the new born animals, including simple tasks such 
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as “mucking out” stalls or pens.  It is these chores or activities that potentially expose such 
children to high loads of the bacteria and hence the acquisition of Q fever disease.   
This risk was demonstrated in two of the paediatric cases presented above, highlighting 
the source of infection from indirect animal contact. In both cases, the children had no 
known direct dealings with any animals or their products prior to becoming unwell and it 
was only post-diagnosis that the potential exposure and risk scenarios were identified.  
These children were exposed indirectly from other family members, who must now be 
considered as an important source of infection, and identified the need for preventive 
strategies, including possibly vaccination, for children of parents working in “high risk” 
occupations.  
The risk of infection to children from secondary sources, including their parents was clearly 
demonstrated by the case of the 4 year old boy from Nanango who was infected from 
animal products carried by his mother. It is this indirect animal exposure that may lead to 
the inhalation of C.burnetii from contaminated clothing, footwear or work tools thus placing 
those who come in close proximity with these articles at high risk of contracting Q fever. 
This case was particularly interesting as it highlights the progression of acute Q fever to a 
chronic infection in a child.  The presentation of chronic Q fever in children is considered to 
be extremely rare14, particularly as the presentation in children primarily occurs as 
osteomyelitis. In this chronic case, cardiac infection and involvement was considered the 
likely source but could not be confirmed, which is not uncommon in Q fever endocarditis. 
Throughout the review of the cases above it was noted that Q fever was eventually 
considered in the majority of presentations, and the appropriate serology was requested.  
However, in these cases the initial serology and antibody results were negative or 
equivocal therefore a diagnosis of Q fever was dismissed without consideration for follow 
up serological testing.  In two cases, the results of serology testing were confused by 
positive results for antibodies to other infectious agents. In Case 1 these were IgM positive 
antibody reactions to BFV and EBV which confounded the recognition of Q fever as the 
true cause of the disease. Cross reactivity of IgM antibodies is a well-recognised 
phenomenon in serological testing, and can be attributed to non-specific polyclonal 
stimulation during the disease process of B-lymphocytes which are primed for IgM 
antibody production. Such a cascade of IgM molecules to various antigens may lead to 
non-specific binding and false-positive reactions and thus an incorrect diagnosis.  
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Even when evidence of acute Q fever infection was indicated by antibody results in Case 
2, it was discounted, because the clinical presentation was not in the expected context, 
and hence the results were considered as an IgM cross-reaction similar to that described 
above. Here the results of PCR testing for C.burnetii DNA were conclusive, and confirmed 
that during early stages of Q fever infection PCR is the testing method of choice (This was 
discussed previously in Chapter 6). 
The case studies presented emphasise the need for physicians to consider the disease in 
context, and examine case histories in detail, including family history and circumstance. 
Also, the initial results of serology and antibody testing should be considered with caution 
and supplementary or retrospective serology may be recommended.  Perhaps in children, 
the onset of symptoms is rapid and more intense than in adults, and the early serology 
results are not truly indicative of the disease. In these cases, Q fever PCR testing may be 
a more accurate tool for diagnosing the infection.  
Interestingly, it was observed that the majority of patients described above had 
thrombocytopenia which was identified as part of their initial blood investigation in 
determining a cause of infection.  Thrombocytopenia is a common manifestation 
associated with all tick-borne disease yet in none of the cases described in this Chapter 
was there any indication of tick involvement in the disease.  The Centre for Disease 
Control (CDC) described that only 25% of Q fever cases present with a thrombocytopenia, 
but in all the cases above there was a noted decrease in platelets during the patient’s 
initial infection.  This may be a manifestation only observed in children, or perhaps in 
severe Q fever cases such as described in Case 5. 
Finally, the risk of infection from indirect exposure to animal products cannot be 
underestimated, as recently demonstrated by the extensive and costly outbreak of Q fever 
in The Netherlands. Here the majority of the 4000 recorded cases were indirectly exposed 
to the bacteria shed from infected goats. In Australia, there is currently a growing industry 
in goat farming for their milk, and with this, an increasing potential risk for infection of the 
general population with C.burnetii.  
Given the evidence presented in the cases above, demonstrating the risk factors 
associated with Q fever in children, and the growing goat farming industry, it may be 
prudent for Australian Public Health authorities to consider the wider distribution of the Q 
fever vaccine, QVax® (bioCSL, Australia), to include, not only those individuals in 
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occupations “at risk” but also their families and other individuals that have regular close 
contact. This should also include all staff working at veterinarian clinics where there has 
been a clear risk identified with the exposure to domestic pets, as well as people in 
occupations that expose them to native animals such as Park Rangers and government 
workers that are involved in activities in areas that may have been contaminated by wildlife 
secretions and tissues. Such a strategy would help in reducing the overall rate of Q fever 
infections in Australia, and result in considerable savings of the health care dollar.   
7.6. Significant Outcomes from this Chapter 
 This was the first study highlighting that indirect transmission of Q fever to children 
must be considered as a realistic source of infection. 
 These cases were presented in unusual clinical settings not immediately associated 
with Coxiella infection, as a result the appropriate follow up Q fever testing was not 
performed. 
 Coxiella is highly infectious and the increased risks associated with direct or indirect 
transmission within family groups in rural settings should be considered in the 
application of an effective vaccination strategy. 
 Vaccination should also be considered for individuals in occupations not traditionally 
associated with risk of Q fever infection such as Park Rangers or those working with 
wildlife. 
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8.1. Introduction 
Q fever disease and the epidemiology associated with the infection are very complex.  The 
worldwide distribution, reservoirs, routes of transmission and vectors are multifarious and 
make research and investigations difficult, especially for comparison studies.  Research 
and diagnosis of the disease has improved with the introduction of molecular techniques 
such as PCR and genome sequencing, and these tools have opened the way forward for 
investigations into the biology of the bacteria and the disease states causes by the 
organism. 
There are many factors that hinder comparative investigations involving Coxiella burnetii.  
Culturing the organism is hazardous and requires Biosafety Level 3 conditions, because 
the organism is considered a major biological warfare agent (Category B) by the Centre for 
Disease Control (CDC, Atlanta, USA). Therefore, comparative analysis using traditional 
methods have been limited, as sufficient bacteria for these techniques have often not been 
available, and clinical or environmental samples positive for Coxiella are the only samples 
used in such studies. 
 Also, culturing of Coxiella is difficult and requires enrichment media and animal derived 
cell culture systems which have long incubation times of up to 7 days. In addition, 
considering that the organism is highly infectious, culturing and purification of the organism 
carries considerable risk for laboratory scientists, and therefore has been restricted to 
laboratories with the appropriate facilities.  
Modern techniques of whole genome sequencing allow the entire genetic code of the 
bacteria to be determined.  This permits direct comparisons and evolutionary relationships 
to be established using bioinformatics. 
The effectiveness and real-time monitoring of results made possible by molecular 
techniques, have allowed for rapid diagnosis of the disease states of Coxiella, and have 
provided an essential tool to terrorism investigation bodies for assessing potential 
biological warfare threats that employ Coxiella burnetii.  These tools aid in identifying 
potential sources of the bacteria. 
8.1.1. Taxonomy of Coxiella burnetii in the Molecular Era  
The bacteria are obligate, intracellular organisms.  They are gram negative, non-motile, 
pleomorphic cocobacillary bacteria, ranging in size from 0.2-0.4µm x 0.4-1µm.. It is these 
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phenotypic attributes that resulted in the bacteria being originally classified in the phylum 
of Proteobacteria, order Rickettsiales, categorized with the Rickettsiaceae family, in the 
genus Rickettsia species burneti1. Philip in 1943 renamed the organism to Coxiella burnetii 
after further cultural and biochemical investigations1.  
However, the introduction of molecular techniques such as PCR and the development of 
genome sequencing, has made enormous improvements in the correct classification of 
Coxiella.  Sequencing of the 16s rRNA gene has allowed for the molecular differentiation 
between species, as these regions are highly conserved and are often used in 
phylogenetic analysis, because these genes have slow rates of evolution and mutation.  
The analysis of the Coxiella 16s rRNA showed more genetic diversity between C.burnetii 
and the other Rickettsias, and subsequently it was established that the Coxiella are most 
closely related to the genus Legionella and hence Coxiellae were reclassified into the 
order Legionellales, family Coxiellaceae2.   
C.burnetii is the only species that has been formally recognised in the genus Coxiella.  
There is >99% homology between all the strains sequenced using 16s rRNA comparing 
gene sharing3.  A new Coxiella, Coxiella cheraxi, was isolated from Australian fresh water 
crayfish and although initially considered a new species, the rRNA, sodB and com1 genes 
sequenced from this new organism showed a >95% homology with C.burnetii4.   
8.1.2. Genome of Coxiella burnetii 
The first full Coxiella genome was sequenced in 20035. This was the Nine Mile Phase I 
RSA493 isolate which was isolated from a tick host retrieved in Montana in 1935. It 
produced a 1,995 Kbp circular chromosome.  There are currently six C.burnetii genomes 
that have been sequenced in entirety. Nine Mile RSA 4935 (NC_002971.3), two sequences 
from human endocarditis patients CbuG_Q212 (NC_011527.1)  and CbuK_Q154 
(NC_011528.1)6, a strain isolated from a rodent, the Dugway 5J108-1116 (NC_009727.1), 
strain  RSA 331 (Henzerling strain) (NC_010117.1),  isolated from a patient in Italy in 1945 
and recently a strain sequenced from The Netherlands Coxiella burnetii Z3055 
(NZ_LK937696.1) linked to the large Q fever outbreak in 2007. These sequences show a 
variation in the Coxiella bacterial genome between ~2.0 to 2.2 Mb in length, and display 
considerable genetic homology between each other  when examined with 16s rRNA 
sequencing2.   
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The Coxiella genome is comprised of circular chromosomes generally associated with one 
independent plasmid or the genome contains integrated sequences homologous with 
plasmids.  There have been four plasmid types labelled QpH17, QpRS8, QpDG9, QpDV10 
along with one plasmid from a Chinese isolate without labelling11.   Initial studies 
suggested that there was a correlation between plasmid type and disease state, however, 
this has since been disproved as plasmid QpH1 was detected in both acute and chronic 
patients3. A recent study suggested that the proteins encoded by the plasmids have an 
essential role in the modification of the host cell during infection12.   
8.1.3. Typing of Coxiella Isolates 
C. burnetii is highly infectious, and the variety of potential sources for natural infection from 
proximity of livestock, consumption of their products, exposure to dust and other sources 
of infection identified in Chapter 5,  make it of paramount importance to be able to 
investigate the source of any outbreak. The discrimination between different strain types of 
C.burnetii  was initially very difficult as the conventional serological methods were 
unsuccessful13.  An attempt to use the difference in the lipopolysaccharide banding 
patterns produced was also unsuccessful in differentiating Coxiella isolates14 and the 
typing of plasmids gave limited discrimination8.  Typing of strain isolates was hence based 
on their description of source, geographical origin and clinical manifestation.  However, the 
great diversity associated with Coxiella and the disease states initiated, a broad host range 
and widespread distribution only increased the importance of strain differentiation for 
epidemiology studies and clinical diagnostics.  
8.1.4. Genotyping of Coxiella burnetii 
The advancement in molecular technology and sequencing has led to the molecular 
characterisation of complete bacterial genomes. Whole genome sequencing is the ultimate 
method for performing direct comparisons between strains. However, even with vastly 
reduced cost of sequencing technology, it is still not practical, nor financially viable for 
many laboratories to perform such analyses.  This has influenced the development of 
other typing methods for comparisons between Coxiella strains. The earlier typing 
methods that were used to discriminate strains were created using the restriction fragment 
length polymorphisms (RFLP)9,15–17.However, these methods required growth of the 
organism which is hazardous and lacked inter laboratory reproducibility.  Discrimination of 
Coxiella strains based on sequencing the com1, mucZ and isocitrate dehydrogenase 
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genes has also been used with limited results18–21. The introduction of real-time PCR 
technology and the availability of whole genomic sequences on public databases has seen 
a new emergence of genotyping methods.  From 2005, highly discriminative assays were 
developed including multi-space sequence typing (MST), multilocus variable number 
tandem repeat analysis (MLVA) and single nucleotide polymorphism (SNP).  
8.1.4.1. MST- Multispace Sequence Typing 
The MST method analyses the intergenic regions of coding genes.  These non-coding 
regions (= “spacer”) are used for typing because they are not constrained by selective 
pressure to encode functional proteins, as are coding genes. This method was first applied 
in 2005 and was able to separate 173 isolates of Coxiella into 30 sequence types. This 
method showed correlation with both geographical and plasmid clusters that had been 
previously described22 and allowed for direct inter laboratory comparisons owing to the 
resolution power delivered by a sequencing technique.  Results were analysed through the 
use of internet-based data-links that allow comparisons with other strains lodged on a 
central database (http://ifr48.timone.univ-mrs.fr). 
8.1.4.2. Multilocus Variable Number Tandem Repeat (VNTR) Analysis (MLVA) 
The use of software to identify naturally occurring tandem repeats enabled the 
identification of small repeat units recurring at loci throughout the genome, and this can 
vary between different isolates.  The variation between repeat copy numbers is largely due 
to insertions and deletions that are the result of DNA replication mutations along with 
recombination mutation events23.  This technique has been widely used for typing other 
organisms and has become the reference typing method.  Bacteria such as Neisseria 
meningitidis, Bordetella pertussis, Staphylococcus aureus, Streptococcus pneumonia, 
Haemophilus influenza, Mycobacterium tuberculosis and Yersinia pestis are differentiated 
using MLVA. 
Genotyping  by multilocus  VNTR  analysis  (MLVA)  involves  the  amplification  of  
several variable number tandem repeats (VNTR)  loci by PCR. The specific amplicons are 
sized and converted to a repeat copy number. Profiles are produced comprised of copy 
number alleles from each locus; these in turn are compared to different strains. For the 
typing of Coxiella burnetii isolates, two MLVA typing schemes have been developed, both 
in 2006 by Svraka et al24 and Arricau-Bouvery et al25 .  The method developed by Arricau-
Bouvery et al incorporates 17 VNTR loci that could be analysed in 2 separate panels. The 
first panel of 10 loci was more adaptable for analysis using conventional gel 
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electrophoresis detection methods as repeat sequences were 9-126 bp in length.  The 
second panel, containing 7 loci, had much smaller repeat units of 6-7 bp in length and 
were targeted for use using more sophisticated automated, sizing methods such as 
capillary electrophoresis25. The selected loci are deemed to be relatively stable supported 
by the fact that isolates of the reference strain Nine Mile (RSA493) from different 
laboratories with widely varied cell culture passages showed no differences24. In addition, 
like the MST-method, a web based data repository has been established facilitating 
comparative analysis with known strain repeat patterns (http://minis atellites.u-psud.fr/). 
8.1.4.3. SNP Single Nucleotide Polymorphism Typing  
SNP typing methods have been developed based on mismatches previously identified by 
MST genotyping.  These assays are designed to be rapid and inexpensive using real-time 
PCR systems.  One analysis designed 14 SNP assays to genotype over 40 Coxiella 
isolates which could be divided into 8 distinct genotypes26. This method showed good 
correlation relating to geographic origin, infection characteristics, and plasmid types of 
isolates. 
8.1.4.4. Determination of Most Discriminative Typing Method for Coxiella  
The method of choice for genotyping is dependent on the power of discrimination. A 
numerical value can be assigned between various methods using a modified Simpson’s 
index formula described by Hunter and Gaston27. This publication describes an index of 
discrimination for various typing methods centred on the possibility of two separate strains 
being characterized as the same genotype. The index is used to compare the various 
typing methods for Coxiella and the method with the highest index is used as the greatest 
discriminatory method (Table 8.1)28.  
From this index the two current methods with the greatest discriminative power are the 
MLVA and MST typing methods for Coxiella. The MST typing method has been used to 
perform the most comprehensive genotyping study with 173 isolates from various 
geographical locations worldwide22. However, this study contained isolates mainly from 
Europe and the discrimination based on geography produced some interesting clustering 
with all the Canadian strains having the same genotype, with France having 30 different 
genotypes and yet one of the specific genotypes was isolated on 4 different continents.   
There was however, no data from Australian isolates or Q fever patients included in the 
genotyping analysis22. 
 243 
 
 
Table 8.1: The Hunter-Gaston Discrimination Indices for five Coxiella typing methods 
available. (The higher the index the greater the discriminative power).  
METHOD AUTHOR DISCRIMINATION INDEX 
MLVA (Panels 1 and 2) Arricau-Bouvery25 0.99 
MST Glazunova22 0.92 
RFLP Hendrix9 0.87 
SNP analysis Huijsmans29 0.85 
com1 sequencing Sekeyova20 0.54 
 
8.2. Specific Aims Addressed in this Chapter:  
Very limited genotypic data was available for C.burnetii detected in Queensland. Following 
the detection of the bacteria in various clinical samples as described in Chapter 5, this 
study sought to address this knowledge gap, and used MLVA typing to characterise 
C.burnetii in these samples. Specifically the study sought to: 
 Determine if different strains of Coxiella circulate in Queensland 
 Determine if the strains that are present in Queensland are similar to those 
identified in other parts of Australia, and the world 
 Examine if genetically similar strains circulate in the environment as those identified 
in human infections 
 Investigate if there is an association between geographical location and genotype 
 
8.3. Methods 
8.3.1. Samples Used for Strain Typing 
There were a total of 63 samples that were included as part of the MLVA study. There 
were 51 samples from Coxiella-positive human subjects that were examined by MLVA 
analysis to determine strain variation of the bacteria. These samples were acquired from 
the Queensland Public Health laboratory, and comprised samples from 33 males, 16 
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females and in two the gender was not recorded. The subjects were aged between 5-77 
years of age, with an average age of 43.5 years.  The sample types included blood, bone, 
tissue, heart valve and placenta.  These samples were collected between 2006 and 2013 
from patients residing in Queensland and previously diagnosed with Q fever. These 
samples were all confirmed Coxiella positive using PCR.  
There were an additional 12 environmental samples analysed for C.burnetii strain variation 
using MLVA strain typing.  These included urine samples from 8 animals: canines, felines 
and flying foxes. There were 5 dust samples that were identified as containing Coxiella 
DNA which were included in the MLVA typing study and were part of the environmental 
samples investigated.  All these environmental samples were obtained from Queensland 
locations and were previously identified as PCR positive as described in Chapter 5 as part 
of the identification of potential sources of infection to populations in Queensland.  
Demographic data were available for all of these samples. 
8.3.2. MLVA Typing Method  
The MLVA strain typing was performed using the published methods by Klasson et al30 
which had been modified from a previously published method by Arricau-Bouvery et al 
(2006)25. These methods had been adapted to the MLVA6-Nijmegen method which is 
widely used, and takes advantage of the six highly variable loci ms23, ms24, ms27, ms28, 
ms33, ms34. These loci were found to be the most valuable in the outbreak context in The 
Netherlands and correspond to VNTR panel 2 proposed by Arricau-Bouvery et al25 with the 
exception of target ms31.  
8.3.2.1 MLVA Typing Using MLVA6 and profiling via Capillary Sequencing Detection 
Originally the Queensland samples were screened for the MLVA6 targets including ms23, 
ms24, ms27, ms28, ms33 and ms34 as previously described 25,30,31.  Table 8.2 shows the 
6 loci and the expected amplicon size and number of repeats detected when Nine Mile is 
used as a control.  The clinical samples were processed by conventional PCR using the 
primers shown in Table 8.3 and products were detected on a 1.5% agarose gel.  Figure 
8.1 shows the PCR products obtained for human and animal samples screened. These 
samples were sequenced and the data investigated for repeat units.  
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Table 8.2: The 6 loci used in the MLVA analysis of Queensland C.burnetii-positive samples and 
the amplicon size and numbers of repeats as observed in Nine Mile strain25,30,31.  
Locus 
Amplicon 
Size (bp) 
Forward Primer 
5`-3` 
Reverse Primer 
5`-3` 
No. of 
Repeat 
Units 
ms23 133 CGCMTAGCGACACAACCAC GACGGGCTAAATTACACCTGCT 9 
ms24 26 TGGAGGGACTCCGATTAAAA GCCACACAACTCTGTTTTCAG 27 
ms27 89 TCTTTATTTCAGGCCGGAGT GAACGACTCATTGAACACACG 4 
ms28 111 AGCAAAGAAATGTGAGGATCG GCCAAAGGGATATTTTTGTCCTTC 6 
ms33 104 TCGCGTAGCGACACAACC GTAGCCCGTATGACGCGAAC 9 
ms34 101 TTCTTCGGTGAGTTGCTGT GCAATGACTATCAGCGACTCGAA 5 
Samples were processed by conventional PCR, gel detection and Sanger sequencing as 
described in 8.2.3.1 above. The final analysis however, was limited to the three loci shown 
in red as these were the loci that produced better sequencing results. 
 
 
Figure 8.1: Agarose gel showing PCR amplification products obtained for MLVA6 Sanger loci 
ms27, ms28 and ms34. M= DNA marker  
The positive DNA products were “cleaned up” to remove remaining contaminants from the 
PCR reaction and prepared for Sanger sequencing by AGRF (Australian Genome 
Research Facility- Brisbane, Australia). Sequence data was generated however, it proved 
to be difficult to obtain good and consistent sequence data for all 6 loci using this method 
on the Queensland samples. The analysis was then limited to the 3 loci for which 
adequate sequence information was available for all samples. These were ms27, ms28 
and ms34. 
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Table 8.3: Primers used in the PCR of recognised VNTR repeat regions for Coxiella from Arricau Bouvery et al25 first description. This table of 
primers was taken from Vincent et al28. These primers were used in the fragment analysis of the Queensland samples performed in . Primer named 
with the prefix NL_ are modified primers described by Tilburg et al32 specifically for use on clinical samples not isolates. The primers highlighted in red 
were used specifically for the analysis of Queensland samples   
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8.3.2.2 MLVA Typing Using 3 Loci and Capillary Electrophoresis Detection 
A limitation of the above method was the inability to obtain usable MLVA profiles for some 
of the samples with low bacterial loads. Capillary electrophoresis detection using 
fluorescently labelled amplicons has been used successfully to overcome this limitation. 
Although the use of additional loci may add value when investigating a wider genetic 
diversity, the use of 3 loci only was deemed to be sufficient for easy and rapid 
classification of C. burnetii into 4 main clusters33. This was addressed in this study, by 
using a set of 3 markers as had been used successfully in the outbreak in The 
Netherlands to analyse clinical samples30.  These loci produce very small amplicon targets 
which are more suitable for analysis by capillary electrophoresis.   
The investigation by Vincent28  into the discriminatory power of each loci using the Hunter-
Gaston discrimination index (HGDI) showed that  a single loci, ms24 was able to produce 
a HGDI of 0.83 (0 being no discrimination and 1 having complete discrimination) compared 
to a HGDI of the total 16 loci of 0.89.  There were three loci that gave good discriminative 
power when used in combination; these were ms24, ms28 and ms33. This considered, 
further analysis of Queensland samples by MLVA used these loci (ms24, ms28 and ms33) 
followed by capillary electrophoresis.  
Another key to using the capillary electrophoresis method was to ensure the use of 
controls/standards for all of the loci under investigation. This ensured that results obtained 
were standardised and consistent across runs of analysis. It is important to ensure that 
sample sizing is relative to the controls rather than being an absolute value. Therefore, 
MLVA analysis in this study used a subset of targets from Panel 2 (Table 8.4), and the 
more sensitive detection method of capillary electrophoresis of fluorescently labelled 
amplification products for the designated loci.  These loci have repeat units much smaller 
than those in panel 1; repeat units are only 6-7bp in length.   
The PCR primers for the loci ms24, ms28 and ms33 were synthesised by Invitrogen (Life 
Technologies, Victoria, Australia). In order for amplicons to be detected by capillary 
separation on the 3130 xl Genetic Analyser (Life Technologies, Victoria, Australia), it was 
necessary for the primers to be fluorescently labelled.  In these reactions the forward 
primer was labelled with the Fluorophore 6-carboxyfluorescein (FAM).    
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Table 8.4: Specific VNTR loci from C.burnetii Nine Mile with the expected amplicon size 
and the number of repeats determined by Arricau-Bouvery et al25 for the direct comparison 
to Queensland samples. 
Locus Amplicon Size (bp) No. of Repeats 
ms01 198 4 
ms03 229 7 
ms07 1112 8 
ms12 1074 8 
ms20 402 15 
ms21 210 6 
ms22 246 6 
ms26 127 4 
ms30 306  6 
ms36 477  4 
ms23 157 8 
ms24 344 27 
ms27 276 4 
ms28 276 6 
ms31 285  5 
ms33 262 9 
 
Reactions were set up comprising 1x PCR Buffer, 1.5 mM of magnesium chloride, 200μM 
of dNTPs, 1U of  recombinant Taq DNA polymerase (Invitrogen, Life Technologies, 
Victoria, Australia), 400nM each of primer, 15μL, 1μL of DNA and nuclease free water to a 
total reaction volume of 25μl. Amplification was performed in a Maxygene ThermW1000  
thermal cycler (VWR International, Queensland, Australia) or a 7500 Fast Real Time PCR 
System (Life Technologies, Victoria, Australia) and consisted of a 10 minute hold at 94°C 
followed by 40 cycles of denaturation at 94°C for 30s, annealing at 60°C for 30s and 
elongation at 72°C  for 1 minute. Amplification was completed by a final extension of 7 
minutes at 72°C. To check that amplification had been successful, 5uL of each reaction 
was run on a 1.8% agarose gel (Figure 8.2).  
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Figure 8.2: Confirmation of PCR product as visualised by gel electrophoresis of the 
Queensland samples for the loci ms28 along with control samples and the Nine Mile strain 
Where a product was visualised following gel electrophoresis, 10ul of the remaining 
reaction was sent to AGRF (Australian Genome Research Facility- Brisbane, Austalia) for 
capillary separation using the Applied Biosystems 3730 xl analyser (Life Technologies, 
Victoria, Australia).The amplicon size was determined by analysing the subsequent data 
using Peak Scanner v 1.0 (Applied Biosystems). Samples where no products were 
visualised were also submitted to AGRF for capillary separation. This was because 
capillary electrophoresis has greater sensitivity and was able to detect amplification 
products which could not be visualised on the gel.  
The number of amplicon repeats present in amplification products of each loci were 
calculated in relation to the results obtained for the C. burnetii Nine Mile control strain 
(Table 8.5). These MLVA profiles were compared to strains entered on the online 
database http://mlva.uUpsud.fr/mlvav4/genotyping/index.php, along with strains previously 
identified from Australia (accessed June 2015). Profiles that showed no correlation with 
those entered on the database and hence deemed to be novel, were assigned an 
annotation in the format of: CbQldxx, where xx was a two digit number. Any new MLVA 
genotypes were allocated genotype names as previously described by Vincent28 and 
followed on from the latest Australian genotype discovered. 
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8.4. Results 
8.4.1. MLVA Typing Using MLVA3 Sanger and Loci ms27, ms28 and ms34 
Of the 63 samples examined, there were 11 samples for which MLVA genotyping data was 
obtained using the MLVA3 method with 3 loci. These included 10 samples from humans 
and one canine sample.  When these samples were compared to profiles produced for the 
Australian isolates previously described by Vincent28 and those samples lodged on the 
MLVA databases, there were four novel MLVA genotypes identified from Queensland, and 
seven samples that had profiles similar to those identified in  other Australian isolates 
(Table 8.5).    
Table 8.5: The Queensland samples screened using three discriminative loci and the 
related MLVA genotypes obtained using the methods described by Arricau-Bouvery et al25 
and Klaasen et al30. 
Sample  Host Origin  ms27 ms28 ms34 MLVA Genotype Location/Postcode 
Nine Mile  tick USA 4 6 5   
NOVEL GENOTYPES IDENTIFIED   
QldQ01 human Queensland 3 5 4 Novel CbAu15 Blackstone, 4304 
QldQ11  human Queensland 2 6 2 Novel CbAu18 Chermside, 4032 
QldQ30  human Queensland 3 5 1 Novel CbAu19 Ingham, 4850 
QldQ32 human Queensland 4 5 3 Novel CbAu17 Beachmere, 4510 
EXISTING GENOTYPES DETECTED    
QldQ16 human Queensland 3 5 2 10 CbAu matches* Townsville, 4814 
QldQ02  human Queensland 3 5 - 11 CbAu matches* Lowood, 4311 
QldQ08  human Queensland 3 5 - 11 CbAu matches Marsden, 4132 
QldQ13  human Queensland 3 5 2 10 CbAu matches Cluden, 4811 
QldQ19  human Queensland 3 5 2 10 CbAu matches Proserpine, 4800 
QldQ25  human Queensland 3 5 2 10 CbAu matches Ravenshoe, 4886 
Qld305  canine Queensland 3 5 2 10 CbAu matches NA 
Number of Different Queensland Alleles 
Detected 
3 2 4   
 
 NA = Not available. * Matches 10 or 11 genotypes previously identified28. 
The use of sequence data in alignments was used to determine the number of alleles 
detected at each of the loci (Figure 8.3). The phylogenetic relationship between the 
samples genotyped with the MLVA3 Sanger method for the set of 3 loci (ms27, ms28, 
ms34), using only the alleles as for discrimination show the four novel genotypes (samples 
QldQ01, QldQ11, QldQ30, and QldQ32) to be similar to the other Queensland genotypes 
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detected with the exception of sample QldQ32 which had a MLVA genotype more closely 
related to that of the Dugway rodent strain and the Nine Mile strain.  
  There were two samples QldQ01 and QldQ32 that were identified by both the first set of 
genotyping loci and the second set of loci as novel MLVA genotypes.  These samples 
were unique from any other samples or isolates in the MLVA database and were named 
CbAu15 and CbAu17.  The other two novel genotypes detected in samples QldQ11 and 
QldQ30 were named CbAu18 and CbAu19 using the nomenclature used by Vincent for 
previously described Australian genotypes28. The locations of residence for the patients 
with these unique genotypes are highlighted in red on the map of Queensland (Figure 8.4). 
Interestingly there were three Queensland samples QldQ08, QldQ02 and the novel 
genotype from sample QldQ30, that had similarities to the D19 human isolate previously 
identified from Queensland (Figure 8.3) 
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Figure 8.3: The sequence data alignment for some Queensland samples genotyped using MLVA typing at loci ms28 directly comparing 
the Queensland samples with the reference strain of Nine Mile.  This loci shows the Nine Mile strain contains a 7 bp repeat sequence 
that is detected as 6 units. There was one of the Queensland samples that also has the 7bp 6 unit repeat QldQ11. All the other 
Queensland samples sequenced had only a 5 alleles at this loci. 
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Figure 8.4: The geographical distribution of the Queensland samples genotyped using the three 
loci ms27, ms28 and ms34.  
  = Novel genotypes identified in Queensland   = Other genotypes that have previously been 
described 
 
8.4.2. MLVA typing using 3 loci and sizing by capillary electrophoresis 
Of the 63 original samples, 52 were available for further examination with the 3 loci 
capillary electrophoresis method. MLVA data was generated for 19 of the 52 Queensland 
samples using the loci ms24, ms28 and ms33. The raw data for the Queensland samples 
following capillary electrophoresis identification is shown in Appendix 8.7 at the end of this 
Chapter, with the amplicon size and the number of repeat units ascertained at each of the 
specific loci.  
There were three samples that produced complete profiles by capillary sequencing, and 16 
samples with partial profiles for the three loci screened. These were compared to the 42 
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Australian isolates previously genotyped28, and also compared to over 340 global isolates 
that had been genotyped and uploaded to a public database for reference. 
 (http://mlva.u-psud.fr/mlvav4/genotyping/index.php.) The results of this comparison are 
shown in Table 8.6. 
From the Queensland samples screened, there were 6 different alleles identified for the 
ms24 loci, a single allele from the ms28 locus and 3 different alleles from the ms33 loci. 
The three novel genotypes identified by this analysis from Queensland samples have been 
compared to known Australian genotypes, with 8 of the 14 Australian genotypes sharing 
similar alleles at the loci ms24, ms28, ms33 (Table 8.6). Of these three, two were also 
identified by the MLVA6 Sanger method (QldQ01 and QldQ32), and one was newly 
identified by the capillary method (QldQ28). 
A phylogenetic tree with the strains from Queensland and Australia and along with strains 
commonly referenced such as Nine Mile, Henzerling and Dugway and the inclusion of   
strains that were obtained from similar sources and sample types were compared.  The 
Queensland samples that had more than one loci with an identified allele for discrimination 
were displayed in a dendogram.  There were 5 Queensland samples collected from 
humans that showed profiles that were closely related to the MLVA genotypes previously 
identified from Australian isolates.  These were sample QldQ13 related to CbAU01 or 
CbAU013, sample QldQ21 typed to Australian genotype CbAU05, sample QldQ22 related 
to CbAU02 and CbAU05, and sample QldQ23 related to CbAU08 and CbAU010 (Figure 
8.5).  There were three Queensland samples, QldQ01, QldQ28 and QldQ32 collected from 
human patients that produced novel profiles, and were uniquely different from the 
Australian isolates previously genotyped.  Two of these samples showed closer genetic 
phylogeny with isolates taken from humans and sheep from both The Netherlands and 
France. The geographical location of the genotypes identified by the 3 loci capillary 
electrophoresis method are shown in Figures 8.6 and 8.7. 
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Table 8.6: Queensland samples with positive alleles at loci ms24, ms28, and ms33. 
Sample  Host Origin  ms24 ms28 ms33 Genotype Location 
Nine Mile tick USA 27 6 9   
Henzerling   7 3 4   
CbuG human Nova Scotia 8 4 7   
Dugway rodent USA 5 4 8   
CbuK human USA 9 5 7   
Q177   9 5 7   
Frankrijk070 human Netherlands 12 5 7   
CWZ155 cattle  12 5 9   
Frankrijk033 sheep Netherlands 13 5 8   
Frankrijk080 human Netherlands 13 5 8   
Cb#061 goat  12 5    
Cb#017 sheep France 10 5 9   
Cb#013 goat France 10 5 8   
AuQ01  Australia 16 5 5 CbAU01  
AuQ30  Australia 19   CbAU14  
AuQ05  Australia 14   CbAU05  
AuQ29  Australia   6 CbAU13  
AUQ13  Australia 17 5 5 CbAU06  
AUQ10  Australia 17 5 5 CbAU06  
AUQ05  Australia 14 5 4 CbAU05  
AUQ02  Australia 14 5 5 CbAU02  
AUQ08  Australia 15 5 5 CbAU02  
QldQ01 human Queensland  5 10 Novel  CbAu15 Blackstone, 4304 
QldQ07 human Queensland 15   CNBD Nobby,4360 
QldQ13 human Queensland 16 5  
CbAU01/ 
CbAU013 
Cluden,4811 
QldQ19 human Queensland 12 5  3 matches* Dingo Beach,4800 
QldQ20 human Queensland 16   CNBD New Farm,4005 
QldQ21 human Queensland 14 5 4 CbAU05 Redcliffe,4020 
QldQ22 human Queensland 14 5  
CbAU02/ 
CbAU05 
Black Duck 
Creek,4343 
QldQ23 human Queensland 15 5  
CbAU08/ 
CbAU010 
Pimpama,4209 
QldQ25 human Queensland  5  CNBD Malandra,4886 
QldQ28 human Queensland 10 5 13 Novel  CbAu16 Aurukun,4871 
QldQ32 human Queensland 13 5 4 Novel  CbAu17 Beachmere,4510 
QldQ33 human Queensland  5  CNBD Ipswich,4305 
QldQ40 feline Queensland  5  CNBD Numinbah 4211 
QldQ44 feline Queensland  5  CNBD Daisy Hill,4127 
QldQ76 dust Queensland  5  CNBD Fitzgibbon,4018 
QldQ36 human Queensland  5  CNBD NA 
QldQ37 human Queensland  5  CNBD NA 
QldQ38 human Queensland  5  CNBD NA 
QldQ39 human Queensland  5  CNBD NA 
    Number of Different Queensland Alleles  6 1 3   
      
AUQXX are Australian isolates previously described by other studies28; CNBD = could not be 
determined. *Three possible genotype matches were identified from the international database
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Figure 8.5: Phylogenetic tree displaying the Queensland samples identified using MLVA, highlighting the similarity seen with the 
Australian isolates and the diversity shown by two samples showing a closer relationship to the French strains
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  Novel Genotypes identified in Queensland        Other Genotypes that have previously been described 
 
Figure 8.6: Queensland map showing the geographical 
distribution of the Queensland samples genotyped using 
MLVA. There were three novel MLVA types identified from 
patients residing in Queensland highlighted in the different 
colours  
 
Figure 8.7: South East Queensland map showing the geographical 
distribution of the Queensland samples genotyped using MLVA. 
There was one novel MLVA types identified from a patient in South 
East Queensland highlighted in yellow 
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8.4.3. Combined MLVA Results Using Both the MLVA3 (Sanger) Method and the 3 
Loci Capillary Electrophoresis Method. 
The MLVA data generated from both methods used above were combined and examined. 
In all, there were 25 samples for which at least one locus could be amplified and sized the 
number of repeats determined (Table 8.7).  
Table 8.7: Summary of combined results for MLVA profiles obtained with MLVA6 Sanger and 
the capillary electrophoresis methods. * Matches 3 strains in international MLVA database. 
Sample Name Source MLVA3 (Sanger) Capillary Electrophoresis Genotype 
  ms27 ms28 ms34 ms24 ms28 ms33  
Nine Mile Control 4 6 5 27 6 9  
Samples with at least 3 MLVA loci be either assay 
QldQ01 human 3 5 4 - 5 10 Novel CbAu15 
QldQ11 human 2 6 2 - - - Novel CbAu18 
QldQ30 human 3 5 1 - - - Novel CbAu19 
QldQ32 human 4 5 3 13 5 4 Novel CbAu17 
QldQ28 human - - - 10 5 13 Novel  CbAu16 
QldQ21 human - - - 14 5 4 CbAU05 
QldQ16 human 3 5 2 - - - 10 CbAu matches 
QldQ13 human 3 5 2 16 5 - CbAU01/ CbAU013 
QldQ19 human 3 5 2 12 5 - 3 matches* 
QldQ25 human 3 5 2 - 5 - 10 CbAu matches 
Qld305 canine 3 5 2 - - - 10 CbAu matches 
Samples with at least 2 MLVA loci by either assay 
QldQ02 human 3 5 - - - - 11 CbAu matches 
QldQ08 human 3 5 - - - - 11 CbAu matches 
QldQ22 human - - - 14 5 - CbAU02/ CbAU05 
QldQ23 human - - - 15 5 - CbAU08/ CbAU010 
Samples with only 1 MLVA locus by either assay 
QldQ07 human - - - 15 - -  
QldQ20 human - - - 16 - -  
QldQ33 human - - - - 5 -  
QldQ40 feline - - - - 5 -  
QldQ44 feline - - - - 5 -  
QldQ76 dust - - - - 5 -  
QldQ36 human - - - - 5 -  
QldQ37 human - - - - 5 -  
QldQ38 human - - - - 5 -  
QldQ39 human - - - - 5 -  
No of Different Alleles 3 2 5 7 2 4  
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Following comparison against >300 strains already in the MLVA database and to 14 
unique isolates that have been previously genotyped from Australia, it was shown that this 
study had identified 5 novel genotypes in Queensland. These novel genotypes together 
with previously identified Australian genotypes are shown in Table 8.8. 
 
Table 8.8: Queensland novel genotypes compared to previously identified Australian 
genotypes with similar alleles in the loci ms24, ms28 and ms33 
 Strain Loci 
  ms24 ms28 ms33 ms27 ms28 ms34 
Reference Nine Mile 27 6 9 4 6 9 
Australian 
Genotypes* 
CbAU01 16 5 5 3 5 2 
CbAU13 16 5 6 3 5 2 
CbAU10 15 5 4 3 5 2 
CbAU08 15 5 5 3 5 2 
CbAU02 14 5 5 3 5 2 
CbAU05 14 5 4 3 5 2 
CbAU03 13 5 5 3 5 2 
CbAu07 ND ND ND 3 6 2 
CbAu09 ND ND ND 3 5 3 
CbAU04 13 6 11 3 6 2 
Novel 
Genotypes 
CbAu15 -1 5 10 3 5 4 
CbAu16 10 5 13 ND ND ND 
CbAu17 13 5 4 4 5 3 
CbAu18 ND ND ND 2 6 2 
CbAu19 ND ND ND 3 5 1 
No. of Different Alleles** 5 2 6 3 2 4 
 
Legend: -1= MLVA typing was performed but no result was obtained as opposed to no 
allele being detected; ND= MLVA typing not performed due to insufficient sample. 
* This is only a selection from the 14 unique Australia genotypes, and are the Australian 
genotypes that share common alleles with the Queensland novel genotypes  
** The number of different alleles identified in the Australian and Queensland genotypes
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One of these novel genotypes, identified in specimen QldQ32, had complete profiles for 
both MLVA assays (3 loci each), and was named CbAu17 following the convention for 
naming novel Australian isolates described by Vincent28.  
The profile for this sample was generated from blood collected from a 31 year old female, 
who was a resident of Caboolture (postcode 4510) which is an urban residential town on 
the outskirts of Brisbane. This patient was working in an abattoir at the time, and was not 
vaccinated against Q fever. This new genotype was similar to genotypes Cb#013, Cb#017, 
Cb#020 and Cb#061, which were isolates obtained in France from sheep and goats. 
Three other novel genotypes were identified from samples QldQ01, QldQ11 and QldQ30. 
These gave complete MLVA profiles with the MLVA6 Sanger method but a partial profile 
for QldQ01 only in the capillary electrophoresis method. The novel genotypes assigned to 
the Coxiella in these samples were CbAu15, CbAu18 and CbAu19 respectively.  
Sample Qld01 was a blood sample taken from a 55 year old male residing in Bundamba in 
the semi-rural suburbs of Ipswich, in South East Queensland.  This suburb is within 4 
kilometres of the largest meat processing plant the Southern hemisphere. The genotype 
assigned (CbAu15) showed a MLVA profile that was similar to, but genotypically different 
from other isolates typed from Australian samples, but closely related to genotypes 
identified in France from humans, goats and sheep.   
The two other unique genotypes CbAu18 and CbAu19 were both detected in blood 
samples.  The first patient QldQ11 with genotype CbAu18 was a 52 year old female who 
resides in suburban Brisbane and submitted a blood sample for the laboratory 
investigation of pyrexia of unknown origin, and was subsequently diagnosed with Q fever.  
The second patient QldQ30 with the unique genotype CbAu19 was a 62 year old male with 
a history of frequent exposure to ticks and animal products.  This man was a farmer on a 
property north of Townsville (postcode 4810), a rural area with high numbers of annual Q 
fever notifications.  
The last sample from which a unique Coxiella genotype was detected was Qld28, which 
was assigned the name CbAU16.  On MLVA analysis this sample gave a profile for the 3 
loci (ms24, ms28 and ms33) in the capillary sequencing method, but not in any of the loci 
used for the MLVA6 Sanger method. This genotype was detected in Q fever PCR positive 
DNA from a 48 year old Australian indigenous male who was being investigated for the 
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causative agent of septic shock. This patient resided in the indigenous community of 
Aurukun (postcode 4871), located in Queensland’s north, inland from Cairns.    
There was one complete MLVA profile obtained with the 3 loci using the capillary method 
from sample QldQ21. None of the loci could be characterised from this sample using the 
MLVA6 Sanger method. This MLVA profile was the same as a previously described 
Australian isolate genotyped with a novel profile and was named CbAU05. This unique 
Australian genotype had been previously detected in 4 isolates AuQ05, AuQ09, AuQ39, 
and AuQ42 described by Vincent28. These four isolates were from New South Wales. DNA 
for this Queensland MLVA analysis had been isolated from the prosthetic heart valve of a 
77 year old male patient, who resided in South East Queensland, at Redcliffe (postcode 
4020), part of Metropolitan Brisbane.   
There were five Queensland samples that gave complete MLVA profiles with the MLVA6 
Sanger method and none or partial profiles with the capillary electrophoresis method. 
Three of these gave identical profiles with the MLVA6 Sanger profile, and had 2 or 1 loci 
detected by the capillary method (Table 8.7). One of these, sample QldQ13 was classified 
as either Australian genotype CbAU01 or CbAU013 based on the additional profile 
obtained with the m24 and m28 loci for this sample. The MLVA profiles for the remaining 
samples showed possible matches to 10 or 11 different genotypes previously described for 
Australian isolates.  
Sample Qld19 was taken from the placenta of a 29 year old female living at Dingo Beach, 
in Central Queensland. This lady delivered a stillbirth child near full term. Her previous 
antenatal laboratory investigation had been normal, and on delivery the results of serology 
for Q fever were negative for IgM and IgG antibodies. However, a placental biopsy taken 2 
days later than the bloods for mothers serology was positive for C.burnetti by PCR. This 
was the sample that was subsequently analysed by MVLA. This sample showed a MLVA 
profile for 5 loci, ms27, ms28, ms34, ms24 and ms28, which was similar to 3 other 
genotypes on the international MLVA database.  These were Cb#061 isolated from a goat, 
Frankrijk070 isolated from a human aortic valve in France, and CWZ155 which was 
isolated from cow’s milk in Qatar.   
The remainder of the samples showed only partial profiles for either the MLVA6 Sanger 
method or the capillary electrophoresis method. Of these, two, QldQ22 could be typed to 
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previously identified Australian genotypes CbAU02 or CbAU05 and sample QldQ23 
aligned with either CbAU08 or CbAU010 based on the capillary method, which offered 
greater discrimination power than the MLVA6 Sanger profile.  
There was not enough data generated for the other samples by either method to assign a 
genotype with any confidence. However, all showed 5 unit repeats on the ms28 locus, 
which was the value most commonly determined for Australian isolates reported to date. 
The location of all genotypes identified by both the MLVA6 Sanger and capillary 
electrophoresis methods were mapped, and their locations in Queensland are shown in 
Figure 8.8. 
 
Figure 8.8: Geographic location 
of all Coxiella genotypes identified 
in Queensland as part of this 
study. 
 
Unique genotypes are shown with 
red markers 
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8.5. Discussion:  
Globally, there have been several Q fever outbreaks where the origin of infection has yet 
to be identified.  This was due to a lack of epidemiological markers available using 
traditional bacterial typing methods.  Discriminative typing methods are essential for the 
surveillance and evolutionary tracking of Coxiella, and a number of different methods have 
been assessed in order to determine the one to provide appropriate discrimination 
between strains. This resulted in a detailed analysis of the limited Coxiella sequence data 
available, and the identification of tandem repeat loci which may be used to assess the 
molecular divergence of Coxiella strains.  In this study, MLVA was applied as the method 
of choice, because it provided good discriminatory power, higher than MST, and the 
profiles generated for the Queensland samples were directly comparable to MLVA profiles 
recently generated by another group in Victoria, Australia. 
MLVA is now widely accepted as a typing tool for Coxiella as it provides consistency in 
results and the power to reveal molecular diversity among isolates globally. This has been 
aided by the development of international databases for which strains can easily be 
assessed and compared to other local and global strains.   
In MLVA, up to 17 different genomic target-regions have been used for differentiation of 
Coxiella strains, but even so comparison of results from different laboratories remains 
problematic. However, the results from a recent study in Germany showed that although a 
combination of 8 MLVA markers provided the highest discriminatory power for 
attributing C. burnetii isolates to genotypes, it was sufficient to use three MLVA markers 
alone for rapid classification of C. burnetii into 4 main clusters33. In following this 
recommendation, this study applied MLVA analysis using two panels each of three loci to 
analyse the Coxiella-positive samples identified in this study. 
PCR rather than serology was used extensively to diagnose acute Q fever cases during 
the large and protracted outbreak in The Netherlands (2007–2010). This led to the 
possibility of directly typing Coxiella from clinical material with its obvious advantages of 
timesaving and rapid instigation of appropriate control measures. Clinical material usually 
only contains low amounts of Coxiella-specific DNA which makes it very difficult to get 
reliable typing results. This can be partially overcome by shortening primer lengths to 
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improve sensitivity. This may not be applicable to all known markers, but a reduced panel 
of three markers was used successfully in the Dutch outbreak to analyse clinical 
samples30.  Four different genotypes could be clearly identified using this method. 
The use of MLVA for Coxiella typing however, allows for the genomic analyses of strains 
directly from the clinical or environmental samples by selecting the appropriate panel to 
use for discrimination25. In this study the investigation into the molecular diversity within 
Queensland was also performed using clinical samples, along with environmental samples 
containing Coxiella DNA.  These samples also contained relatively low bacterial load, and 
the major challenge arose from the very low amounts of Coxiella- specific DNA available to 
provide reliable results. This was addressed by using the shorter primer sets for 2 panels 
of 3 markers. The first included the loci ms27, ms28 and ms34, and the second panel 
included the loci ms24, ms28 and ms33 which had been used successfully used in the 
Dutch outbreak to analyse clinical samples30.  
A previous study in Australia has identified 14 unique MLVA genotypes compared to the 
global data available on the international database28.  These genotypes, named CbAu01-
14, were identified in bacterial isolates obtained from clinical samples, predominately from 
New South Wales. These isolates proved to be very different from those detected in the 
Northern hemisphere, including those identified in The Netherlands outbreak. The 
Australian isolates were typed using the extensive 17 loci panel and compared to other 
isolates screened with the same or slightly modified extensive panel.  Similarly to the 
previous observations, it was determined from the Australian data that the same level of 
discrimination could be obtained by using 3 select loci which resulted in identifying  the 
same degree of diversity using the Hunter and Gaston index28.   
However, in limiting the number of loci, accurate sizing of the amplicons is extremely 
important to generate meaningful results. This study examined the use of PCR primers 
from Panel 2 shown in Table 8.3.  In the first method applied, the amplicons generated by 
these were detected by gel electrophoresis and sized by analysis of the sequencing data 
generated by Sanger sequencing. This was partially successful for most samples, but for 
some it was difficult to accurately assign the number of repeats in each amplicon, and 
often the sequence data generated was difficult to interpret with confidence. Since 
accurate size determination was important for the calculation of repeat unit numbers, it 
was decided that gel based analysis did not provide the consistency of results required, 
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and was not suitable for the analysis of samples with low bacterial loads. Capillary 
electrophoresis was a more sensitive method that had previously been applied for MLVA 
amplicon detection and sizing using Panel 2 primers 25. This method was then used to re-
examine the samples in this study for MLVA analysis. The results of the two methods 
applied in this study were examined together and analysed in context. 
In the study described here, there were fifteen MLVA genotypes that could be identified 
from two loci or more from the Queensland samples screened. Five of these were unique 
to Queensland, and the remaining ten were similar to previously described Australian 
genotypes.  These stains seemed to cluster together and may represent a novel genomic 
group. The samples were mainly blood samples collected from both acute and chronic Q 
fever patients.  
One sample QldQ19 showed a MLVA profile consisting of five loci, and matched three 
possible genotypes identified in goats, cattle and humans. This case involved a stillbirth in 
a 31 year old female, as a result of Q fever infection, and would seem one of the very rare 
cases where acute Q fever results in the demise of the human foetus. Although such 
cases are rare they must be considered as a real threat to the well-being of the unborn 
child. The diagnosis of infection in this case was made by PCR on placental material after 
birth, and serology of the mother was negative giving no indication of acute Q fever 
infection. The origin of infection was not identified in this case34,35. 
There was one patient, QldQ22, which had been vaccinated with Q Vax® two months prior 
to being diagnosed with acute Q fever.  The MLVA profile for 2 alleles that was obtained 
from a blood sample showed a genotype of either CbAu02 or CbAu05.  This proved that 
the infection was not the result of vaccination.  This could be a potential source of infection 
in some subjects. In such cases the use of MLVA to characterise the infecting organism 
would definitively determine if such infections were vaccine derived. 
One sample with a unique Queensland genotype was derived from an Australian 
indigenous male living in Northern Queensland at Aurukun. At the 2011 census, this town 
had a population of 1,295, including 1,193 Indigenous people. Q fever in the indigenous 
population is considered to be rare36, however, there have not been many studies to 
assess the true prevalence in this population.   
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This study found that a genotype represented by the same MLVA profile (ms27=3; 
ms28=5; ms34=2) was present in both humans and a dog sample. This highlights that 
single genotypes can be co-shared between humans and their environment, and indicated 
that animals and perhaps other environmental sources played an important part in 
transmission of disease. Unfortunately, many of the animal and other environmental 
samples examined in this study failed to provide a complete MLVA profile, presumably due 
to very low bacterial loads, and hence no firm conclusions could be formulated to identify 
their role the dissemination of disease. A further, more comprehensive investigation will be 
initiated to examine this question, but this is outside the scope of this present study. 
All genotypes identified from Australia, including these recently typed from Queensland, 
showed a very close relationship to each other. However, they showed a substantial 
difference from other genotypes associated with disease from other parts of the world. It 
has been suggested that the strain type that was responsible for the large scale outbreak 
in The Netherlands was a hyper-virulent strain and that the genotypes that differed by only 
a single repeat were micro-variants of the original strain, rather that the spread of infection 
from multiple sources with different strains of Coxiella.  The same may apply to the 
Australian strains and genotypes. The rates of infections identified in Chapter 3 were much 
higher in Queensland than any other part of the world. This may be due to the presence of 
more pathogenic strains circulating in Australia. Australia is an island geographically 
separated by sea from the rest of the world. This is ideal for the evolution of novel Coxiella 
strains which may be more pathogenic, as well as the clonal expansion of these in 
localities within Australia such as regions in Queensland which may be separated by 
1000’s of kilometres. Such conditions would allow for variants to exist and to continue 
evolving over time without impacting on the rest of the country. 
To date, no “classical” virulence factors like toxins or pore-forming proteins have been 
identified among Coxiella. This lack of understanding of the virulence mechanisms makes 
it difficult to develop appropriate tools to recognise organisms with different pathogenic 
profiles. The application of discriminating methods like MLVA, produces a molecular 
“signature” and hold promise for providing a means for differentiating isolates. However, 
the growing technical power of whole genome sequencing has the potential to replace the 
current loci and target based methods, and especially next-generation sequencing 
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technology, has the potential to rapidly expand the Coxiella genome information database, 
and our understanding of the biology and epidemiology of this important pathogen. 
 
8.6. Significant Outcomes from this Chapter 
This was the first study to examine the molecular epidemiology of Coxiella burnetii in 
Queensland, and examined the genetic profile of bacteria detected in humans, animals 
and the environment. The findings were summarised as follows: 
 The MLVA typing method using three loci could be successfully used to genotype 
Coxiella direct from clinical specimens. In this study both the methods using Sanger 
sequencing and capillary electrophoresis provided comparable results. 
 Unique genotypes of Coxiella circulate in Queensland.  These are molecularly 
distinct from Australian isolates and from global isolates currently listed on 
international databases. 
 Potentially the same genotype of Coxiella can co-circulated in humans and in dogs, 
suggesting that these genotypes are widely shared in the environment and confirms 
that animals may be an important part of the chain of infection. 
 The novel Queensland genotypes were widely distributed across Queensland, and 
were not confined to a specific location. 
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8.8. Appendix 8.1: MLVA Raw Data  
Data obtained from the 3130 xl Genetic Analyser (AGRF) determining the size of the 
amplicon and then the unit repeat number within the target loci 
Sample Fragment Size Peak Height No of repeats 
QF007-ms24 186.103 16465 15 
QF013-ms24 193.0346 13026 16 
QF019-ms24 164.9403 32539 12 
QF020-ms24 193.1607 32711 16 
QF021-ms24 178.4346 31699 14 
QF022-ms24 178.7287 32568 14 
QF023-ms24 186.3721 32564 15 
QF028-ms24 151.7328 32707 10 
QF032-ms24 172.8587 32737 13 
NM-ms24 269.7463 32715 27 
NM-ms24 269.4071 32494 27 
Arandale-ms24 192.183 31349 16 
AuQ05-ms24 178.4532 30471 14 
AuQ30-ms24 212.8736 31246 19 
D19-ms28 269.5702 13189 5 
Qld01-ms28 269.2811 32493 5 
Qld13-ms28 269.8906 32651 5 
Qld19-ms28 270.0682 32709 5 
Qld21-ms28 269.5273 32070 5 
Qld22-ms28 269.8036 32531 5 
Qld23-ms28 269.6164 32682 5 
Qld25-ms28 269.8108 32668 5 
Qld28-ms28 269.6634 32564 5 
Qld32-ms28 269.8266 32587 5 
Qld33-ms28 269.95 32751 5 
Qldu40-ms28 270.1376 19083 5 
Qld44-ms28 270.0463 11377 5 
Qld76-ms28 269.5842 33586 5 
Qld36-Ms28 270.0029 32720 5 
Qld38-ms28 269.9225 32708 5 
Qld39-ms28 270.2321 32726 5 
Qld40-ms28 270.0494 32728 5 
NM-ms28 274.9772 32146 6 
NM-ms28 275.1871 32344 6 
Arandale-ms28 269.62 32012 5 
Qld01-ms33 270.1003 32353 10 
Qld21-ms33 224.1398 32617 4 
Qld28-ms33 287.901 32694 13 
Qld32-ms33 224.4633 32634 4 
NM-ms33 260.4049 32704 9 
Arandale-ms33 232.0021 32551 5 
Pearson-ms33 239.3747 32566 6 
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Chapter 9 
 
Development of a Cell Mediated Immunity 
Assay to Determine Previous Exposure to 
Coxiella burnetii 
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9.1. Introduction 
9.1.1. Host Immune Response  
Coxiella burnetii is an intracellular bacterium and typically replicates inside the host cells. 
The principle host cells involved are the macrophage, monocytes, microglia and dendritic 
cells1.  Following infection, the bacteria survive and multiply within the macrophage 
phagosome created within the cell.  The Coxiella gene products are able to modify 
interfaces of the phagolysosome and utilise metabolic products of the autophagic pathway 
for the bacteria’s replication2.  The initial innate and adaptive immune response is inhibited 
during the long incubation period within the macrophage, however,as infection progresses, 
both these are eventually initiated.  
It has been well established that adaptive immunity is essential to cure Q fever infection3. 
Patients that are receiving immunosuppressive treatment therefore, are at greater risk of 
developing chronic Q fever and are unable to mount an effective immune response to the 
bacteria1. 
The host adaptive immune response can be divided into antibody-mediated immunity 
(AMI) or cell-mediated immunity (CMI) (Figure 9.1).  Studies of the host immune system 
show that both AMI and CMI are involved in host defences against Coxiella. The CMI is 
believed to be the major immune response, effective against invasion of the intracellular 
bacteria, and is the major mechanism for control of infection in patients with acute Q fever.  
During infection, the phagocytic cells are able to present Coxiella antigen-la complexes on 
their cell surface, resulting in a cascade of T cell activation and the production of cytokines 
including interleukin 1 (IL-1), IL-2, Tumour Necrosis Factor-α (TNF- α ) and interferon-
gamma (INF-Ɣ)4.  
The role of T cells in the control of C.burnetii infection has been well documented in mouse 
models. One study showed that athymic mice deficient in T cells, when challenged with 
C.burnetii, showed no effect on bacterial invasion and bacterial growth, highlighting the 
important role of T cells in the infection process5. Another study showed SCID mice that 
are devoid of T and B cells succumb to infection, demonstrating the major role of the 
adaptive immune response for the control of C.burnetii infection6. INF-Ɣ plays a role in 
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restoring the ability of the host cell to disperse viable Coxiella7, and the production of INF-
Ɣ is essential for the early control of infection8. 
 
 
 
Figure 9.1: The two main 
classes of adaptive immune 
response 
Lymphocytes respond to a 
C.burnetii infection. In the 
AMI response, B cells 
secrete antibodies that 
neutralize the bacteria. In the 
CMI response, T cells kill the 
Coxiella-infected cells. 
(Figure adapted from Molecular 
Biology of the Cell. 4th edition Alberts 
B et al. New York: Garland Science; 
2002.) 
 
 
 
 
Although the role of T cells and their response to vaccination has not been well studied9, it 
has been demonstrated that individuals vaccinated with formalin-inactivated C.burnetii 
exhibit specific lymphoproliferation  and IFN- Ɣ production in response to the bacterial 
antigens10. As a result of previous vaccination or natural infection, the cellular immune 
response is persistently sensitised to Coxiella and this is the bases for the use of the 
intradermal skin test as a tool for pre-vaccination screening.  
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9.1.2. Vaccine 
The vaccine Q Vax® (bioCSL, Melbourne, Australia) has been licenced for use in “at risk” 
populations in Australia since 1989. Q Vax® is a whole cell, phase I, Henzerling strain, 
formalin inactivated preparation, containing a Thiomersal preservative11.  It is administered 
as a 0.5mL dose containing 25µg of Coxiella burnetii. The vaccine has a 98% efficacy 
lasting at least 5 years12, and was implemented by the NQFMP commencing in 2000, 
targeting workers in high risk occupations. In the second phase of the program, 
vaccination was extended to include adults in families of rural workers. However, uptake of 
the vaccine in other countries around the world has been limited due to the considerable 
adverse reactions that have been associated with vaccine administration. 
9.1.3. Adverse Vaccine Reactions 
There were a number of common adverse reactions reported during clinical trials of the 
vaccine, including local tenderness in about 50% of vaccinees, followed by a third of 
subjects reporting local erythema.  Local oedema was also reported along with transient 
headaches and “flu-like symptoms. Other presentations included dizziness, aching joints 
and swollen glands13. Some of these reactions, including tenderness, erythema and 
oedemas at the vaccine administration site, have also been observed with other bacterial 
vaccines and are not uncommon.  The development of short-lived flu-like illness after 
vaccination is the result of the cellular immune response being stimulated14.  However, the 
adverse reactions that may occur in a vaccine candidate previously exposed to Coxiella, 
can be a severe local reaction such as site abscess formation or granuloma, extending to 
severe generalised adverse systemic reactions including lymphadenopathy and chronic 
fatigue syndrome (QFS)15. 
There have been several documented cases of severe adverse reactions after Q fever 
vaccination.  One case involved the development of an immune abscess.  Within hours of 
vaccination the site was inflamed, which resulted in the lesion becoming indurated and 
finally breaking down to form a sinus which was only cured with surgical intervention.  The 
subject then developed QFS.  Follow up serology from the abscess exudate showed high 
Coxiella antibody titres. This case highlights the importance of using effective pre-
screening techniques to safeguard against adverse reactions and more serious clinical 
complications.  
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If vaccine candidates with pre-existing immunity are vaccinated they exhibit ‘sensitisation’ 
to Q fever antigens through the release of cytokines by memory T cells. This is the result 
in a heightened cell mediated immune response, which can be maintained by low-level 
persistence of the organism or its antigens after infection. Vaccinating these previously 
exposed persons may lead to severe local inflammatory reactions and general systemic 
reactions as described above.  Such reactions are not inevitable and are unpredictable, 
and represent re-stimulation of the sensitised CMI response leading to hypersensitivity 
reactions. 
9.1.4. Pre-vaccination Screening 
Pre-vaccination screening helps to identify subjects that have been previously exposed to 
Coxiella and hence sensitised to bacterial antigens. These subjects are at risk of 
experiencing a serious hypersensitivity reaction if they are re-exposed through 
vaccination16.   
Currently there are three steps used in pre-vaccination screening to identify those 
previously exposed. 
1. History:  A detailed medical history to identify previous infections with Q fever 
and to ensure the subject has not previously been vaccinated for Q fever. 
Those identified as having a positive history of Q fever exposure are immediately 
excluded and require not further investigation. 
2. Skin Test: An intra-dermal injection of diluted Q Vax® is administered, and in 
addition 
3. Serological Profile: A blood sample is collected and screened for phase II IgG 
antibodies to Coxiella by a standard laboratory method such as IFA. 
These two testing regimes (steps 2 and 3 above) measure two different immune pathways.  
The skin test is indicative of the CMI response, and is the primary test15.  The serological 
screening detects antibodies previously produced as a result of past exposure and 
provides additional confirmation of the subject’s exposure status, if ambiguous or 
inconclusive results are obtained with the skin test.  
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There are a number of factors to consider while using the skin test as a means of 
identifying previous exposure.  Only experienced personnel can perform and interpret skin 
tests successfully, and there are a number of errors that can complicate the interpretation 
of skin test results. For instance, important factors are: 
 The depth of injection; subcutaneously is too deep, the injection should be 
intradermal.   
 The location on the inner forearm for administering the intradermal injection.   
 The length of time between injection and interpreting the results. Early reading of 
the skin test may result in the erythema being mistaken for a positive reaction.   
Serology screening also has some limitations when used as an indicator for previous 
exposure. The serological markers may decline over time and may in fact be negative in a 
previously exposed subject17.   
9.1.5. Cell Mediated Immune Response Screening 
As already discussed, activation of T cells leads to the direct production of cytokines 
including the secretion of INF-Ɣ.  The direct measurement of INF-Ɣ resulting from the T 
cell response to stimulating antigens, may be achieved in the Enzyme-Linked 
ImmunoSpot (ELISPOT) assay, by measuring the amount of secreted cytokine produced, 
which in turn can be quantified or linked to individual cells.  This technique has already 
been applied in clinical diagnostics, and is currently used for the detection of Tuberculosis.  
It has also been used extensively in the monitoring of transplant recipients for graft 
tolerance or rejection. 
The ELISPOT assay allows visualization of individual cells that have been stimulated and 
responded by producing INF-Ɣ. Each coloured spot that develops on the assay membrane 
is the direct result of the reactive response induced by the Coxiella stimulus in a single 
reactive T cell. Thus, the ELISPOT assay provides both qualitative and quantitative 
information regarding the CMI response in a subject previously exposed to Coxiella 
burnetii. 
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9.2. Specific Aims Addressed in this Chapter 
Recent studies have investigated INF-Ɣ based assays, including a whole-blood INF-Ɣ 
production assay and a Coxiella ELISPOT assay, as potential diagnostic tools for Q fever 
diagnosis, including chronic Q fever. This was the first ever attempt to use CMI in Q fever 
pre-vaccination screening.   
The study in this chapter sought to establish Proof of Principle, and to develop and 
evaluate the use of a Coxiella ELISPOT assay for use as a pre-vaccination screening tool. 
The aims addressed were: 
 To develop an in house ELISPOT method to measure INF-Ɣ production from T 
cells stimulated with Coxiella 
 To test the ELISPOT method on blood samples collected from subjects of known 
immune status to C.burnetii 
 Evaluate the suitability of this ELISPOT assay as an alternative to the intradermal 
skin test used routinely for assessing Coxiella immune status in vaccine candidates  
 
9.3. Methods 
9.3.1. Samples  
Whole blood samples collected into 5ml Lithium Heparin tubes (Becton Dickinson, North 
Ryde, Australia) were taken from three previously vaccinated subjects. These comprised: 
(i) Subject S1: a recently vaccinated subject (<1 year post vaccination).  
(ii) Subject S2: approximately 5 years post vaccination.  
(iii) Subject S3: a non-vaccinated, non-exposed subject, to act as a negative 
control.  
(iv) Subject S4: this subject was approximately 10 years post vaccination.  
The blood samples from these four subjects were processed as described below to isolate 
the peripheral blood mononuclear cells (PBMC’s) (section 9.2.3). 
At the same time, serum samples were collected for the measurement of phase I and II 
Coxiella IgG antibodies.   
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9.3.2. General Principle of the ELISPOT Assay  
The ELISPOT assay is a highly sensitive immunoassay that measures the frequency of 
cytokine-secreting cells at the single-cell level. Cells are cultured on a surface coated with 
a specific capture antibody in the presence of stimulus antigen. Cytokines such as INF-Ɣ 
that are secreted by the cells will be captured by the specific antibodies on the surface. 
After an appropriate incubation time, cells are removed and the secreted molecule is 
detected using a detection antibody in a similar procedure to that employed by the ELISA. 
The detection antibody is biotinylated and is followed by a streptavidin-enzyme conjugate 
step. By using a substrate with a precipitating rather than a soluble product, the end result 
is visible as spots on the surface. Each spot corresponds to an individual cytokine-
secreting cell (Figure 9.2). 
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Figure 9.2: Basic principles of the ELISPOT assay applied for the detection of IFN- Ɣ in 
the study below. (Figure was adapted from https://www.mabtech.com/knowledge-
center/assay-principles/elispot-assay-principle/elispot-step-step) 
9.3.3. T cell Isolation 
The PBMC’s containing T cells were isolated from heparinised blood using a Ficoll 
gradient. A patient’s blood was diluted 1:2 with RPMI 1640 – L Glutamine (Gibco by Life 
Technology, Victoria, Australia) in a 50ml conical tube. Ficoll 10ml was layered into a new 
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50ml conical tube and then 10ml of the patient’s diluted blood was gently overlayed using 
a 5ml pipette to maintain an interface between the Ficoll and the diluted blood.  This was 
spun in a Beckman Coulter Allegra X-22 Series (Victoria, Australia) bench centrifuge at 
400g, at room temperature for 30 minutes with both the acceleration and the deceleration 
reduced to 5 minutes with no brake. This produced an interface by which the buffy coat 
containing the PBMC’s could be visualised as distinct from the plasma and the Ficoll 
(Figure 9.3) 
 
Figure 9.3:  The PBMC interface layer between the plasma and Ficoll after centrifugation 
The buffy coat containing the PBMC’s was removed and added to a new sterile 50ml 
conical tube and topped up to 50ml with RPMI L-Glutamine at room temp to wash the 
cells.  The cells were spun at 300g/1200rpm for 12 minutes at room temperature to pellet 
cells and remove contaminates. The wash step was repeated and the final wash solution 
media was removed, and cell pellets were resuspended in 10 ml of complete media – 
(RPMI L-Glutamine + 10% foetal calf serum + 1% antibiotics).  White blood cells were 
counted at a dilution of 1:2 with Trypan Blue (2%), using a haemocytometer.  The cells 
were then adjusted to a concentration of 106 cells per well for pre-stimulation with Coxiella 
antigens. 
9.3.4. The In House ELISPOT Assay 
9.3.4.1 Pre-stimulation of T cells with Coxiella Antigens 
Two antigen preparations and the PBMC’s from 3 patients, S1, S2, S3, were trialled in pre-
stimulating the T cells for the production of IFNƔ.  PBMC’s were inoculated into a 24 well 
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tissue culture plate at a concentration of 106 cells per well.  Two stimulus antigens were 
evaluated. These were (i) 4 µg/ml and 20 µg/ml final concentration per well of the Coxiella 
whole cell phase I and II combined CFT antigens (Virion/Serion (Wurzburg, Germany), and 
(ii) the Q Vax® CSL vaccine (Commonwealth Serum Laboratories, Victoria, Australia), at a 
50 µg/ml final concentration.   
For the initial stimulation of the T cells, the final total volume was made up to 2 ml with 
RPMI, containing 10% foetal calf serum and antibiotics.  The T cell suspensions and 
stimulus antigens were incubated at 37⁰C for 20 hours.  The pre-stimulated T cells were 
washed as previously described and pelleted for seeding into the ELISPOT test plate. The 
CFT antigens and the Q Vax® were added to the test plate as per Figure 9.4. 
 
Figure 9.4: Pre-stimulation plate configuration showing antigens and subjects tested. 
(Final concentrations used:   A. CFT phase I and phase II combined = 20 µg/ml;                                               
B. CFT phase I and phase II combined = 4 µg/ml and Q Vax® phase I =1µg/ml)   
9.3.4.2. Re-stimulation of T cells with Coxiella Antigens  
The commercially available MabTechplus  ELISPOT plates from Resolving Images (Victoria, 
Australia) were used in the assay.  A re-stimulation of the T cells with Coxiella antigens 
was performed in the ELISPOT plate following the pre-stimulation or priming of the T cells 
in cell culture as described above. 
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The plate was prepared as per the manufacturer’s recommendations, which included the 
preparation of the plate by washing with PBS four times before blocking the wells with the 
same media used as in the pre-stimulation of the T cells. Blocking was for at least 30 
minutes at room temperature. The culture media were removed and the addition of the 
pre-stimulated, primed T cells and stimulus antigen were added to the wells.  
The cells were loaded at a concentration of 105 cells per well in RPMI with 10% foetal calf 
serum following by the addition of the Coxiella antigen for re-stimulation. The combined 
CFT phase I and II antigens only (25 µL of each phase), were used as the re-stimulating 
antigen and added in duplicate wells.  The combined CFT phase I and II antigens were 
loaded to give a final concentration of 20µg/ml of antigen in each well with a final volume 
of 100µL in the well. 
PHA was used as a non-specific T cell stimulator to act as a positive control, and monitor 
the T cells ability to produce IFN-Ɣ. It was used at a concentration of 10µg/ml per well.  
The negative well had the addition of T cells with no stimuli, to ascertain a baseline for 
INF-Ɣ production and to account for any non-specific stimulation (Figure 9.5). The 
ELISPOT plate was wrapped in aluminium foil to prevent evaporation and incubated at 
37⁰C with humidity and 5% CO2 for 14 hours. 
 
Figure 9.5: Configuration of cells tested with stimulus antigens and control wells.  
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The “no antigen” well was used as a non-stimulus control, and PHA as a positive control to 
monitor cytokine release after non-specific stimulation. A and B were duplicate wells with 
20µg/ml of combined CFT phase I and II antigens added. 
9.3.4.3. Detection of IFN-Ɣ-producing cells 
The detection of cells producing IFN-Ɣ was achieved by the removal of the media from the 
plate and washing the plate 5 times with PBS.  The biotin labelled detection antibody 
provided in the kit was diluted in PBS with 5% foetal calf serum at a concentration of 
1µg/ml. 100 uL was added to each well and incubated for 1 hour at room temperature.  
The plate was washed as before.  The substrate solution provided in the kit was loaded to 
each well and left until the development of spots occurred.  The colour production was 
stopped by washing the wells extensively in tap water.  The wells were left to dry 
completely, away from direct light and the collation of spots was achieved using the 
ELISPOT plate reader (AID EliSpot Reader, ResolvingIMAGES, Victoria, Australia) 
9.4. Results 
9.4.1. Results of the Optimisation of Coxiella Stimulation  
The combinations of two different antigen stimuli were trialled to ascertain which antigen 
stimulus produced maximum activation of the T cells to produce measurable INF-Ɣ.   
Subject S1, who had been most recently immunised against Q fever showed a marked 
response to both the CFT I+II antigens that were used in pre-stimulation and re-stimulation 
(Figure 9.6; Table 9.1). There was a 264-fold increase in the number of INF-Ɣ-producing T 
cells that responded to the antigens in the plate.  The subject (S2) that was vaccinated 5 
years prior to testing showed little INF-Ɣ production when challenged with Coxiella 
antigens. The non-vaccinated subject (S4) showed some reactivity in the T cells to the Q 
Vax® stimuli.  
It was determined that the stimuli which initiated the greatest production of INF-Ɣ was the 
CFT antigen phase I and phase II combination, at a concentration of 20µg/ml. This was 
used in the ELISPOT testing for the four subjects examined in the study below.   
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Figure 9.6: Illustration of 
ELISPOT plate readings 
from Coxiella pre-stimulus 
trial. 
 
 
  
Table 9.1:  Details of ELISPOT optimisation of pre-stimulating 
antigens with PBMC’s from three subjects. The number of T 
cell producing INF-Ɣ is shown. (S1 = Recent vaccination <1 
year; S2 = Vaccinated approximately 5 years; S3 = Not 
previously vaccinated). 
Position Subject Stimuli 
Cells Producing 
INF-Ɣ 
A1 S1 PHA 505 
B1 S1 CFT I+II (20µg/ml) 264 
C1 S1 CFT I+II (4µg/ml) 73 
D1 S1 Q Vax (1µg/ml) 8 
E1 S1 No Stimuli 0 
F1 S2 PHA 355 
G1 S2 CFT I+II (20µg/ml) 4 
H1 S2 CFT I+II (4µg/ml) 0 
A2 S2 Q Vax (1µg/ml) 5 
B2 S2 No Stimuli 4 
C2 S3 PHA 414 
D2 S3 CFT I+II (20µg/ml) 0 
E2 - Blank - 
F2 S3 CFT I+II (4µg/ml) 3 
G2 S3 Q Vax (1µg/ml) 25 
H2 S3 No Stimuli 4 
 
 288 
 
 
 
 
 
9.4.2. Results of ELISPOT Analysis for Four Subjects Tested  
PBMC’s isolated from the four test subjects S1, S2, S3 and S4 were analysed in the 
ELISPOT assay described above. Cells were tested in duplicate wells, using 20 µg/ml of 
stimulus antigen. The number of cells producing INF-Ɣ for each subject and the controls 
are shown in Table 9.2. 
The n-fold scores were calculated for each subject tested to provide an indicator of the 
level of INF-Ɣ production in activated T cells expressed as the number of coloured spots, 
using the number of spots produced with non-stimulated T cells as the denominator.  
n-fold scores were calculated as follows: 
 
        T cell count with stimuli         =   variation in INF- Ɣ production   (n-fold)  
                 T cell count NO stimuli 
 
The greatest number of T cells to produce INF-Ɣ were from subject S1 who had been most 
recently vaccinated (<1 year post vaccination), with an average of 275 INF-Ɣ producing 
cells and an n-fold score of 32. Subject S2 who had been vaccinated approximately 5 
years prior to testing had an average n-fold score of 13, and subject S3 who had no prior 
exposure to Coxiella by either natural infection or vaccination showed a low reaction to the 
stimulus antigens with an average of 55 cells producing INF-Ɣ, and an n-fold score of 3.  
However, the subject (S4) who had been vaccinated more than 10 years prior, also 
showed a low number of T cells producing INF-Ɣ; average = 61, which was similar to the 
non-vaccinated subject. When the n-fold score was calculated for subject S4, this was 
determined to be 15 which was in fact similar to subject S3 who had been vaccinated for 
approximately 5 years. These subjects were able to produce higher differential levels of 
INF-Ɣ than the subject that had never been challenged with Coxiella. 
The Coxiella serology was also performed on these subjects by IFA.  Serology for IgG 
phase I and II showed the non-vaccinated subject (S3) had no evidence of past exposure 
to Coxiella.  The recently vaccinated subject, S1 had detectable Coxiella IgG antibodies to 
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phase II, and subject S2, vaccinated 5 years ago, showed a weak antibody response on 
the IFA to Coxiella phase II antigens.  Subject S4, vaccinated more than 10 years ago, had 
no detectable IgG antibodies on the IFA to either phase I or phase II antigens. 
 
Table 9.2:  Subjects 1-4 and the numbers of T cell producing INF- Ɣ, along with the 
comparison of stimulated T cells compared to non-stimulated T cells expressed as an n-
fold number.   
                 
 
Stimuli 
Cells Producing 
INF-Ɣ 
Variation from 
No Stimuli (n-fold) 
Average 
n-fold score 
S1 
PHA 336 37  
CFT I+II (20µg/ml) 230 26 32 
CFT I+II (20µg/ml) 319 35  
No Stimuli 9 1  
S2 
PHA 297 49  
CFT I+II (20µg/ml) 75 13 14 
CFT I+II (20µg/ml) 89 15  
No Stimuli 6 1  
S3 
PHA TNTC ~  
CFT I+II (20µg/ml) 50 3 3 
CFT I+II (20µg/ml) 61 3  
No Stimuli 18 1  
S4 
PHA 118 30  
CFT I+II (20µg/ml) 61 15 15 
CFT I+II (20µg/ml) 61 15  
No Stimuli 4 1  
(S1 = Recent vaccination <1 year; S2 = Vaccinated approximately 5 years; S3 = Not 
previously vaccinated; S4 = Vaccinated for >10 years). TNTC – too numerous to count. 
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9.5. Discussion 
Q fever vaccination with Q Vax® is only available to “at risk” populations in Australia.  This 
vaccine was supported by the Australian government with the implementation of the 
NQFMP, which saw large numbers of workers in high risk occupations offered access to 
the vaccine.  However, results previously described in Chapters, 3,4 and 5 of this thesis 
have highlighted that other populations within Australia, including children, were also at 
risk of contracting the disease, and hence need to be considered in future vaccination 
strategies. 
Candidates with previous exposure to Coxiella are at increased risk of hypersensitivity 
reactions if vaccinated with Q Vax® 18.  Q fever skin testing is traditionally used to measure 
in vivo cell-mediated immunity to C. burnetii in pre-vaccination screening as the primary 
immune response indicator, to exclude individuals with pre-existing immunity. The skin test 
has major procedural drawbacks, and can be troublesome for the tested subjects, 
particularly children. Even more important is the response induced by the in vivo skin 
testing. The injection of C. burnetii antigens, may cause higher antibody titres and higher 
in vitro levels of IFN- Ɣ to C. burnetii in participating subjects, and therefore affect 
subsequent Q fever diagnostics 19.   
The measurement of in vitro IFN- Ɣ and IL-2 to monitor the treatment of chronic Q fever 
has previously been described20. In this setting, the discontinuation of antimicrobial 
therapy strongly depends on the result of follow up serology. However, in practice the slow 
serological decline results in longer treatment, and the need for additional biomarkers to 
monitor treatment of chronic Q fever is evident. In this respect the measurement of CMI, 
specifically the production of IFN- Ɣ from stimulated T cells, against C.burnetii plays a 
pivotal role.  
Following the recent outbreak in The Netherlands the demand to monitor patients for the 
development of chronic Q fever is ever increasing, as this stage of the disease carries a 
high mortality rate21.  With over 4000 cases of acute Q fever having been reported in The 
Netherlands, a diagnostic tool to predict chronic Q fever has become imperative.  The use 
of CMI to measure the cellular response can lead to a more effective diagnosis and 
treatment response. 
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The relevance of measuring IFN- Ɣ production profiles, as diagnostic correlates of memory 
T cell responses, has been studied outside the field of Q fever, and is reflective of the 
immune response induced by intracellular pathogens such as Coxiella.  Therefore, the 
CMI response that occurs as a result of natural infection with Coxiella was considered to 
be a more suitable mechanism for measuring previous exposure to C.burnetii, than the 
traditional skin test.   
The findings in this study showed that an ELISPOT assay developed to measure IFN- Ɣ 
production in PBMC’s was, potentially, a more suitable method to determine pre-existing 
immunity to C.burnetii. The results obtained with a limited number of vaccine exposed 
subjects, showed a potential for this assay to be implemented as a pre-vaccination 
screening tool to replace the skin test. The use of the ELISPOT assay for the 
determination of previous exposure has many advantages over the current skin testing 
regime. The ELISPOT assay can be repeated in order to ascertain a true exposure profile.  
This is a limitation of the skin test, which, on first use will initiate a low level immune 
response with activation of T cells. Subsequent use of the skin test in these subjects may 
lead to an interpretation of previous exposure, and hence preclude them from effective 
vaccination against Coxiella. There is also the high risk of the vaccine candidate suffering 
an adverse reaction with the administration of a follow up skin test. This exposure may 
also give rise to an antibody response which is producing short lived heightened results19.  
The value of being able to simulate a CMI response with Coxiella antigens using the 
ELISPOT assay, allows for perpetual monitoring of an exposure response and hence aid 
the decision for vaccination.    
 Although the results of this study were promising, clearly it had some limitations. First of 
all, only a small number of subjects were studied, and a larger cohort of samples needs to 
be examined to determine the practical utility of this method for pre-vaccination screening. 
Such a study has commenced in our laboratory, under my supervision, seeking to 
determine the immune status of 200 veterinary students and controls before the 
administration of the Q Vax® vaccine. The results of the ELISPOT will be correlated with 
serological markers and the results of skin tests. However, this larger study is ongoing, 
and has not yet generated enough data to be included in the study described in this thesis. 
Secondly, this study was performed on the vaccine induced immune response to one 
strain of Coxiella, the Henzerling strain, administered in the Q Vax® vaccine. The CMI 
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immune response that is produced by naturally infected or exposed subjects may 
potentially be different to that measured in the CMI ELISPOT assay from a vaccine 
induced immune response. The response elicited may also vary depending on the strain 
type of the infecting bacteria.  These factors will also need to be further investigated to 
ensure the ELISPOT method described here will accurately reflect exposure status and 
help protect vaccine candidates from wrongly receiving the vaccine and hence potentially 
enduring adverse reactions.   
Thirdly, although the level of IFN- Ɣ produced was quantifiable in terms of number of 
cytokine-producing cells, this will vary depending on the individual’s effective T cell 
response.  However, by using each subject’s own T cells as both a positive control to 
assess an individual’s T cells ability to produce IFN- Ɣ with the PHA stimulus, and as a 
negative control which aids in the assessment of non-specific stimulation and a baseline to 
which a direct comparison can be made, the level of IFN- Ɣ produced as a direct result of 
the Coxiella stimulus can be determined.  
Clearly, there is a need to determine the cut-off for the assay to give an indication of the 
level of expression that is indicative of previous exposure to Coxiella.  Also, it was shown 
here that subjects tested, including the naïve subject S3, produced some cytokine release 
from cells that were not stimulated with antigen, thus potentially confounding the 
interpretation of results. The background cytokine expression observed was presumably 
due to non-specific stimulation of the T-cells, or perhaps a low level of previous exposure 
to Coxiella antigens which were not detected by the skin test in subject S3. 
For that reason the n-fold score was applied in this study and potentially proved to be a 
reliable predictor of immune status against Coxiella for the subjects examined. From the 
limited number of subjects investigated, there was a clear increase in n-fold score 
associated with subjects previously vaccinated against Q fever when compared to the non-
vaccinated subject. In fact this indicator proved to be more indicative than relying on the 
presence of IgG antibodies as an indicator of previous exposure. Subjects S3 who was 
naïve, and S4 who had been vaccinated approximately 10 years previous, both failed to 
show a presence of Coxiella IgG. Yet S4 showed an n-fold score that was indicative of 
previous exposure and S3 did not.    
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To establish an appropriate cut-off is extremely important for determining previous 
exposure and hence aid in the administration of the vaccine. As shown by the results 
above, some subjects that are considered naïve to previous exposure may have a low 
level of IFN- Ɣ production which could be the result of previous low level exposure to the 
bacteria from the environment or perhaps the direct response of the macrophages and T 
cells to the pre-stimulation of cells with Coxiella antigens in a previous skin test. An 
appropriately validated ELISPOT method would prove invaluable to identify such 
individuals and would aid in the selection of vaccine candidates. 
The ELISPOT method described will aid greatly in identifying those individuals with a CMI 
response to Coxiella, and hence assess their suitability as potential Q Vax® candidates. In 
addition, the accurate assessment of previous exposure will reduce the number of adverse 
reactions that may result from vaccinating previously exposed individuals.  It also offers a 
safer method over traditional skin testing, along with reducing the inconsistencies 
associated with interpreting skin test results. Finally, it would be a major improvement for 
the pre-vaccination screening of children who are more prone to adverse reactions 
following skin testing, and suffer with more serious complications. However, the prevention 
of adverse reactions and truly addressing the lack of confidence surrounding the current 
pre-vaccination screening, would require the development of a safer vaccine. 
 
9.6. Significant Outcomes from this Chapter 
 Assay parameters were determined to assess pre-existing exposure to Coxiella 
antigens using an in house ELISPOT assay. 
 The ELISPOT assay successfully identified three subjects who had differing 
intervals of previous exposure, and proved to be more accurate than the 
assessment of IgG antibody status. 
 The calculation of an n-fold index proved to be a valuable tool for calculating the 
differential of cytokine release between activated memory T cells and non-specific 
reactions. The use of this factor allowed the accurate categorisation of previous 
exposure versus naïve status. To our knowledge this study is the first to use this 
calculation for the assessment of Coxiella immune status.   
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10.1. Epidemiology of Coxiella burnetii in Queensland 
This study was commenced at a time when there were very little data regarding Q fever in 
Queensland. The primary aim was to gather sufficient information about the true extend of 
the disease in the Queensland community, and from this formulate a recommendation for 
an appropriate vaccination strategy that would benefit the community as a whole. 
Specifically, the work performed in this thesis aimed to extend the state of knowledge 
regarding Q fever in Queensland, and was the first comprehensive study which examined 
the epidemiology of Coxiella burnetii and sought to determine potential sources of infection 
and factors which might influence the correct diagnosis of the disease, and their impact on 
determining accurate exposure rates.  
Q fever has been reported globally, and this study also confirmed that Q fever disease was 
a significant health threat in Australia and in particular Queensland. Yet despite this fact, 
Australia has the only licenced vaccine available for humans, but this is currently restricted 
to those identified as being at high risk of Q fever, through their occupational practices.  
The results of this investigation determined that not only is Q fever an important clinical 
disease occurring in rural Queensland but that the disease was being reported at a higher 
than expected rate in cities and urban communities. Queensland reported the highest 
average yearly notification rates compared to any other location in the world1. The results 
here showed that high rates of notification occurred in both subjects identified as being at 
high risk of contracting Q fever, and those for which no known risk factors were identified. 
Alarming were the numbers of increasing notifications that occurred in children from 
Queensland. These high notification rates might be the result of increased clinical vigilance 
and/or more widespread laboratory screening for the disease, or simply the presence of 
higher and wider sources of exposure, such as higher bacterial loads in the Australian 
environment. 
Previous notification data for Queensland have been restricted to only very small “snap 
shot” studies centred on the introduction of the vaccine and the implementation of the 
NQFMP. The comprehensive data obtained in this study, assessed a number of factors 
that could explain the high numbers of notifications that were observed in the Queensland 
population.   
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High notifications recently occurred during an outbreak of Q fever in The Netherlands. This 
country recently endured a large scale epidemic for which the close proximity to infected 
animals and farms played a key role for the dissemination of the bacteria, resulting in the 
reporting of thousands of animal and human cases. In Queensland, vast distances span 
localities and communities, compared to regions in Europe and in particular The 
Netherlands. Queensland boasts huge geographical separation between its communities, 
towns and cities.  This large physical separation could be considered a control measure 
which limits the dissemination and distribution of Coxiella, leading to less disease and 
fewer notifications.  Nevertheless, in spite of these large geographical distances 
separating communities, Queensland continues to report large numbers of cases from all 
over the state consistently with time, in spite of employing large scale, government funded 
vaccine campaigns targeting at risk populations. 
 The study in this thesis emphasised the importance that disease awareness played in the 
recognition and diagnosis of Q fever.  Even with the large government campaign for Q 
fever vaccination and its associated educational program, there was again an increase in 
notifications and disease. The increase in awareness did not only apply to the medical 
fraternity, but also involved the rural community generally. However, there was an 
alarming increase in the number of notifications reported from females at two specific time 
points in Queensland, which could again be explained by the awareness in the community 
raised by the education program that was associated with vaccination. Very recently, 
community awareness has been raised even further in Australia, through media reports on 
the Australia Broadcasting Commission television programs highlighting the seriousness of 
Q fever disease in the context of the recent epidemic in The Netherlands. This increased 
awareness, based on recent findings, including publications that have arisen from the 
study described in this thesis, will contribute towards the formulation of Public Health 
policy for an effective vaccination strategy for the population at large. 
However, Q fever notification data alone were not a true reflection of the extent of 
exposure occurring in the Queensland population. This could only be assessed accurately 
by examining the seroprevalence in the population. To date this study is the first extensive 
investigation examining the prevalence of Coxiella antibodies in the Queensland 
population.   
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Taken together, the data from the seroprevalence and notification studies showed 
surprising results, which have an impact on the perception of the risk of Q fever in the 
community. Both studies showed that the risk of exposure and subsequent disease is not 
just confined to rural communities, but also poses a significant risk to people living in urban 
or metropolitan regions.  This fact, together with the observation that high rates of Coxiella 
exposure occurred in low risk populations, raised the question about sources of Coxiella 
exposure, other than those traditionally associated with ruminants and farming activities.   
It is widely accepted that large ruminants, such as cattle, sheep and goats, are the most 
common source of Coxiella infection in humans. Also, a recent seroprevalence study in 
Northern Queensland showed native macropods should be considered as potential 
sources of infection. This thesis presented data identifying potential sources of Coxiella 
exposure never before explored, and was the first study in Queensland that demonstrated 
the presence of Coxiella DNA in domestic animal samples, and also detected Coxiella 
DNA in ticks removed from both domestic and native animals. 
Moreover, it was the first report to identify the presence of Coxiella in native flying foxes. 
Flying-foxes have an important ecological role because their feeding behaviour helps 
disperse seeds and spread the pollen of native plants.   Flying foxes are known to travel 
long distances and excrete faeces and bat spat (indigestible seeds and fruit in spit or 
saliva), this increases the distribution of Coxiella from those animals that are infected with 
the bacteria, and may be directly responsible for the spread in the general environment. 
The close association of flying foxes and horses has been well established during 
investigations into transmission of the deadly Hendra Virus, and it seems highly likely that 
the high incidence of Coxiella in horses reported in Chapter 5 of this study may be the 
result of this co-habitation. This general spread of Coxiella in the environment would also 
explain the high detection rate observed in other animal species, and the higher than 
anticipated exposure observed in humans in low risk environments, such as  urban 
populations where no direct animal contact was recorded. The high rates of Q fever 
disease reported in this thesis, occurring in populations in Queensland previously not 
considered for vaccination due to the perceived low risk of exposure, may now be 
attributed to other sources such as domestic pets and local wildlife.   
Queensland, and in particular South East Queensland and the city of Brisbane, enjoy an 
all year round climate well suited for outdoor living. This in turn sees many Queenslanders 
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spend time in outdoor rooms, patio and or decks, which in turn provide shelter and living 
alternatives for local animals and wildlife.  The close proximity to these animals can lead to 
the exposure of subjects to Coxiella through the direct contact with infected animal faeces, 
urine or even birthing products.  Also, an increased risk arises from the aerosolization of 
contaminated soil and dust particles through either the use of vacuum cleaners and 
garden blowers or through the other cleaning mechanisms such as using high pressure 
water hoses which create fine spray and mist. With drought conditions prominent over 
many years in Queensland, the introduction of such devices to remove dust, dirt and 
unwanted animal products without the use of water, employing wind forces such as 
blowers has increased.  These practices provide the potential for animal owners to 
distribute or aid in disseminating Coxiella from infected domestic animals in addition to the 
spread by natural forces.  
There has been a recent re-emergence of interest in Q fever in the Australian media and 
again there have been many cases reported where a clinical diagnosis of Q fever has 
been made in the absence of evidence of animal contact.  Queensland is situated in a sub-
tropical region which makes perfect climatic conditions for the growth of plants and 
grasses.  This sees many Queenslanders cutting household lawns on a regular basis.  
This activity can aid in the dispersion of contaminated animal faeces along with creating 
aerosols from which Coxiella can be inhaled.  There have been other diseases in which 
the distribution of pathogens into the general environment has been created using 
machinery. The recent tunnelling and excavation works performed in Brisbane, directly 
adjacent to the Royal Children’s Hospital at Herston, saw an alarming increase in the 
number of oncology patients acquiring aspergillus infections.  Such similar activities also 
occur on the outskirts of metropolitan areas with the creation of new housing development. 
These areas are typically land parcels that have previously been used for grazing cattle or 
rearing farm animals, and dispersal of soil from these areas carries an increased risk of 
releasing dust-borne Coxiella into the immediate environment.   
The infection of Q fever in humans is widely associated with the inhalation of contaminated 
dust, yet there were no studies in Australia that investigated dust as a potential source of 
infection. The studies that have been performed have been restricted to environments 
considered to be at high risk of potential infection such as shearing sheds and barns. 
Therefore this was the first study to investigate the presence of Coxiella in dust collected in 
 302 
 
 
 
air samplers from a number of locations throughout Queensland, and proved the potential 
for dust from the general environment as a source of infection to humans. 
However, there was a study performed in the USA that showed high levels (24%) of 
Coxiella DNA present in soil samples, yet these results conflicted with low notification rates 
(51 cases annually)  and the results of seroprevalence studies for that country which 
reported low prevalence rates (2.5%).  This disparity may be the result of animal-derived 
reagents utilised in the assays, such as bovine serum albumin.  These reagents were 
shown previously to be contaminated with Coxiella DNA as they are derived from animal 
origin. This was highlighted recently in The Netherlands outbreak as part of a larger 
investigation2,and  would explain the discordances seen between high rates of Coxiella 
detected in environmental samples and the low seroprevalence and the low incidence of 
clinical disease reported in the USA.   
10.1.1. Molecular Epidemiology of Coxiella 
This was the first study to identify unique genotypes of Coxiella present in samples 
collected in Queensland.  There were also genotypes that were closely related to those 
previously identified in NSW, the state reporting the second highest notification rates 
globally.  In addition, samples were identified with similar allele profiles from both animal 
sources and from clinical human cases proving that animals play a role in the chain of 
infection of humans.  
The geographical isolation of Australia has allowed for the clonal expansion of unique 
strains of Coxiella.  This may have resulted in the development of genotypes with higher 
pathogenicity or perhaps hyper-virulent strains, as occurred in The Netherlands, and 
hence may account for the higher rates of disease notified in Australia and Queensland.   
10.2. Clinical Presentation and Diagnosis of Q Fever 
Q fever is a disease that is under-recognised globally. This also was the case in 
Queensland, even though the state has the highest notification rate in the world. There are 
a number of factors that may contribute to this observation, and these were explored in 
this study. Typically in urban settings of Queensland a patient presenting to a general 
medical practice with symptoms of flu-like illness would receive a provisional diagnoses of 
a viral infection, which is self-limiting and the treatment would be rest and recovery. It 
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would only be upon representation with persisting symptoms that subsequent laboratory 
investigation be requested for respiratory pathogens only and these generally would not 
include Q fever screening. In many cases a diagnosis was not made or at worst a 
misdiagnosis might occur.  However, even if Q fever investigations were initiated, the 
diagnostic algorithm currently includes specific IgM and IgG antibody detection with the 
ELISA assay, which this study has shown to be less effective than the IFA and PCR at 
diagnosing acute Q fever.   
Also, this study has highlighted the importance to again raise awareness of the disease in 
the clinical community, and for the need to modify the current diagnostic protocols to 
include PCR testing for early acute infections which, with the current algorithm, were not 
detected. Undetected cases may result in more serious medical complications including 
the development of chronic Q fever or chronic QFS. Chronic QFS is a debilitating and long 
lasting illness that places a huge burden on the physical and mental health of the patient, 
along with compounding financial implications associated with long-term health care.  It 
has been calculated that significant annual income is lost to both industry and personal 
income as a result of Q fever infections, particularly chronic infections and chronic QFS. In 
fact the largest workers compensation claim in Australia has been awarded to an abattoir 
worker diagnosed with chronic Q fever. 
10.2.1. Unusual Clinical Presentations of Q Fever 
Many cases of Q fever are diagnosed in Queensland annually, however, this thesis 
highlighted the significant impact that the disease can have on individuals, families and the 
wider community. Chronic Q fever in children is a rare disease and this study described an 
acute infection in a child that progressed to chronic disease which was complicated by an 
underlying cardiac condition.  The inclusion of children in an effective vaccine program 
would have prevented extensive medical care required by this patient for the rest of their 
life.  
This study also identified infections occurring in children as a result of indirect exposure to 
the bacteria.  One of these studies included the investigation into a family which all 
contracted Q fever within 3 weeks of each other. The source of infection was never 
identified.  It seems likely that the male adult may have indirectly infected some family 
members; however,it seems unlikely that he would have infected all members of the 
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families given the ages of 3 years to adult. This case study may be a rare case of person 
to person spread of the infection. There has only been one other case of person to person 
transmission recorded and that was again among a family3.  If this were another case of 
person to person spread, then it highlighted the infectiousness of Coxiella and the risk it 
posed to entire families who have one family member working in a high risk occupation. 
Another unusual case identified in this study was the detection of a unique Australian 
strain of Coxiella in the placenta of a woman who delivered a stillborn child. This genotype 
has only previously been detected in Australia. Reports previously published, have 
identified the risks associated with pregnant women contracting Q fever, and have 
included the development of chronic Q fever and the high associated risks of miscarriage 
and abortion.  These data also recognised the significance that Coxiella strain types have 
on the outcome of the pregnancy4.  The carriage of Coxiella during pregnancy, not only 
poses a risk to the foetus, but also is a potential risk to the medical staff and midwives 
involved in the care of the patient when termination or delivery is performed. There have 
been previous cases reported where human to human spread has occurred during a 
delivery4,5.  These risks are also factors associated with mortuary staff whilst handling the 
deceased and preparing autopsies and bodies for burial.  
A case of Q fever, with a genotype unique to Queensland, originating from an Australian 
indigenous male was detected in this study. There have been very limited data reported 
regarding the rate of Coxiella infection in the indigenous population of Australia, and there 
has been speculation that Q fever in this ethnic group occurs less frequently than in the 
Caucasian population.  The Northern Territory of Australia has the highest indigenous 
population (30% of the population) and its economy relies heavily on the cattle industry, 
yet no cases were reported before 2002.  There have been 10 cases reported since, with 4 
diagnosed in indigenous patients.  
The indigenous population of Australia lead an almost nomadic lifestyle, living very close 
to the land and the animals that share it. From birth, members of this population group are 
constantly exposed to low levels of the bacteria from the environment and hence may 
have developed an immune response which prevents the development of acute Q fever. 
To investigate this hypothesis, a seroprevalence study of Coxiella in this population of 
Australians needs to be conducted.  
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The need for wider distribution of the vaccine was very clearly demonstrated by a severe 
case of Q fever detected in a wildlife park ranger working in a Queensland National Park. 
This patient was extremely ill with life threatening disease requiring intensive medical care, 
with the subsequent development of medical complications including chronic fatigue 
syndrome, and faces the prospect of never fully recovering from the disease6.  This case 
reinforced the fact that community and medical awareness must be extended to consider 
the risks of all subjects working with animals, or environments where animals reside, and 
reinforced the need to extend government funding for the vaccination program, which 
would prevent such occurrences.   
There was no question that Q fever is a serious disease that has a significant impact on 
the health of many Australians.  It is responsible for significant morbidity which can be 
related directly to a substantial extra burden on the health care system. Many patients are 
incapacitated for weeks and even months, and with the development of chronic QFS, 
many go on to endure long term sequelae as a result of Q fever infection. The potential 
impact of Q fever on the Australian society has recently been brought to the public’s 
attention by a number of media stories aired on television by the Australian Broadcasting 
Commission following awareness in the media of Q fever and its effect on the population in 
The Netherlands.  With an expanding interest in goat farming, Australia is potentially facing 
an increased risk of Q fever epidemics in this sector, which in turn poses a substantial risk 
to the population at large. These media stories highlighted the debilitating nature of both 
the acute and chronic states of the disease, and featured some of the “hardest” outback 
men quoting “I would have been happy to die when I was lying in hospital with Q fever. I 
was that sick I couldn't have cared if I'd died”. Another patient interviewed, who contracted 
Q fever, was subsequently placed on life support and has never fully recovered6.  
10.3. Q fever in Children 
At the time of commencement of this study, there was very little known about Q fever in 
Queensland children and the risks associated with contracting the disease.  This study 
was the first to identify accurately the number of children contracting Q fever, and in doing 
so has identified an increase in those numbers over time. This study also showed that the 
disease was not limited to rural children living in close proximity to livestock, but might 
affect children living in cities equally. Children residing in both high and low risk regions 
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were being exposed at the same rates. However, children in both locations are not 
included in the national vaccination strategy, and with a possible increase in Coxiella 
dissemination through dust and wildlife, might be at increased risk of infection as reflected 
by the increasing numbers of paediatric cases.  
Q fever disease is not well understood in the paediatric populations both globally or in 
Australia.  Children are often exposed to the bacteria; however, the rates of infection 
reported in this group were low. Often children tend to have much closer contact with 
animals and pets than adults, and this may be how children can be exposed to Coxiella 
and acquire infection. Children, more so than adults, regularly present with symptoms 
including fever and respiratory like illnesses for which they are given the tentative 
diagnosis of “flu” or a “flu-like illness and no laboratory investigations are requested. Or the 
child is under investigation for a respiratory disease for which there is no laboratory 
conformation and the infectious etiological agent is never identified. However, with the 
recent reviews of Q fever disease in children, there is a general push for a safe and 
effective vaccine to be developed as many rural children cannot avoid the potential 
exposure to the organism from a number of different sources.  With this fact in mind, some 
rural practitioners have chosen to vaccinate younger children who fall outside the 
recognized target group for vaccination, and who are at high risk of exposure to the 
disease7. 
The data presented throughout this thesis highlighted the risk of Q fever infection to 
children. The recent media coverage confirmed this, and specifically describes cases of Q 
fever in children, even profiling severe cases in which the children had long term medical 
follow-up and complications. Yet, despite these warnings, a licensed vaccine and a 
comprehensive vaccine strategy for children is still lacking. 
10.4.  Preventing Q fever in the Future 
The need for a comprehensive vaccination strategy, which encompasses all sectors of the 
Australian population, is indisputable. Yet, despite having an effective vaccine against 
Coxiella, it is limited to adults at risk of infection and, until this study, there was no data 
regarding other populations that may be at risk of infection, especially children.  This thesis 
has identified a number of risk factors for the Queensland population in regards to the 
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transmission of Coxiella, and has shown there is a need to protect the children of 
Queensland who are at risk of the disease, either as a result of geographical or residential 
location, or because of a family member working in a previously recognised high risk 
occupation.   
The current, licensed vaccine in Australia, Q Vax®, has not been formulated for children, 
and has been identified as having potentially severe adverse reactions as a consequence 
of receiving the vaccine.  In addition, current pre-vaccination screening is inadequate to 
assess the true rate of previous exposure in vaccine candidates.  
Therefore a successful vaccination strategy would need to address these issues before a 
comprehensive preventative program can be initiated. This would need to include the 
development of a new vaccine, perhaps a recombinant antigen, which would limit the side 
effects associated with the current whole-cell vaccine, and the introduction of a pre-
screening procedure that would accurately assess pre-existing immunity. Yet, so far there 
have been no developments in this area.   
The need for a better pre-screening protocol was recognised at the commencement of the 
study described in this thesis, and it was deemed important to include the development of 
such an assay in this study. As a result proof of principle was established for an assay 
which used a cell meditated immunity assay for the assessment of pre-existing Coxiella 
exposure of vaccine subjects.  This assay was a major improvement, and will also aid in 
screening children for Coxiella immune status.  Also, this assay will prevent potentially 
dangerous hypersensitivity reactions in subjects with previous Coxiella exposure who are 
subjected to the bacterial antigens during the current skin test administration. Another 
major advance in using the CMI method is that it would reduce the subjectivity or incorrect 
interpretation associated with the skin test, and hence improves the pre-screening 
procedure. 
10.5. Conclusions 
Never before has a comprehensive study been conducted that identified the true exposure 
rate to Coxiella burnetii in the Queensland population. This thesis has provided a 
significant contribution to narrowing this knowledge gap, and identified those populations 
at risk of the disease along with previously unrecognised potential sources of infection. 
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Also, based on the outcomes from this study, a revised diagnostic approach is 
recommended that will improve the accurate identification of disease across all population 
groups. Furthermore, the discovery of novel genotypes in Queensland may aid in better 
understanding the extremely high numbers of notified Q fever cases in Australia, and will 
aid in the development of new effective vaccines.   
So far, the occurrence of Q fever in children has been largely ignored, but this thesis 
clearly highlighted that this disease was a serious threat, and that children must be 
included in any public health preventative measures, including vaccination, that may be 
introduced in the future. To facilitate this, the cellular immune assay described in this study 
should be applied and will provide a safer and more effective mechanism for which pre-
screening of vaccine subjects can be performed. 
Taken together, the comprehensive data presented in this thesis will make a significant 
contribution to raising the awareness of Q fever in Queensland and Australia, and will help 
facilitate a more comprehensive approach to a preventative public health strategy that will 
ultimately lead to more effective control of this serious disease. 
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